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ABSTRACT 
Background: There is controversy regarding the effect of blood product transfusion 
on patients undergoing liver transplantation. De Boer et al. suggested an association 
between platelet transfusion and increased mortality in liver transplantation (de Boer 
et al., 2008). This thesis evaluates the consequences of blood transfusion during the 
intraoperative and postoperative period in liver transplant recipients. 
Methods: A retrospective multivariate analysis of data involving 434 liver transplant 
recipients at our institution from 2002 to 2011 was conducted. The primary outcomes 
were patient and graft survival rates at 1 and 5 years following liver transplantation. 
The secondary outcomes included the incidence of postoperative acute kidney injury 
(AKI) / dialysis and postoperative infection and the duration of endotracheal intubation, 
intensive care unit (ICU) stay and hospital stay.  
Results: Transfusion of ≥5 units of pooled platelets was associated with decreased 5-
year patient mortality and 5-year graft failure. Platelet transfusion was also associated 
with an increased incidence of postoperative AKI, infective complications, and duration 
of endotracheal intubation. Packed red blood cell transfusion (PRBC) was not 
associated with increased mortality or graft failure. PRBC transfusion was associated 
with an increased incidence of AKI. Fresh frozen plasma transfusion was associated 
with increased 5-year patient mortality, duration of endotracheal intubation and 
duration of hospital stay. The transfusion of cryoprecipitate was not associated with 
increased mortality or graft failure following liver transplantation but was associated 
with an increased ICU stay when ≥20 units were administered. 
Conclusion: This thesis demonstrated that the transfusion of platelets was associated 
with decreased long-term patient mortality and graft failure following liver 
11 
 
transplantation. This contrasts to previous studies which linked blood product 
transfusion to increased patient mortality and graft failure. 
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1 LITERATURE REVIEW 
 Introduction 
Orthotopic liver transplantation is a surgical procedure where a diseased liver is 
replaced by a donor liver in the original anatomic position. This procedure is the 
definitive treatment for patients with end stage liver disease. Liver transplantation is a 
highly technical and complex surgical procedure which is associated with a 
requirement for large volumes of blood transfusion products; comprising packed red 
blood cells, fresh frozen plasma, platelets, and cryoprecipitate. In recent years, drugs 
and recombinant factor VIIa have been used to reduce the requirement for blood 
component transfusion. 
 Search Strategy 
A detailed review of the medical literature (available until December 2017) was 
performed to determine the evidence surrounding the association between blood 
product transfusion and outcomes in orthotopic liver transplantation. The Medline 
database was searched using the following search terms: Liver Transplantation, (Liver 
adj5 (Transplant* or graft* or allograft)), (Hepat* adj5 (Transplant* or graft* or 
allograft)), Blood Component Transfusion, Erythrocyte Transfusion, Platelet 
Transfusion, Plasma Exchange, Blood Cells, Erythrocytes, Blood Platelets, Plasma, 
Factor VIII, Factor VII, Fibrinogen, von Willebrand Factor, red blood cell*, packed cell 
transfusion*, fresh frozen plasma,  ffp, platelet*, Cryoprecipitate*, Cryo. The results 
were limited to human studies and studies focussing on paediatric patients were 
excluded. The resulting 930 article abstracts were screened for relevance to the topic, 
with papers not relating to transfusion in liver transplantation excluded. The PubMed 
database was also searched for recent articles on blood transfusion in liver 
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transplantation within the past year. The articles citing the sentinel papers regarding 
red blood cell and platelet transfusion in liver transplantation were also reviewed. 
 History and background 
The first human liver transplantation was performed in 1963 by Thomas Starzl and his 
colleagues in the United States. The first five patients died of haemorrhagic 
complications. The first successful transplantation was performed by Starzl in 1967. 
Initial survival rates were poor, with a 24% one year survival rate in adults. Advances 
in surgical techniques and improvements in postoperative care and preoperative 
patient preparation have decreased mortality rates. From January 1985 until the 31st 
of December 2014, 4506 patients had undergone orthotopic liver transplantation (3711 
adults and 795 children) in Australia and New Zealand. In 2014, 263 (221 adults and 
42 children) patients underwent liver transplantation (S.V Lynch, 2014).  
Advances in anaesthesia have reduced the blood loss associated with orthotopic liver 
transplantation. These include the avoidance of hypothermia, monitoring and 
correction of coagulopathy and electrolyte abnormalities, and intraoperative blood 
salvage (Singh et al., 2012). The monitoring and correction of coagulopathy involves 
the identification of the potential causes of bleeding, prediction of blood loss and the 
administration of haemostatic therapy (coagulation factors or drugs). The use of 
advanced physiological monitoring, good communication with the surgical team and 
the evaluation of intraoperative coagulation profiles are important aspects of 
anaesthesia in liver transplantation. The coagulation tests used during liver 
transplantation include prothrombin time, activated partial thromboplastin time, platelet 
count and fibrinogen levels. These are combined with point of care tests which 
measure overall clotting function. The point of care tests include thrombelastography 
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and Sonoclot devices. Thrombelastography measures the viscoelastic properties of 
fibrin from the start of clot formation to complete dissolution of the clot. 
Thrombelastography is useful in the evaluation of the overall interaction between 
platelets, coagulation factors and red blood cells (based on the cell theory of 
coagulation). A variation of thrombelastography is rotation thrombelastometry 
(ROTEM®, Germany) that measures rotational viscoelastic properties during clot 
formation. Both these tests can detect hyperfibrinolysis in bleeding patients (Roullet et 
al., 2010). The Sonoclot device measures the changes in impedance to the movement 
of a probe oscillating 1µm vertically at a frequency of 200 Hz as a blood sample clots 
(Hett et al., 1995).  
The avoidance of hypothermia is essential in liver transplantation. In the presence of 
normal levels of coagulation factors, hypothermia leads to coagulopathy and delayed 
wound healing (Singh et al., 2012). Wolberg et al. investigated the effects of 
temperature on coagulant enzyme processes and platelet function. They also 
evaluated the effects on activated partial thromboplastin time (aPPT) and in vitro 
models of coagulation. They found that platelet aggregation and adhesion were 
significantly reduced (p < 0.05) at 33oC compared with platelet function at 37oC. The 
surface of the test material covered by adherent platelets was reduced by 33% at 33oC 
and 47% less at 23oC when compared to the surface area covered at 37oC. At 23oC 
aPPT was prolonged (175 ± 58 units at 23oC vs 47.3 ± 9.9 units at 33oC, P < 0.05). 
The monocyte tissue factor Xa generation was decreased at 23oC (0.391 ± 0.11) and 
33oC (0.87 ± 0.10) compared with enzyme activity at 37oC (1.0) (Wolberg et al., 2004). 
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 Blood loss 
During an orthotopic liver transplant procedure, the recipient’s diseased liver is 
removed. As the liver is a highly vascular organ, transplantation can result in massive 
blood loss. Pathophysiological abnormalities associated with liver disease potentiate 
bleeding. These include portal hypertension, varices and deficiency of clotting factors 
such as Von Willebrand factor (vWF), factors II, VII, IX, and X.  
 Preoperative factors 
Liver cirrhosis, cholestasis and splenomegaly are associated with increased bleeding 
during liver transplantation. Coagulation factors II, VII, IX, and X are synthesised in the 
liver. These factors are deficient in liver disease, resulting in coagulopathy. 
Thrombocytopenia is common in liver transplantation patients. Splenomegaly 
secondary to portal hypertension results in increased platelet sequestration (Li et al., 
2012a). The decreased production of thrombopoietin in the diseased liver decreases 
platelet synthesis and leads to thrombocytopenia.  
The aetiology of a patient’s liver disease has a direct effect on their platelet count and 
coagulation profile. Juttner et al. conducted a prospective study of 34 patients who 
underwent liver orthotopic transplantation. Blood samples were taken preoperatively, 
during the anhepatic phase and after reperfusion. Platelet aggregation tests and flow 
cytometry were used to evaluate GPIIb/IIIa and GPIb binding sites on platelets as well 
as P-selectin (a cell adhesion molecule on the surface on activated platelets) levels. 
The coagulation profiles (aPTT, PT, fibrinogen, Factor V assay and antithrombin 
levels) and thrombopoietin concentration in serum were also measured. The authors 
found that patients with viral, alcohol related or metabolic liver disease had significantly 
lower (P<0.001) platelet counts, increased activated partial thromboplastin times, 
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decreased prothrombin times, decreased fibrinogen levels, decreased factor V activity 
and decreased antithrombin in comparison to patients with cholestatic or malignant 
liver disease. There were no significant changes in factor V activity. 
Table 1: Parameters of plasmatic coagulation in patients according to diagnosis 
(Juttner et al., 2009) 
 
The risk factors that predispose to blood transfusion include age, severity of liver 
disease (determined by the Model for End-stage Liver Disease (MELD) score), 
preoperative haemoglobin and plasma fibrinogen levels (Mangus et al., 2007, Sabate 
et al., 2012). 
The MELD Score is used to prioritise the allocation of orthotopic liver transplantation 
to the sickest patients. It was initially developed to predict mortality rates in patients 
with portal hypertension undergoing transjugular intrahepatic portosystemic shunts. 
The MELD score is calculated from three laboratory measurements: serum creatinine, 
serum bilirubin and the international normalised ratio (INR). The formula is: MELD = 
9.57 × loge(creatinine) + 3.78 × loge(total bilirubin) + 11.2 × log (INR) + 6.43. The MELD 
score is a scoring system for assessing the severity of liver disease. It was 
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subsequently useful in determining prognosis and prioritising for receipt of liver 
transplants.  
There is controversy regarding the use of the MELD Score for predicting post-
transplant survival in orthotopic liver transplantation. Batista et al. conducted a 
retrospective study on 288 liver transplant patients between 2003 and 2009. The area 
under the curve of the receiver operating characteristic of MELD score to predict 24 
month survival was 0.504 which suggested that it had a low discriminatory power 
(Batista et al., 2012). In contrast, Brandao et al. in a retrospective study of 436 liver 
transplant patients, found that there was a significant difference in survival rates 
between patients with MELD scores less than 15 compared with patients with MELD 
scores greater than 21. The survival rates at 3 months were 88.0% for patients with a 
MELD score less than 15 and 75.0% for those with a MELD score greater than 21 
(P=0.01). At 6 months, survival rates were 85.7% for patients with a MELD score less 
than 15 and 73.3% for those with a MELD score greater than 21 (P=0.03). The overall 
survival rates (P=0.3) and 12 month (P=0.08) survival rates were not significantly 
different (Brandao et al., 2009).  
Conclusive data on the link between MELD score and survival following liver 
transplantation is lacking. It is validated as a tool for predicting survival in patients with 
advanced liver disease and as such is used to allocate organs for liver transplantation 
(Kamath and Kim, 2007). Further large multicentre studies are required to determine 
whether post-transplant mortality can be predicted from the preoperative MELD score. 
 Intraoperative factors 
Multiple intraoperative factors contribute to blood transfusion in orthotopic liver 
transplantation. Mangus et al. performed a retrospective study of 526 liver transplant 
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procedures. They found that total anaesthesia time was a predictor for estimated blood 
loss during liver transplantation using multivariate analysis (Mangus et al., 2007). The 
median anaesthesia time was 4.67 hours (mean 4.95 hours). In 105 patients (19.9%) 
the total anaesthesia time was less than 4.00 hours with a median blood loss of 600 
mL. In 337 patients (63.9%) the median blood loss was 1000 mL when the total 
anaesthesia time was between 4.02 and 5.98 hours. The total anaesthesia time in 85 
patients (16.1%) was greater than 6.00 hours and this was associated with a median 
blood loss of 1775 mL. The target haemoglobin level during liver transplantation in this 
study was 100 g/L. A weakness of this study was the use of the packed red blood cell 
transfusion volume as a surrogate measure for blood loss. This was obtained from the 
anaesthesia records alone and blood loss was not corroborated with other 
independent measurements (eg. volume in suction apparatus or the weight of 
sponges). The problem with using the number of transfused blood components as a 
measure of blood loss is that it does not account for the presence of preoperative 
anaemia which could potentially increase transfusion requirements.  
The administration of large volumes of crystalloids or colloids to treat haemodynamic 
instability may worsen coagulopathy (Massicotte et al., 2012, Sabate et al., 2012). This 
results from the dilution of coagulation factors. The efficacy of platelets and 
coagulation factors is reduced by hypothermia following the infusion of cold fluids and 
blood replacement products. Acidosis resulting from metabolic disturbances during 
surgery contribute to coagulopathy by impairing thrombin generation as well as 
accelerating fibrinogen degradation (Martini, 2009). The addition of citrate to stored 
blood (to prevent clotting in blood products) can cause hypocalcaemia which also 
worsens coagulopathy. In these patients the metabolism of citrate is decreased as a 
result of impaired hepatic function and this leads to citrate toxicity. 
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De Pietri et al. performed a retrospective cohort study of 386 patients undergoing liver 
transplantation. They found that the use of thromboelastography (TEG) and the 
administration of fibrinogen during liver transplantation was associated with decreased 
transfusion of packed red blood cells (1502 vs 794 mL, P < 0.001), fresh frozen plasma 
(537 vs 98 mL, P < 0.001) and platelets (158 vs 75 mL, P < 0.005) (De Pietri et al., 
2016). 
The intraoperative blood loss and transfusion requirements are influenced by several 
factors in the three stages of liver transplantation surgery: the preanhepatic period 
(Stage I), the anhepatic period (Stage II) and the reperfusion period (Stage III).  
Stage I of the transplantation procedure involves the removal of the diseased liver and 
the dissection of the vascular structures of the liver. Dilated collateral blood vessels 
associated with portal hypertension contribute to an increase in bleeding during this 
stage of transplantation.  
Fibrinolysis may be a cause of bleeding during stage II and III of liver transplantation. 
This is caused by a decreased uptake of tissue plasminogen activator during the 
anhepatic phase as well as an increased release of tissue plasminogen activator from 
the transplanted organ after reperfusion. In a study of 20 patients who underwent liver 
transplantation, Wang et al. found that the haemoglobin concentration, platelet count 
and fibrinogen concentration were significantly decreased during anhepatic and 
reperfusion phases compared with their preoperative values (P < 0.01). The 
decreases in haemoglobin, platelet and fibrinogen concentration 60 minutes following 
reperfusion were approximately 20g/L (mean of 100g/L decreasing to 80g/L), 10x109/L 
(mean of 90x109/L decreasing to 80x109/L) and 0.5g/L (mean of 1.9g/L decreasing to 
1.4g/L) (Wang et al., 2008). Wang et al. suggested that the decreased fibrinogen 
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concentration was a result of increased fibrinolysis. A weakness of this study was a 
small sample size. 
 Postoperative factors 
Bleeding from the vascular anastomoses as a consequence of fibrinolysis are a major 
cause of postoperative bleeding. Postoperative coagulopathy can also  be a sign of 
graft non-function (Ikegami et al., 2012). Thrombocytopenia can also contribute to 
postoperative bleeding. Thrombocytopenia may result from the consumption of 
platelets in haemostatic processes and sequestration by the donor liver following 
reperfusion (Pereboom et al., 2008). The profile of the recovery of platelet counts is 
linked to rates of patient survival. In a retrospective study of 449 adult patients 
undergoing liver transplantation, Pereboom et al. showed that a greater degree of 
platelet count recovery was associated with a decreased fifteen-day mortality following 
orthotopic liver transplantation. The authors also found that platelets have both 
positive and negative effects in liver transplantation. The positive effects included 
improved tissue repair and liver regeneration mediated by serotonin, while the 
negative aspects were platelet mediated ischaemia and reperfusion injury of the liver 
graft (via induction of sinusoidal endothelial cell apoptosis) (Pereboom et al., 2008).   
 Transfusion volumes 
 Predictors 
McCluskey et al, developed a risk index to predict massive blood transfusion (defined 
as transfusion equal to or greater than six units of packed red blood cells within the 
first 24 hours of surgery) in a retrospective cohort study of 460 liver transplant 
recipients (between January 1998 and March 2004).  Utilising multivariate logistic 
regression, seven pre-operative risk predictors for massive blood transfusion were 
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identified. These included age (greater than 40 years), haemoglobin concentration 
(less than or equal to 100g/L), international normalised ratio (between 1.2 and 2.0 or 
greater than 2.0), platelet count (less than or equal to 70 x109 /L), creatinine (≥ 110 
µmol in females or ≥120 µmol in males), albumin (<28g/L) and previous 
transplantation. Each variable was allocated one point on the risk index (scored out of 
eight), but when an international normalised ratio was greater than 2.0, two points 
were allocated (McCluskey et al., 2006). In patients who had a risk index ≥3, the 
probability of receiving a massive blood transfusion was 80%. The McCluskey index 
had a sensitivity of 58%, specificity of 87%, positive predictive value of 76%, and 
negative predictive value of 73%. The receiver operating characteristic curve for the 
risk index was 0.79, indicating that the index was a good predictor. McCluskey et al 
also found that the MELD score was predictive of blood transfusion requirement. The 
median MELD score for those who received less than six units of packed red blood 
cells was 13.3, whilst those who received six or more units had a median MELD score 
of 22 (P<0.0001). 
In a retrospective study, Escoresca Ortega et al. applied the McCluskey index to a 
cohort of 99 liver transplantations at their institution between January 1, 2005 and 
December 31, 2006 (Escoresca Ortega et al., 2008). The authors found that the 
McCluskey model was a good predictor for increased blood transfusion requirements 
amongst their patients when the McCluskey score was 5 or greater. Within this cohort 
the sensitivity of the McCluskey Index was 80%, the specificity was 84%, the positive 
predictive value was 95.5% and the negative predictive value was 50%. The 
transfusion requirements were significantly less in the patients with a score less than 
5. This was observed during the first 24 hours after transplantation and during the 
patient’s total hospital stay. The mean transfusion requirements for each of the blood 
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components for patients who scored less than 5 on the McCluskey index compared 
with those who scored higher were: 3.84 units vs 9.67 units for packed red blood cells 
in the first 24 hours (P<0.0005), 4.88 units vs 13.67 units for total number of transfused 
packed red blood cells (P<0.0005), 3.04 units vs 8.83 units for plasma in the first 24 
hours (P<0.0005), 4.35 units vs 11.72 units for total plasma (P<0.001), 2.71 units vs 
9.28 units for platelets in the first 24 hours (P<0.003), and 3.69 units vs 14.89 units for 
total platelets transfused (P<0.004). A limitation to this study was the small sample 
size. Further studies with larger samples are needed before conclusions regarding the 
applicability of the index can be made. 
Cywinski et al. analysed 804 orthotopic liver transplantation procedures between 
January 2001 and June 2010 and found that preoperative MELD score and lower 
preoperative platelet count were associated with increased packed red blood cell 
transfusion and red cell salvage requirements (Cywinski et al., 2014). They formulated 
a model to predict blood product transfusion in liver transplant surgery, but their model 
had a poor correlation with predicting large blood product transfusion requirements.  
Preoperative MELD score and preoperative haemoglobin levels were independent 
predictors for intraoperative blood product transfusion in a study conducted by Liu et 
al. (Liu et al., 2015). The utility of the MELD score in predicting blood product 
transfusion was also supported by a study by Fernandes et al. (Fernandes et al., 
2017).  
The risk of bleeding and transfusion requirements in liver transplantation is determined 
by the patient’s age, severity of hepatic disease, and haemoglobin and fibrinogen 
levels. The administration of cryoprecipitate or fresh frozen plasma when the patient’s 
plasma fibrinogen levels decrease below 1.5g/L reduces the risk of bleeding. However, 
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thrombotic complications are a potential complication (Sabate et al., 2012). Sabate et 
al. recommended that platelets should be only administered if the platelet count is 
below 50,000 /mm3 and the patient is actively bleeding due to the risk of 
thromboembolic events. 
Li et al confirmed that a plasma fibrinogen concentration below 1.5g/L was a predictor 
of the need for blood transfusion. The investigators conducted a retrospective analysis 
of 181 patients undergoing living donor liver transplant and identified that haemoglobin 
levels <100g/L (odds ratio: 2.126, 95% CI 1.041 to 4.345, P=0.039), platelet counts of 
<70x109/L (odds ratio: 2.282, 95% CI 1.252 to 7.502, P=0.022), fibrinogen levels 
<1.5g/L (odds ratio: 2.317, 95% CI 1.105 to 4.895, P=0.026) and a history of upper 
abdominal surgery (odds ratio: 3.065, 95% CI 1.128 to 4.616, P=0.014) were 
independent risk factors for transfusion of six or more units of packed red blood cell 
units within 24 hours of orthotopic liver transplantation. Although platelet counts 
<70x109/L were associated with increased transfusion requirement, Li et al. found no 
decrease in long term survival. It was not the standard practice at their institution to 
administer large amounts of platelets for thrombocytopenia. They suggested that the 
association between previous upper abdominal surgery and increased transfusion of 
blood products was due to intra-abdominal adhesions (Li et al., 2012a). 
Rana et al. conducted a retrospective study of 233 liver transplant recipients (between 
the 1st of January, 2006 and the 31st of December, 2008) with 2.5 years of follow up 
data. The cohort included 104 patients with hepatitis C as the primary etiology 
requiring transplant, 30 patients with alcohol related disease and 13 patients with non-
alcoholic steatohepatitis. Utilising multivariate analysis they found that a donor graft 
warm ischaemia time greater than 46 minutes (odds ratio: 7.4, 95% CI 3.0 to 18.5 
P<0.001), serum bilirubin levels greater than 21mg/dL in the recipient (odds ratio: 3.4, 
33 
 
95% CI 1.2 to 9.3, P=0.02), a history of previous surgery (odds ratio: 1.7, 95% CI 1.02 
to 2.9, P=0.004),  and prolonged hepatectomy time (odds ratio: 1.01 per minute, 95% 
CI 1.0 to 1.02, P=0.03)  were risk factors associated with intraoperative transfusion 
requirements of 28 or more red blood cell units in orthotopic liver transplantation (Rana 
et al., 2013). One of the strengths of the study was that all the 233 liver transplants in 
the study were performed by one surgeon, minimising surgical technique as a 
confounding factor. 
Araujo et al. in a retrospective multivariate analysis of 758 consecutive adult liver 
transplant patients found that preoperative prothrombin time, haemoglobin level, age 
and pathology of the recipient were significant predictors for transfusion requirement 
in orthotopic liver transplantation (Araujo et al., 2010). However, the model developed 
to predict transfusion requirement had poor predictive value (R2 = 0.308). 
Massicotte et al. in a retrospective cohort study of 503 liver transplants demonstrated 
that haemoglobin concentrations at the start of an orthotopic liver transplantation 
procedure are the strongest predictor of packed red blood cell transfusion 
requirements. The risk of transfusing packed red blood cells was decreased by 1.1% 
for each increase of 1g/L of starting haemoglobin concentration (Massicotte et al., 
2012). In contrast to other studies, Massicotte et al. found that MELD Score did not 
predict blood losses and blood product transfusion requirements (Massicotte et al., 
2009).  
Estmat Gamil et al., using multivariate analysis in a retrospective study of 286 liver 
transplant patients, reported that the presence of ascites (P=0.003) and an INR of 
greater than or equal to 1.6 (P<0.001) were significantly associated with an increased 
requirement for transfusion of six or more units of red blood cells blood. The patients 
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who had an INR of less than 1.6 received a median of 4 units of red blood cells 
(P<0.001) and 4 units of fresh frozen plasma (P<0.001). The patients who had an INR 
of 1.6 or greater received a median of 8 units of red blood cells and 7 units of fresh 
frozen plasma. When patients with an INR of less than 1.6 were compared with those 
who had an INR of 1.6 or greater, there was a significant difference between duration 
of ICU stay (median of 5 days vs 11 days, P<0.001) as well as total hospital stay 
(median of 25 days vs 38 days, P<0.001). The volume of packed red blood cell 
transfusion was also identified as a predictor of overall survival (P=0.005) (Esmat 
Gamil et al., 2012).  
Stanca et al. in a retrospective study of 100 liver transplant patients identified that 
increased spleen volume and low platelet count at the time of liver transplantation were 
predictors of persistent thrombocytopenia (<150,000/µL) following liver transplantation 
(Stanca et al., 2010). These may predict the need for postoperative platelet 
transfusion. 
Massicotte et al. in a retrospective study of 206 liver transplantations demonstrated a 
link between preoperative baseline platelet count and transfusion requirement. The 
patients who received greater than four units of packed red blood cells had a mean 
starting platelet count of 78 ± 52 x109/L. The patients who received four or less units 
of red blood cells had a mean starting platelet count of 106.8 ± 68 x109/L. The duration 
of surgery and starting international normalised ratio were also predictors of blood 
transfusion (Massicotte et al., 2004).  The patients who received four or less units of 
red blood cells had a mean operative time of 247.0 ± 61.7 minutes and a starting INR 
of 1.61 ± 0.60. Those who received greater than four units had a mean operative time 
of 299.7 ± 74.8 minutes and a starting INR of 2.28 ± 1.28. 
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In summary, the McCluskey index can predict packed red blood cell transfusion 
requirement. The variables in the McCluskey index (recipient age, preoperative 
haemoglobin concentration, INR, preoperative platelet count, creatinine levels, 
albumin levels and history of previous liver transplantation) have been shown to be 
predictive of transfusion requirements in numerous other studies (Esmat Gamil et al., 
2012, Massicotte et al., 2009, Thompson et al., 2014). The usefulness of the 
McCluskey index may depend on the patient characteristics of different transplant 
centres. The index may be poorly applicable in centres with a vastly different patient 
demographic (eg. significantly different MELD score). 
 Minimising blood loss 
 Surgical techniques 
Advances in surgical techniques for orthotopic liver transplantation have resulted in 
decreased blood loss and transfusion requirements. A retrospective cohort study of 
200 patients by Findlay et al. showed significantly shorter operative (P<0.001) and 
anhepatic times (P<0.001) and decreased intraoperative blood transfusion (P<0.001) 
in recent liver transplantations (Findlay et al., 2013). The investigators compared a 
cohort of 100 adult liver transplant patients from 1990-1991 with another cohort of 100 
patients from 2005-2006. The median intraoperative transfusion requirements in the 
1990-1991 group were 11.0 units of red blood cells, 11.0 units of fresh frozen plasma, 
11.0 units of platelets, and 10.0 units of cryoprecipitate. This was in comparison to a 
reduced median intraoperative transfusion requirement in the 2005-2006 group that 
received 2.0 units of red blood cells, 0 units of fresh frozen plasma, 4.0 units of 
platelets, and 0 units of cryoprecipitate. The mean anaesthetic (484.6 ± 90.2 minutes 
vs 379.5 ± 97.6 minutes), surgical (404.6 ± 90.3 minutes vs 284.0 ± 84.9 minutes) and 
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anhepatic times (115.1 ± 28.2 minutes vs 72.0 ± 15.4 minutes) were longer in the 
1990-1991 group when compared with the 2005-2006 group. The authors suggested 
that the reduction in transfusion requirements were due to improvements in surgical 
techniques as transfusion triggers were similar in these two cohorts.  
Interventional radiology techniques to control portal hypertension are used to minimise 
transfusion and complications during orthotopic liver transplantation. The transjugular 
intrahepatic portosystemic shunt reduces hepatic portal venous pressure and ascites. 
Menegaux et al. in a case series of 38 patients undergoing orthotopic liver 
transplantation compared 25 patients who had a transjugular intrahepatic 
portosystemic shunt compared with 13 patients which had a prior surgical 
portosystemic shunt. They showed that the transjugular intrahepatic portosystemic 
shunt was superior to the surgical portosystemic shunt and decreased the median 
intraoperative packed red blood cell requirements (5 units vs 12 units),  fresh frozen 
plasma (0 units vs 8 units), platelets (0 units vs 1 unit),  operating time (9 vs 13 hours), 
length of intensive care stay (3 vs 5 days) and length of hospital stay (12 vs 24 days) 
(Menegaux et al., 1994).  
The two main techniques used to perform orthotopic liver transplantation are: (a) the 
conventional technique, which involves clamping the inferior vena cava and portal vein 
or utilising venovenous bypass and (b) the “piggyback” technique, which avoids 
venovenous bypass and preserves the inferior vena cava. A Cochrane systematic 
review by Gurusamy et al. showed that transfusion requirements were not significantly 
different between the conventional orthotopic liver transplant technique with veno-
venous bypass and the piggy-back technique (Gurusamy et al., 2011a). The graft 
warm ischaemic time was shorter for the piggy-back technique when compared with 
the conventional method (mean difference -11.50 minutes; 95% CI -19.35 to -3.65; P 
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< 0.01). The piggy-back technique was associated with more respiratory infections 
than the conventional technique (75.8% versus 44.1%; P = 0.01) (Gurusamy et al., 
2011a). 
 Pharmacological methods 
The pharmacological methods used to decrease blood loss during liver transplantation 
include the use of antifibrinolytics (such as: aprotinin, tranexamic acid, and epsilon 
amino caproic acid), recombinant factor VIIa, antithrombin III, oestrogen, adrenaline 
and prostaglandin. The use of antifibrinolytic drugs is guided by evidence of fibrinolysis 
with thromboelastography. Antifibrinolytics are also indicated in patients when there is 
diffuse bleeding when the fibrinogen concentration is less than 1g/L (Sabate et al., 
2012). 
Gurusamy et al suggested that the use of recombinant factor VIIa (rVIIa) and 
thromboelastography might decrease transfusion requirements (Gurusamy et al., 
2011b). The thromboelastography variables measured included the reaction time, 
alpha angle, and maximal amplitude. Platelets were transfused when the maximal 
amplitude was <55mm, cryoprecipitate was transfused when the alpha angle was <45 
degrees and fresh frozen plasma was given to target a reaction time of <10 minutes 
(Wang et al., 2010). However the confidence intervals for these interventions in 
reducing transfusion requirements were wide (rVIIa 95% CI: -0.32 to 0.23, 
thrombelastography 95% CI: -1.69 to 0.24) and the results were not statistically 
significant. Gurusamy et al. conducted a Cochrane systematic review of 33 trials until 
September 2011 (involving 1913 patients). They evaluated methods used to decrease 
blood loss and transfusion requirements during liver transplantation. All randomised 
clinical trials that were performed to compare various methods of decreasing blood 
loss and transfusion requirements were included. The interventions analysed included 
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aprotinin, tranexamic acid, epsilon amino caproic acid, antithrombin III, recombinant 
factor vIIa, oestrogen, prostaglandin, epinephrine, blood components, hydroxyl-ethyl 
starch, coagulation monitoring with thromboelastography and the maintenance of a 
low central venous pressure. The authors noted that all of the included trials had a 
high risk of bias (selection bias, attrition bias and reporting bias). Only the 
administration of aprotinin was associated with a statistically significant reduction in 
bleeding and transfusion requirements. Eight trials evaluated the impact of aprotinin 
on blood transfusion. There were 185 patients who received aprotinin and 190 patients 
in the control group. The use of aprotinin was associated with a decrease in blood 
transfusion. In the patients who received aprotinin there was a mean decrease of 0.61 
units of red blood cells (95% CI -0.82 to -0.40) compared with the patients who did not 
receive aprotinin. There was no significant difference between the control group and 
any of the other interventions in terms of mortality, graft loss, major complications, 
length of stay in intensive care, length of stay in hospital, and blood loss or transfusion 
requirements. There was potential for random error due to the small sample size of 
the studies and the high risk of heterogeneity within the studies may have led to an 
overestimation of the benefits of the interventions. Aprotinin was withdrawn in 2008 
after data from retrospective studies and from the Blood Conservation using 
Antifibrinolytics in a Randomized Trial (BART) showed that it increased mortality in 
major open heart operations. The 30 day all-cause mortality for patients who aprotinin 
was 6.0%, compared with 3.9% for patients who received tranexamic acid (relative 
risk 1.55, 95% CI 0.99 to 2.42) (Fergusson et al., 2008). Aprotinin has been withdrawn 
from the market by the manufacturer as the demonstrated increase in mortality was 
substantial.   
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The use of aprotinin has been replaced by tranexamic acid in current liver 
transplantation practice. The administration of tranexamic acid has been associated 
with a decrease in packed red cell transfusion during liver transplantation in a meta-
analysis and systematic review (n=1407) by Molenaar et al. (Molenaar et al., 2007).  
 Control of Central Venous Pressure 
Jones et al and Melendez et al. demonstrated a low intraoperative central venous 
pressure was associated with reduced blood loss in hepatic resection surgery. In a 
retrospective study of 100 consecutive hepatic resections between 1986 and 1996, 
Jones et al. showed that lowering central venous pressure to less than 5 cm H2O was 
an effective method of reducing blood loss during hepatic surgery (Jones et al., 1998). 
In this study, two of 40 patients with a central venous pressure of 5cmH2O or less 
received blood transfusion. The median volume transfused in this group was 200mL. 
In those patients with a central venous pressure greater than 5 cm H2O, 25 of 52 
patients received blood transfusion. In this group the median volume of blood loss was 
1000mL. In a retrospective study of 496 major liver resections, Melendez et al. showed 
that a median blood loss of 645mL was associated with the maintenance of low central 
venous pressure (less than 5 mmHg). There was no significant impairment in renal 
function (defined by raise in creatinine or blood urea nitrogen) associated with low 
intraoperative central venous pressure (Melendez et al., 1998). 
A retrospective study of 175 patients undergoing liver resection was conducted by 
McNally et al. The study confirmed the relationship between central venous pressure 
and blood loss in liver resection surgery. A central venous pressure greater than 10 
cm H2O was associated with blood loss of greater than or equal to 1000mL with an 
odds ratio of 5.52 (95% CI 1.70-17.20, P=0.003) (McNally et al., 2012).  
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Feng et al. performed a randomised controlled trial on 86 adult patients undergoing 
liver transplantation to determine whether the experiences from liver resections could 
be applied to liver transplantation. The patients were either allocated to a control group 
(which received standard care) or a low central venous pressure (CVP) group. In the 
low CVP group, CVP was maintained at 5 mmHg or 40% lower than baseline during 
the preanhepatic phase. This was achieved by the administration of somatostatin and 
nitroglycerine infusions, manipulating the patients posture (with a 5-10 degree reverse 
Trendelenberg patient positioning) and limiting intravenous fluid administration. In the 
low CVP group there was a significant (P<0.05) decrease in intraoperative blood loss 
(1922 ± 1429 mL versus 3111 ± 1933 mL). They also found that the patients with low 
CVP had lower lactate levels at the conclusion of the liver transplant procedure (5.9 ± 
3.0 mmol/L vs 7.2 ± 3.0 mmol/L, P<0.05) and lower mean arterial pressure two hours 
after the start of the transplant (74 ± 11 mmHg vs 84 ± 14 mmHg, P<0.05) compared 
with the control patients. Despite the lower central venous pressure and mean arterial 
pressure, there was no significant change in perioperative renal function and 
postoperative complications (Feng et al., 2010). Although the sample size of the study 
was small, the results are supported by subsequent studies (Massicotte et al., 2012).  
Massicotte et al. conducted a retrospective cohort study of 503 orthotopic liver 
transplantation procedures and confirmed that patients with lower central venous 
pressures had less bleeding during orthotopic liver transplantation. The decreased 
administration of intravenous fluids and maintenance of low CVP, particularly during 
the dissection phase, were important factors associated with reduced intraoperative 
bleeding in orthotopic liver transplantation. In the group of patients who did not receive 
any blood products, the mean central venous pressure just before clamping the vena 
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cava was 7 mmHg compared to 14 mmHg in the group who received blood transfusion 
products (Massicotte et al., 2012). 
In summary, the maintainence of a low CVP during liver transplantation is an effective 
strategy for reducing blood loss and transfusion requirements during liver 
transplantation. This is supported by data from both retrospective studies and 
randomised controlled trials.    
 Complications of transfusion 
Blood product transfusion, especially massive transfusion, are associated with 
adverse outcomes in orthotopic liver transplantation, including: infection, graft versus 
host disease, immunosuppression, increased mortality, systemic inflammatory 
response syndrome, acute lung injury and thrombotic complications (Avkan-Oguz et 
al., 2013, de Boer et al., 2008, O'Brien et al., 2013, Pereboom et al., 2009). Electrolyte 
abnormalities such as hypocalcaemia and hypomagnesaemia may occur with massive 
transfusion as citrate is added to stored blood to bind calcium and prevent clotting. It 
remains uncertain whether blood transfusion products are an independent risk factor 
of negative postoperative outcomes, or if they are simply a marker of more difficult 
surgery.  
 Infection 
Bacterial infections are the major cause of mortality and morbidity following liver 
transplantation and are also one of the most common complications. In a retrospective 
study of 367 adult patients undergoing liver transplantation Avkan-Oguz et al. reported 
that the risk factors for early bacterial infection (within 30 days) of orthotopic liver 
transplantation included deceased donor, a Model for End Stage Liver Disease 
(MELD) score >20, albumin level <2.8g/dL, intraoperative red blood cell transfusion 
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>6 Units, intraoperative fresh frozen plasma >12 units, biliary-enteric anastomosis, 
postoperative intensive care unit stay >6 days, and postoperative length of stay >21 
days (Avkan-Oguz et al., 2013).  
In a retrospective analysis of 207 patients, Li et al. identified intraoperative red blood 
cell transfusion >6 Units as a risk factor for fungal infection following orthotopic liver 
transplantation (Li et al., 2012b). They found that the lung was the most common site 
for both bacterial and fungal infections following liver transplantation. Recipient age 
greater than 45 years, preoperative hyponatraemia (defined as serum sodium <130 
mEq/L), intensive care unit stay longer than 9 days, postoperative bile leak (defined 
as bilirubin concentration in drains greater than plasma level) and severe 
hyperglycaemia (defined as >11.1mmol/L) were also identified as independent risk 
factors for post-transplant bacterial infection. 
In summary, intraoperative transfusion of greater than six units of red blood cells 
during liver transplantation surgery is associated with an increased infection risk. A 
prolonged duration of intensive care unit / hospital stay, MELD score greater than 20, 
hypoalbuminaemia <2.8g/dL, recipient age greater than  45 years, preoperative 
hyponatraemia <130 mEq/L and the intraoperative transfusion of greater than 12 units 
of fresh frozen plasma were also identified as risk factors for postoperative infection 
following liver transplantation.  The mechanism underlying the association between 
blood product transfusion and postoperative infection is unknown. 
 Alternatives to transfusion 
 Cell salvage  
Intraoperative cell salvage is a method of autotransfusion where red blood cells are 
recycled during surgery. It is used extensively in liver transplantation as well as cardiac 
43 
 
and trauma surgery (Vanderlinde et al., 2002). Suction apparatus is used to harvest 
blood lost during surgery which then undergoes filtration, washing and centrifugation. 
A sufficient volume of blood must be collected before being processed (usually greater 
than 500mL, depending on the apparatus). The salvaged red blood cells are 
resuspended at a haematocrit between 50 to 70% in normal saline. This suspension 
is then reinfused into the patient. Since it is an autologous form of blood, adverse 
effects of allogeneic donor blood (such as infection and febrile reactions) are avoided 
(Kuppurao and Wee, 2010).  
Cell salvage is generally contraindicated in the presence of malignancy or infection. 
The cell salvage technique has been widely used to reduce and in some cases avoid 
the need for blood transfusion (Detry et al., 2005, Jabbour et al., 2005, Massicotte et 
al., 2005a). A Cochrane systematic review of 75 trials (36 orthopaedic, 33 cardiac and 
six vascular] by Carless et al found that cell salvage reduced allogeneic blood 
transfusion requirements by 38% (RR = 0.62, 95% CI = 0.55 to 0.70). This equated to 
a mean red blood cell usage reduction of 0.68 units of allogeneic red blood cells in 
patients who underwent surgery utilising cell salvage techniques when compared to 
the control group (Carless et al., 2010). The investigators found no significant 
difference in outcomes between the two groups. The outcomes measured in this study 
included return to theatre for bleeding, blood loss, post-operative complications 
(thrombosis, infection, acute myocardial infarction and renal failure), mortality and 
duration of hospital stay. While this systematic review included a large number of trials, 
many of the trials had a small sample size. This made the review vulnerable to the 
effects of publication bias due to heterogeneity. Trials with a small sample size may 
show larger treatment effects in a meta-analysis and have a lower methodological 
quality (Sterne et al., 2000). A funnel plot revealed the absence of negative studies 
44 
 
associated with cell salvage which suggested a potential for publication bias. Only one 
of the 75 studies reported a method of concealing the treatment and control groups 
and so there was a high risk of bias in the majority of the studies included in the review. 
It is unclear whether the findings by Carless et al. can be applied to liver 
transplantation. 
A Cochrane systematic review of the methods used to decrease blood loss in liver 
transplantation by Gurusamy et al. identified cell salvage as a potential technique to 
reduce blood loss in liver transplantation. However none of the included studies 
analysed data on the efficacy of cell salvage in reducing blood requirements 
specifically in the setting of liver transplantation (Gurusamy et al., 2011b). Massicotte 
et al. in a single centre analysis of the efficacy of cell salvage in liver transplantation 
failed to demonstrate a reduction in blood product transfusion requirements 
(Massicotte et al., 2007). Despite cell salvage being useful in reducing blood product 
transfusion requirements in other types of surgery, there is a lack of evidence 
supporting the applicability of cell salvage in reducing transfusion requirements in liver 
transplantation. 
The disadvantages of using cell salvage include the high costs of equipment and 
consumables associated with the technique.  The complications of cell salvage include 
haemolysis and raised amounts of free haemoglobin, which may cause renal 
impairment. Another potential complication is ‘salvaged blood syndrome’. This 
involves the activation of intravascular coagulation with an associated increase in 
capillary permeability. Deposits of platelet cellular aggregates are formed when 
salvaged blood is diluted in a large volume of saline in a centrifuge bowl (Bull and Bull, 
1990). These aggregates along with activated leukocytes contaminate the 
suspension, causing acute lung injury and renal failure. 
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 Erythropoietin 
Erythropoietin is used to increase haemoglobin levels in patients with severe anaemia. 
It is used preoperatively to optimise haemoglobin before surgery and increase 
production of red blood cells in the postoperative period. Jabbour et al. reported the 
use of erythropoietin in orthotopic liver transplantation in a case series of 27 Jehovah’s 
Witness patients (Jabbour et al., 2005). Erythropoietin (20,000 units subcutaneously 
twice a week or 40,000 units once a week), iron sulphate and folic acid were 
administered to these patients in the preoperative period until a haematocrit of 45% 
was achieved. Most of the patients reached the target haematocrit level within two 
months. Jabbour et al. reported the relative success in their study with 25 of 27 patients 
(93%) surviving to one year. There were 19 patients undergoing living donor 
transplantation and eight deceased donor transplants. The two recipient patients who 
died were from the deceased donor group. It was found that the recipients who 
received deceased donor liver transplantation had less optimisation of haemoglobin 
levels in the preoperative period which may have led to increased mortality. Both of 
the patients in this series who died had kidney disease and were relatively resistant to 
erythropoietin. 
Erythropoietin is not used routinely because there is a lack of demonstrated benefit in 
critically ill patients and there are associated risk of thrombotic complications 
(Zarychanski et al., 2007). It may be of benefit in patients who are unwilling to receive 
blood products (eg. Jehovah’s Witnesses). 
 Acute normovolemic haemodilution 
Acute normovolemic haemodilution is a technique where whole blood is removed from 
the patient shortly before or after the induction of anaesthesia. Circulating volume is 
maintained with crystalloid (in the ratio of 2 to 3 mL for every 1 mL of blood removed) 
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or colloid fluid (in the ratio of 1 mL for every 1 mL of blood removed) (Monk, 2005). 
The removed blood is reinfused as required during surgery. The use of acute 
normovolemic haemodilution reduces haematocrit levels before blood loss. During 
bleeding, fewer red blood cells are lost as a result of this technique. Precautions to the 
technique include patients with haemoglobinopathies (including sickle cell disease), 
active ischaemic cardiac disease and renal failure. It is contraindicated in patients with 
preoperative haemoglobin levels of less than 70g/L (Shander and Rijhwani, 2004).  
Jabbour et al. described the use of acute normovolemic haemodilution in an 
observational study of “transfusion free” orthotopic liver transplantations (Jabbour et 
al., 2005). Nineteen living donor and six deceased donor liver transplant recipients 
underwent acute normovolemic haemodilution. In the living donor recipients, 3.4 units 
of red cells were obtained for acute normovolemic haemodilution, while in the 
deceased donor recipients 2.3 units of red cells were obtained. All of the living donor 
recipients survived (mean follow up of 965 days), while two of the deceased donor 
recipients died (one died intraoperatively from acute graft failure and the other from 
acute anaemia on the second postoperative day).  
There is controversy regarding the efficacy of acute normovolemic haemodilution to 
reduce blood transfusion requirements. A meta-analysis of 24 trials (containing 1218 
patients from predominantly cardiac and orthopaedic cases) by Bryson et al. found 
that acute normovolemic haemodilution reduced the requirement for allogeneic red 
blood cell transfusion by a weighted mean difference of 2.22 units (95% CI:  -3.57 to -
0.86). However the investigators identified poor study design (grouping results from 
different types of surgical procedures and inconsistent amounts of blood withdrawn in 
the preoperative period) that would have led to bias in the results. When the studies 
that were conducted with protocol driven perioperative transfusion were analysed, 
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acute normovolemic haemodilution did not confer a statistically significant benefit 
(weighted mean difference: - 0.25 units, 95% CI:  -0.60 to 0.10) (Bryson et al., 1998).  
A meta-analysis by Segal et al. evaluated 42 trials from cardiac, orthopaedic, 
urological and liver surgery (containing 2233 patients) between 1972 and 2002.  The 
investigators found that the mean volume of allogeneic blood transfusion was 303mL 
lower in the group which had received acute normovolemic haemodilution compared 
with the control group (95% CI: 55 to 551 mL, Q = 862, p < 0.001). No significant 
benefit was found with use of acute normovolemic haemodilution in avoiding 
transfusion compared to standard care (relative risk: 0.96, 95% CI: 0.90 to 1.01) (Segal 
et al., 2004).  
Jarnagin et al. conducted a prospective randomised controlled trial to investigate the 
effects of acute normovolemic haemodilution in patients undergoing major (three or 
more segments) hepatic resection. They analysed data for 130 patients between April 
2004 and March 2007 (63 patients randomised to receive acute normovolemic 
haemodilution while 67 randomised to receive standard care). A strict protocol of 
thresholds was used to guide transfusion in the study. One patient (1.6%) in the acute 
normovolemic haemodilution group received intraoperative allogeneic blood 
transfusion compared with seven patients (10.4%) in the standard treatment group 
(P=0.036). During the overall patient stay, acute normovolemic haemodilution reduced 
the proportion of patients requiring allogeneic red blood cell transfusion, with 12.7% 
(n=8) requiring red blood cells in the acute normovolemic haemodilution group 
compared with 25.4% (n=17) in the standard treatment arm. In patients with increased 
intraoperative blood loss (in excess of 800mL), acute normovolemic haemodilution 
was associated with a reduced proportion of patients receiving fresh frozen plasma 
administration (21.1% compared to 43.3% in the standard treatment arm, P = 0.025) 
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(Jarnagin et al., 2008). The main limitation of the study was that it was underpowered, 
despite it being a prospective randomised controlled trial in patients undergoing liver 
resection. 
Although acute normovolemic haemodilution is a method for reducing intraoperative 
transfusion requirements, it is rarely practiced within liver transplantation because of 
underlying thrombocytopenia, coagulopathy, anaemia and haemodynamic instability 
in the recipients.  
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 Predictors of Mortality 
The causes of mortality associated with the transfusion of blood products include 
haemolytic reactions, transfusion related acute lung injury and infectious 
complications (Webster, 2017). 
Various predictors of patient mortality following liver transplantation have been 
identified. Rana et al. found that transfusion of ≥28 units of packed red blood cells was 
associated with increased mortality following liver transplantation. However they did 
not adjust for MELD score in their multivariate analysis (Rana et al., 2013). De Boer 
et al. also reported an association between increased patient mortality at one-year 
following liver transplantation and the transfusion of packed red cells and platelets (de 
Boer et al., 2008). These effects will be discussed in section 1.9 (page 52).  
Kleine et al. developed a model to predict 3-month mortality following liver 
transplantation. They identified the following factors for increased postoperative 
mortality: MELD score >30, FFP transfusion >13.5 units, acute respiratory distress 
syndrome (defined in their study as a partial pressure of arterial oxygen / fraction of 
inspired oxygen ratio <200 mmHg), packed red cell transfusion  >10.5 units, 
preoperative mechanical ventilation, preoperative dialysis and donor graft steatosis 
>40% (Kleine et al., 2013). A weakness of this model is that it was derived from a 
single centre cohort and is unlikely to be applicable to other liver transplant centres 
due to differences in patient characteristics and clinical practice.  
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 Predictors of Graft Survival 
The factors that have been identified to have effect on liver graft survival are related 
to the quality of the donor graft. These include the donor risk index and degree of graft 
steatosis. 
 Donor risk index 
The donor risk index was a concept proposed by Feng et al. (Feng et al., 2006). It was 
a quantitative index utilising risk factors associated with graft failure following 
orthotopic liver transplantation. This index was derived from data collected from 20023 
transplants from deceased liver donors in the United States between 1998 and 2002. 
The index was then validated against data from 9882 deceased liver donors from 2002 
to 2003. 
Within the liver graft donor risk index, the factors included were donor age, donor race, 
donor height, cause of death, split or partial liver graft, donor height, donor location 
(local/regional/national) and cold ischaemic time. The amalgamation of these factors 
allows for a prediction of relative risk of graft failure for each donor liver graft as 
compared with the ideal donor. 
As these factors will confound the analysis of the effect of perioperative blood product 
transfusion on graft survival following liver transplantation, it is important to control for 
these in the statistical analysis. One of the limitations of this index is that was 
developed from a cohort of patients with demographic characteristics different from 
our patient population.  
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 Steatosis 
The degree of macrosteatosis has been associated with poorer graft survival (de Graaf 
et al., 2012).This finding was not supported by another large study (Feng et al., 2006). 
However due to the lack of differentiation in their data set between macrosteatosis and 
microsteatosis in a large subset of their patients, Feng et al. stated that their data may 
be underpowered to detect an association between macrosteatosis and liver graft 
failure. 
Additionally, the assessment of donor graft steatosis can be subjective (Fiorini et al., 
2004). This may account for the differences in findings between different transplant 
centres. 
 Donation after cardiac death 
The use of donation after cardiac death (DCD) liver grafts is associated with a higher 
incidence of graft failure following transplantation. The hazard ratio of DCD liver grafts 
compared with donation after brain death (DBD) grafts is 1.7 (P<0.001) (Blok et al., 
2016). Graft failure following DCD liver transplantation is associated with 
complications such as primary non-function and biliary ischaemia. 
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 Effects of specific blood products 
 Packed red blood cells 
Packed red blood cells are the most common transfused component of blood within 
orthotopic liver transplantation. Cacciarelli et al.  performed a retrospective study of 
225 adult patients who underwent primary liver transplantation between January 1992 
and December 1994. The patients were divided into two groups: (a) those who had 
received no packed red blood cell transfusion during transplantation (54 patients, 24% 
of total), and (b) those who had received transfusion of at least one unit of packed red 
blood cells during transplantation (171 patients, 76% of total). Using univariate 
analysis, they reported that the transfusion of 5 or more units of packed red blood cells 
was associated with decreased graft (P=0.01) and patient survival (P=0.006). The 
patient and graft survival rates at one year decreased by greater than 15% in patients 
who had received 5 or more units of packed red blood cells compared with those who 
had not received any blood transfusion. However, other factors such as male gender 
and severity of the patient’s medical condition (measured by admission to the intensive 
care unit) had a greater negative impact on survival. Overall patient survival in this 
study was 90% at 1 year and 86% at 3 years. Overall graft survival was 89% at 1 year 
and 85% at 3 years. These overall survival rates are comparable to other centres (de 
Boer et al., 2008, Pereboom et al., 2009). On multivariate analysis, only patient age, 
gender and severity of patient’s medical condition were associated with patient and 
graft survival (Cacciarelli et al., 1999). 
De Boer et al. also reported that intraoperative transfusion of packed red blood cells 
was associated with an increase in mortality following orthotopic liver transplantation 
(de Boer et al., 2008). The investigators conducted a retrospective study orthotopic 
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liver transplantation patients between January 1, 1989 and December 31, 2004. 
During this period 749 orthotopic liver transplants were performed. Repeat transplants, 
paediatric patients and combined organ transplantations were excluded from the 
study. A total of 433 adult patients were included in the study. The patients were 
followed up until the September 1, 2005. They found that the proportion of patients 
who received transfusion of blood products decreased in the period from 1989-1996 
when compared with the period 1997-2004 (100% of patients vs 74% of patients 
respectively). The one and five year patient survival rates were 84% and 76% 
respectively. The patients were divided into three groups: patients who had received 
no red blood cell transfusion, those who had received one to six units, and those who 
had received greater than six units of packed red blood cells. At 12 months the survival 
rates were 88%, 86% and 78% respectively. Using univariate analysis, the variables 
that were associated with a negative effect on both 1 year and 5 year patient survival 
were: the indication for transplantation (which was further stratified into: biliary 
cirrhosis, postnecrotic cirrhosis, acute liver failure, metabolic disease and 
miscellaneous), Karnofsky score, Child Turcotte Pugh (CTP) score, MELD score, cold 
ischaemic time, red blood cell units, fresh frozen plasma and platelets. De Boer et al. 
then used a multivariate Cox regression model to analyse all variables with a P value 
<0.10. From this model, three variables were predictors of 1 year patient survival. 
These were (a) indication for transplant (P=0.020), (b) allogeneic red blood cell units 
(HR 1.055, 95% CI 1.036 to 1.076, P<0.001) and (c) number of platelet units (HR 
1.359, 95% CI 1.064 to 1.736, P=0.014). The independent predictors of 5 year survival 
after multivariate cox regression analysis were allogeneic red blood cell units (HR 
1.047, 95% CI 1.028 to 1.067, P=0.001), platelet units (HR 1.429, 95% CI 1.166 to 
1.751, P=0.001), cold ischaemic time (HR 0.494, 95% CI 0.315 to 0.776, P=0.002) 
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and era of transplantation (HR 0.515, 95% CI 0.315 to 0.843, P=0.008). A secondary 
multivariate analysis comparing RBC transfusion with the Karnofsky score and the 
MELD score to control for disease severity, showed that the intraoperative red blood 
cell transfusion was also implicated in decreasing patient survival rates with a hazard 
ratio of 1.055 per unit transfused (P<0.001) at one year and a hazard ratio of 1.047 
per unit (P=0.001) at five years.  A multivariate analysis of 1 year graft survival found 
that red blood cell transfusion, the indication for transplant, and graft type were 
independent risk factors. Red blood cell transfusion, the indication for transplantation, 
graft size and cold ischaemic time were the independent risk factors for 5 year graft 
survival. The statistical analysis conducted by De Boer et al. attempted to control for 
confounding factors such as the increased administration of red blood cells and 
platelets being associated with sicker patients. Their data demonstrated strong 
association between increased patient mortality and transfusion of both red blood cells 
and platelets. As their study was retrospective in nature, it is difficult to determine 
causality. They commented on the ethical issues involved in conducting a randomised 
controlled trial in orthotopic liver transplant patients due to the critical severity of illness 
in such patients and the lack of suitable alternatives to platelet transfusion. As the 
investigators did not have access to storage time of red blood cells or other blood 
products, the effect of storage time of blood products on patient survival and other 
clinical outcomes was not studied. 
In the study mentioned earlier, Rana et al. supported the association between red 
blood cell transfusion and increased mortality. Using multivariate Cox regression 
analysis, they showed that intraoperative red blood cell transfusion of greater than or 
equal to 28 units was a significant risk factor for mortality (odds ratio 2.5, 95% CI 1.3 
to 4.7, P=0.02) (Rana et al., 2013). On multivariate analysis, hepatocellular carcinoma 
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was the only other variable that was associated with decreased patient survival (odds 
ratio 1.8, 95% CI 1.03 to 3.0, P = 0.004). 
Massicotte et al. also demonstrated a decreased one year survival associated with 
packed red blood cell transfusion. The one year survival was 86.6% in the group which 
received one to four units of packed red blood cells, and 62.5% in the group receiving 
more than four units of packed red blood cells (P=0.002). This is in contrast to a 97.4% 
one year survival for patients who received no blood products (Massicotte et al., 
2005b). The investigators highlighted that their study fulfilled a number of criteria for 
causality including: temporal association, biological plausibility, the presence of a dose 
effect relationship, strength of association, consistency and specificity. However, their 
study was retrospective and as such it is difficult to establish a causal relationship 
between red blood cell transfusion and decreased one year survival. Other 
confounding factors include a variety of immunosuppressant medications used in the 
cohort including prednisone, azathioprine, tacrolimus, cyclosporine and basiliximab. 
The small sample size and a lack of transfusion guidelines were other weaknesses of 
the study. 
Li et al. in a retrospective cohort study of 181 patients studied the outcomes in patients 
which received transfusion of six or greater units of packed red cells compared with 
patients receiving <6 units of packed red blood cells. There were 84 patients in the 
group that received ≥6 units of packed red blood cells and 97 in the group that received 
less than six units. Postoperative infections were observed in 17 of the 84 (20.2%) 
patients which received ≥6 units of packed red cells. This was in comparison to 9 of 
the 97 (9.3%) patients in the group which received < 6 units of packed red blood cells. 
The duration of stay in the intensive care unit was increased in the group of patients 
which received ≥6 units of packed red cells (352.51 ± 47.13 h vs 325.59 ± 43.16 h, P 
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< 0.0001). The survival rates at one, three and five years were significantly decreased 
(P=0.036) in the group that received ≥6 units of packed red cells compared with the 
group receiving less than six units (77%, 73%, 69% vs 89%, 85%, 85% respectively) 
(Li et al., 2012a). The limitations of this study were small sample size (n=207) and 
retrospective analysis. 
A retrospective multivariate analysis of 155 orthotopic liver transplantations by 
Wiederkehr et al. confirmed an association between transfusion of packed red blood 
cells and mortality. When packed red blood cells were transfused, the mortality was 
increased by 17.08% compared with the group which received no packed red blood 
cell transfusion. A higher MELD score was also associated in a higher postoperative 
mortality. Wiederkehr et al. found no significant increase in mortality with transfusion 
of cell salvaged blood, platelets and fresh frozen plasma (Wiederkehr et al., 2010). 
In a retrospective cohort study of 803 orthotopic liver transplant patients between 
January 2004 and June 2009, Chen et al. found no adverse postoperative outcomes 
associated with the transfusion of red blood cells older than 14 days (Chen et al., 
2012). However, they showed that transfusion of red blood cells stored for a longer 
period of time was associated with intraoperative hyperkalaemia (defined as a serum 
potassium greater than or equal to 5.5 mmol/L). During the pre-reperfusion phase, the 
incidence of hyperkalaemia in patients receiving red blood cells older than 14 days 
compared with those who received red blood cells less than 14 days old was 18.1% 
vs 10.2%. During the late post-reperfusion phase the incidence of hyperkalaemia was 
9.0% in the group receiving red blood cells older than 14 days and 3.9% in the group 
receiving red blood cells less than 14 days old. 
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Transfusion associated graft versus host disease is a rare but serious complication of 
blood transfusion. It occurs when a transfusion recipient’s immune system fails to 
recognise donor T lymphocytes as foreign and these proliferate, eventually targeting 
the skin, liver, gastrointestinal system and marrow. Four case reports of transfusion 
associated graft versus host disease in solid organ transplant recipients have been 
identified in the literature (O'Brien et al., 2013). Three of the cases of transfusion 
associated graft versus host disease received blood from HLA haplotype A1 B8 
homozygous donors. The authors suggested that there was an association between 
transfusion associated graft versus host disease and red blood cell transfusion from 
HLA haplotype A1 B8 homozygous donors.  
 Fresh frozen plasma 
The administration of fresh frozen plasma during liver transplantation has been 
associated with increased mortality and morbidity. In a retrospective study of 206 
orthotopic liver transplants by Massicotte et al., the transfusion of fresh frozen plasma 
was associated with packed red blood cell transfusion and decreased one year 
survival (Massicotte et al., 2005b). In this study, the one year survival in patients who 
received no blood products was 97.4% compared with 76.9% in the patients who had 
received fresh frozen plasma. The one year survival in patients who received one to 
four units of fresh frozen plasma was 81.6% (P = 0.038), whereas in the patients who 
received more than four units of plasma the one year survival was 75.6% (P=0.002). 
This demonstrated an association between decreased one year survival and 
increased transfusion of fresh frozen plasma during orthotopic liver transplantation.  
In a prospective study of 200 liver transplantations, Massicotte et al. also 
demonstrated a decrease in packed red blood cell transfusion with the avoidance of 
plasma products. The authors estimated that for every unit of fresh frozen plasma 
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received, the risk of receiving a red blood cell transfusion was increased by 15 times 
(Massicotte et al., 2008).  
Lebron Gallardo et al. in a retrospective study of 245 liver transplants identified a 
relationship between transfusion of fresh frozen plasma and early postoperative renal 
dysfunction in orthotopic liver transplant patients on univariate analysis (Lebron 
Gallardo et al., 2004). The patients who developed early renal dysfunction received 
mean of 3.2 ± 2.06 litres of fresh frozen plasma compared to 2.41 ± 1.43 litres in the 
patients who did not develop early renal dysfunction (P=0.001) (defined as a serum 
creatinine greater than 1.5 mg/dL within three months of liver transplantation). 
Multivariate analysis showed that preoperative serum creatinine, amount of transfused 
packed red blood cells, Acute Physiology and Chronic Health Evaluation II score, and 
postoperative infection were predictors of early renal dysfunction. 
In summary, the transfusion of fresh frozen plasma has been associated with 
decreased one year survival following liver transplantation in a single study. Fresh 
frozen plasma administration has been associated with postoperative renal 
dysfunction on univariate analysis, however this association was not observed on 
multivariate analysis. 
 Platelets 
A number of studies have identified significant clinical effects with the use of platelet 
transfusion during liver transplantation. Two different types of platelets are used 
worldwide: units manufactured from pooled donors and units derived from single 
donors. In the United States platelets from a single donor are most commonly used, 
while in Europe pooled platelets are more common. 
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In a retrospective study of 433 adult patients (previously mentioned in section 1.7.1), 
De Boer et al., using multivariate analysis, demonstrated an association between the 
intraoperative transfusion of platelets and decreased survival (de Boer et al., 2008). 
As disease severity is a potential confounding factor, the authors used Karnofsky 
score and MELD score to minimise the effect of disease severity on transfusion 
requirements. The hazard ratio for each unit of platelets transfused was 1.359 
(P=0.014) for 1 year survival and 1.429 (P=0.001) for 5 year survival. The 12 month 
survival rate was 89% in patients who had received no platelet transfusion, 76% in 
patients who had received one to two units, and 55% in patients who had received 
greater than two units of platelets. The platelets used in the study by De Boer et al. 
were pooled from five donors and their conclusions may not be applicable to centres 
in which single donor platelets are used. 
Pereboom et al. suggested that patients who had received pooled platelet transfusions 
had an increased mortality rate as a result of acute lung injury compared with those 
who had not (4.4% vs 0.4%; P=0.004). The patients who had received platelet 
transfusion had an increased mortality but there was no increase in graft failure 
(Pereboom et al., 2009). Acute lung injury contributed to the deaths of nine patients in 
their study. Eight patients received platelets and one patient did not receive platelet 
transfusion. The incidence of transfusion related acute lung injury has been reported 
to be 1 in 4000 units to 1 in 12000 transfused units (Toy et al., 2012). Although this 
study analysed 449 patients, the study was underpowered to assess a statistical 
difference in mortality from acute lung injury because of the low incidence of 
transfusion related acute lung injury. 
Nixon et al. suggested that the increased mortality from platelet transfusion was a 
result of using pooled platelets derived from four to six donors in transfusions (Nixon 
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et al., 2009). No dose related increase in mortality was associated with platelets 
derived from single donors. Survival rates at one year for their cohort were 95.8%, 
93.0%, and 93.8% for the groups receiving 0, >0-2 and >2 units of platelets 
respectively. The use of platelets derived from apheresis (single donor) and 
leucodepletion in transfusions reduced the incidence of adverse patient outcomes 
following liver transplantation. Further details of their data were not provided. 
Li et al. in a retrospective analysis of 181 living donor transplant patients investigated 
the effect of platelet transfusion on survival rates. In this study, 53 patients received 
platelet transfusion. These patients were divided into two groups: those who received 
greater than two platelet units and those who received two or less. Ten patients 
received greater than two units of platelets. No significant differences in the survival 
rate at one, three or five years were found between the groups (P=0.599) (Li et al., 
2012a). However, the authors did not specify whether pooled or unpooled platelets 
were used. 
In summary, there is considerable controversy regarding the effect of platelet 
transfusion on survival and patient outcomes in liver transplantation. The original study 
by De Boer et al. that reported adverse outcomes associated with platelet transfusion 
have been disputed by several later studies (Chin et al., 2014, Li et al., 2012a). Current 
literature suggests that the increased mortality and morbidity associated with platelets 
may be linked with the use of pooled platelets that can trigger adverse immune 
reactions. While there are many studies on the adverse effects of packed red blood 
cell transfusion, further studies on the effect of platelets are required. 
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 Cryoprecipitate 
Cryoprecipitate contains concentrated quantities of factor VIII, factor XIII, fibrinogen, 
vWF and fibronectin and is administered to correct low fibrinogen levels during liver 
transplantation. There is a scarcity of research examining the effects of cryoprecipitate 
transfusion on outcomes in liver transplantation. A single study was identified in the 
literature review. 
Liu et al. in a retrospective cohort study of 356 liver transplant patients with one year 
follow-up found that intraoperative cryoprecipitate transfusion was associated with a 
relative risk of 3.46 for biliary complications after liver transplantation (95% CI [1.72–
6.97], P,0.001). Biliary complications were defined as a 2-fold increase of serum 
bilirubin greater than normal levels, that were sustained for at least one week and 
occurred within the first year after liver transplantation. The final diagnosis was 
confirmed using magnetic resonance cholangiopancreatography, percutaneous 
transhepatic cholangiography, endoscopic retrograde cholangiopancreatography, 
liver biopsy or intraoperative visualisation.  Biliary complications contribute 
substantially to graft failure and the need for repeat transplantation following liver 
transplantation. Other factors that were found to predict biliary complications included 
a cold ischaemia time greater than eight hours and a high Child-Pugh score. Liu et al. 
postulated that the biliary complications associated with cryoprecipitate administration 
in liver transplantation were caused by micro thrombus formation and immune 
rejection of the graft (Liu et al., 2013). Although an increase in biliary complications 
was identified, Liu et al. did not examine whether cryoprecipitate transfusion was 
associated with decreased graft survival following liver transplantation. 
While an increased incidence of biliary complications has been identified in patients 
who received cryoprecipitate transfusion in one study, no association between the 
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administration of cryoprecipitate and decreased patient or graft survival in liver 
transplantation has been established.  
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 Aim of thesis 
  Study objectives 
  Primary Objective: 
The primary objective of the study was to determine the association between blood 
product transfusion and patient mortality and graft survival following orthotopic liver 
transplantation.  
 Primary Hypothesis One: 
Patients who received perioperative blood product transfusion have an increased all-
cause mortality at one and five years following orthotopic liver transplantation 
compared with patients who did not receive perioperative blood product transfusion. 
 Primary Hypothesis Two: 
Patients who received perioperative blood product transfusion have an increased graft 
failure rate at one and five years following orthotopic liver transplantation compared 
with patients who did not receive perioperative blood product transfusion. 
 Secondary objectives 
The secondary objectives of this study were to determine whether blood product 
transfusion was associated with the incidence of acute renal impairment, requirement 
for dialysis, infection, duration of hospital stay, duration of intensive care unit stay, and 
duration of endotracheal intubation following orthotopic liver transplantation. 
 Secondary Hypothesis One: 
Patients receiving perioperative blood product transfusion have an increased 
incidence of acute renal impairment and requirement for dialysis following orthotopic 
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liver transplantation compared with patients who did not receive perioperative blood 
product transfusion. 
 Secondary Hypothesis Two: 
Patients receiving perioperative blood product transfusion have an increased 
incidence of infection following orthotopic liver transplantation compared with patients 
who did not receive perioperative blood product transfusion. 
 Secondary Hypothesis Three: 
Patients receiving perioperative blood product transfusion have an increased duration 
of hospital and intensive care unit stay following orthotopic liver transplantation 
compared with patients who did not receive perioperative blood product transfusion. 
 Secondary Hypothesis Four: 
Patients receiving perioperative blood product transfusion have an increased duration 
of endotracheal intubation following orthotopic liver transplantation compared with 
patients who did not receive perioperative blood product transfusion. 
 What this thesis adds to current research 
To date, no studies have been published examining the effect of blood product 
transfusion in liver transplant patients in the Australian liver transplantation population. 
In previous international studies, the effects of packed red blood cells and fresh frozen 
plasma have been studied, but there is a scarcity of data examining the effects of 
platelets or cryoprecipitate. This thesis assesses the consequences of blood product 
transfusion within both the intraoperative and the postoperative period (48-hour 
postoperative period) on outcomes following liver transplantation. Previous studies 
were limited to the effect of intraoperative transfusion.  
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 GENERAL METHODS 
 Ethics Approval 
The study protocol was submitted to the Royal Prince Alfred Hospital Ethics 
Committee, in agreement with local research regulations. Approval was obtained from 
the Royal Prince Alfred Hospital Human Research Ethics Committee (Protocol No 
X12-0024 & HREC/12/RPAH/34). The University of Sydney Human Research Ethics 
Committee were informed of the research and a copy of the Royal Prince Alfred 
Hospital ethics committee approval was submitted.  
 Study Design 
This was a single centre, retrospective cohort study conducted at the Royal Prince 
Alfred Hospital, Camperdown, Sydney, Australia. All orthotopic liver transplant 
procedures conducted at Royal Prince Alfred hospital between August 2002 and 
December 2011 were analysed as part of this study. Four hundred and seventy-four 
orthotopic liver transplant cases were recorded during this period. 
 Selection of patients 
The population of this study included all patients receiving a liver transplant from the 
14th of August 2002 to December 2011. There were 474 transplant procedures listed 
in the anaesthetic database during this period. This period of study was selected due 
to the establishment of the anaesthetic liver transplant database in August 2002. The 
anaesthetic database was a major source of data for this research project. A number 
of cases listed in the database did not proceed to completed orthotopic liver 
transplantation and they were excluded as described below.  
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Nine patients who received a combined liver and renal transplant were excluded from 
the analysis. Three liver transplant patients who died intraoperatively were also 
excluded from the analysis. Twenty-five patients who had received a previous liver 
transplant were excluded from the analysis. A further five cases were abandoned due 
to an unsuitable donor graft. After applying these selection criteria, the final number of 
patients included in the analysis was 434. 
 
Figure 1. Patient Flow Diagram for patients included in the study 
  
474 liver transplant 
patients
5 cases abandoned 
due to unsuitable 
donor graft
25 patients with 
previous liver 
transplant excluded
3 intraoperative 
deaths
434 patients in final 
analysis
9 combined renal 
transplant patients 
excluded
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 Inclusion criteria of patients receiving an orthotopic liver 
transplant 
The inclusion criteria for patients eligible for liver transplantation in this study were 
defined by the Transplantation Society of Australia and New Zealand liver recipient 
suitability criteria. These criteria included adult patients with chronic liver disease with 
life-threatening complications – primarily patients with a MELD score greater than 15. 
The other indications included: (a) liver disease with a greater than 50% two year 
mortality without liver transplantation, (b) ascites refractory to diuretic therapy, (c) 
recurrent hepatic encephalopathy, (d) recurrent spontaneous bacterial peritonitis, (e) 
recurrent or persisting gastrointestinal tract haemorrhage, (f) primary or secondary 
sclerosing cholangitis with intractable cholangitis, (g) hepatopulmonary syndrome, (h) 
mild portopulmonary hypertension (mean pulmonary artery pressures < 35 mmHg), (i) 
severe or life threatening metabolic syndromes curable with liver transplantation, (j) 
severe or life threatening polycystic liver disease and (k) acute liver disease unlikely 
to recover spontaneously (defined by the King’s College Hospital Criteria). The 
patients with hepatocellular carcinomas fulfilling the University of California San 
Francisco criteria were also accepted for liver transplantation (TSANZ, 2007, TSANZ, 
2011). 
 Exclusion criteria of patients receiving an orthotopic liver 
transplant 
Exclusion criteria for the eligibility of patients to receive a liver transplantation in this 
study were defined by the Transplantation Society of Australia and New Zealand liver 
recipient exclusion criteria. These include general conditions or circumstances that 
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result in a predicted post transplant survival rate less than 50% at 5 years preclude 
eligibility for liver transplantation. These exclusion criteria also included: prior or 
current malignancy (except for hepatocellular carcinoma meeting the University of 
California San Francisco criteria), active infection (except for Hepatitis B, Hepatitis C 
and HIV), coronary artery disease or cerebrovascular disease which is irremediable or 
associated with a poor prognosis,  severe metabolic syndrome, tobacco users, 
inadequate social support and patients with alcoholic liver disease who are unlikely to 
remain abstinent in the post transplantation period (concurrent social instability, less 
than 50 years of age, repeated cessation treatment failures, polydrug users and those 
with severe mental disorders). Patients with hepatopulmonary syndrome with arterial 
partial pressures of oxygen on room air less than 40 mmHg were not candidates for 
liver transplantation due to the high perioperative mortality rate. (TSANZ, 2007, 
TSANZ, 2011) 
 Study Interventions 
All blood products used during the perioperative period in this study were obtained 
through the Australian Red Cross Blood Service. 
 Packed Red Blood Cell transfusion 
Packed red blood cell components were produced by centrifuging whole blood and 
removing the plasma component. The packed red blood cells were filtered to remove 
leucocytes and suspended in a solution of saline, adenine, glucose and mannitol. The 
mean volume of one unit of packed red blood cells was approximately 260mL.  
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 Fresh Frozen Plasma transfusion 
The Fresh Frozen Plasma used in this study was prepared from either whole blood or 
apheresis plasma. The fresh frozen plasma units contained all coagulation factors and 
had a typical volume of 250 to 310mL. 
 Platelet transfusion 
The platelets used in this study were derived from either whole blood or apheresis. 
Each unit of platelets derived from whole blood were sourced from the buffy coats of 
a pool four ABO identical donors. Each unit of platelets derived through apheresis 
were sourced from a single donor. All platelet units were leucodepleted and irradiated. 
One unit of pooled platelets typically had a mean volume of 326mL whilst one unit of 
apheresis platelets typically had a mean volume of 180mL.  
 Cryoprecipitate transfusion 
The cryoprecipitate units used in this study were prepared by thawing fresh frozen 
plasma at a temperature between 1 and 6 degrees Celsius and recovering the 
precipitate. The precipitate fraction was then refrozen. Cryoprecipitate contains factor 
VII, fibrinogen, factor XIII, von Willebrand factor and fibrinectin. The typical mean 
volumes of each unit of cryoprecipitate derived from whole blood were 36mL whilst the 
typical mean volumes of each unit derived from apheresis were 61mL.  
 
 Definition of outcome measures 
 Mortality 
The date of death was recorded for all patients who had died as of the 1st of May 2014. 
The number of days between the orthotopic liver transplant date and the date of death 
was calculated. The causes of death were also recorded. 
71 
 
 Graft Failure 
The date of graft failure was recorded for all patients who had a graft failure event as 
of the 1st of May 2014. The number of days between the orthotopic liver transplant 
date and the date of graft failure was calculated. The cause of graft failure was also 
recorded. In patients who had a cause of death other than graft failure, these patients 
were censored for the purposes of graft survival analysis. 
 Acute Renal Impairment 
Acute renal impairment was defined as a 50% rise in baseline creatinine at 48 hours 
following orthotopic liver transplantation (using the 2007 Acute Kidney Injury Network 
(AKIN) criteria). As part of this definition, a serum creatinine rise of at least 26.5 umol/L 
(0.3mg/dl) was also classified as acute renal impairment even if a 50% rise in baseline 
serum creatinine was not achieved.  
 Dialysis 
Requirement for dialysis was defined as a need for renal replacement therapy post 
orthotopic liver transplantation. This was recorded if the patient received any form of 
renal replacement therapy in the postoperative period during the admission associated 
with the orthotopic liver transplantation. 
 Infection 
Infection was defined as any infective complication during the postoperative period 
and was recorded from hospital coding summaries from the admission associated with 
the orthotopic liver transplantation. 
 Duration of hospital stay 
The duration of hospital stay was calculated as the number of days from orthotopic 
liver transplantation to hospital discharge. The length of hospital stay was used as a 
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nonspecific marker of benefit or harm following transfusion of blood products in the 
liver transplant population. 
 Duration of intensive care unit stay 
The duration of intensive care unit stay was calculated as the number of days from 
orthotopic liver transplantation to intensive care unit discharge. The length of intensive 
care unit stay was used as a nonspecific marker of benefit or harm following 
transfusion of blood products in the liver transplant population. 
 Duration of endotracheal intubation 
The duration of endotracheal intubation was calculated as the number of hours from 
endotracheal intubation to extubation. The duration of endotracheal intubation was 
used as a surrogate marker of lung injury following transfusion of blood products in the 
liver transplant population. 
 Other Definitions 
 Previous major abdominal surgery 
Previous major abdominal surgery was defined as a previous abdominal surgery 
involving a laparotomy or open abdominal wound – eg. Open cholecystectomy, open 
appendicectomy.  
 Corrected body mass index 
The corrected body mass index was calculated by subtracting the volume of ascites 
(removed intraoperatively and measured within the suction apparatus) from the 
patient’s preoperative weight and recalculating the body mass index from this 
corrected weight. The corrected body mass index was calculated by the following 
formula: Corrected Body Weight = (Preoperative body weight – volume 
ascites)2/Height. It was assumed that 1000 millilitres of ascites were equivalent to 
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1000 grams. This method under estimates for the weight of ascites in each patient 
because the specific gravity of ascites in end stage liver disease is variable. The mean 
volume of ascites in our study was 1.6 litres. 
 Surgical Technique 
All patients underwent liver transplantation with either the “piggy back” technique or 
the “cross clamp” technique. One hundred and forty-seven patients underwent liver 
transplantation via the “piggy back” technique. Two hundred and sixty-three patients 
underwent liver transplantation via the “cross clamp” technique.  
 Data collection 
The data for these transplants were sourced from the Royal Prince Alfred Hospital 
anaesthetic liver transplant database, Royal Prince Alfred Hospital Liver Unit 
database, Royal Prince Alfred Hospital Intensive Care Service electronic medical 
records as well as paper anaesthetic charts and paper medical records. Each of these 
data sources were prospectively maintained at the time of orthotopic liver 
transplantation. 
The data fields collected from the RPA liver transplant unit database included: 
transplant number (ie. 1 for a first time transplant, 2 indicating a retransplant), degree 
of steatosis, transplant type (whole or split liver graft), operative time, graft total 
ischaemic time, graft warm ischaemic time, graft cold ischaemic time, donor type 
(donation after brain death or cardiac death), donor ABO blood group, donor age, 
donor sex, donor risk index, date of graft failure, cause of graft failure, date of patient 
death and cause of patient death. The adverse event data was also obtained outlining 
adverse events under the categories: abdominal, biliary system, cardiovascular, graft, 
haemopoietic, malignancy, neurological, other, renal, respiratory, infection, technical, 
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thromboembolic, vascular and wound events. Time to event were recorded in the 
number of days post transplantation as well as the management were also detailed. 
Survival times were calculated by determining the difference in the number of days 
from the date of liver transplantation to the date of liver graft failure or patient death. 
The follow up data to the 1st of June, 2014 was used in the analysis of outcomes for 
this study. 
The data fields collected from the RPA intensive care service electronic database 
included post-operative transfusions within the first 48 hours of orthotopic liver 
transplantation (including, packed red blood cells, fresh frozen plasma, platelets, 
cryoprecipitate), administration of Factor VIIa, the length of Intensive Care Unit stay in 
days, the duration of endotracheal intubation in hours, and the need to “return to the 
operating theatre” for operative intervention within 72 hours. The electronic records 
were available for liver transplantation cases from 2008 onward. For cases from 2002-
2007 the electronic records were unavailable due to a change in computer system in 
2008. The aforementioned data was collected from paper printouts from the ICU 
computer system which were included in the paper medical record files of each patient 
in this period. The blood transfusion records were checked against blood bank product 
dispensing record sheets and the anaesthetic record in the patient’s medical record 
files.  
At our institution, platelets are sourced from the Australian Red Cross Blood service. 
These were obtained from a pool from four identical ABO donors. As the platelet 
transfusions were sometimes recorded as 4 units instead of one pool of platelets in 
the anaesthetic transplantation database, the records were checked against the 
intraoperative anaesthetic charts and transfusion records. The corrected values were 
recorded as pools of platelets transfused. 
75 
 
The data from the Royal Prince Alfred anaesthetic liver transplant database were 
available for orthotopic liver transplant patients from the 14th of August 2002 onwards 
and is a prospectively maintained electronic database with details entered by liver 
transplant anaesthetists at the time of transplantation. The data that was sourced from 
this database included the following details: the preoperative albumin, ALP, ALT, AST, 
GGT, bilirubin, serum creatinine, CTP score, degree of encephalopathy, haemoglobin, 
HCO3, INR, APTT, fibrinogen level, MELD score, PCO2, pH, Platelet level, PO2, 
Hepatitis B and C status, serum sodium levels. The transplant variables that were 
collected included: date of transplant, patient age, indication for transplant, 
intraoperative transfusion (units of transfused cryoprecipitate, FFP, Packed red blood 
cells, platelets, anaesthetist, surgeon, surgical technique (X-Clamp, Piggy Back, 
VVB), degree and volume of ascites, operative time, ischaemic time, warm ischaemic 
time. The laboratory measurements collected at the end of the case included: APTT, 
Base excess, Fibrinogen, FiO2, Hb, INR, lactate, PCO2, pH, Platelet count, PO2, 
temperature and urine output. 
The details from the anaesthetic liver transplant database were correlated with the 
preoperative anaesthetic forms – which also included patient height and weight, 
previous major abdominal surgery (defined as open abdominal procedures or 
laparotomy).   
The intraoperative anaesthetic records were reviewed for factor VII use and correlated 
with transfusion records in the electronic anaesthetic transplant database. 
The serum creatinine levels at 48 hours post liver transplantation were obtained for all 
the subjects in the study from the hospital electronic medical records system. 
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 Data management 
All the collected data were stored electronically. The data were entered into a Microsoft 
Excel spreadsheet using a customised data form. The data from this study that have 
been collected, analysed and reported has been attached in a CD-ROM. 
 Confidentiality 
The data collected about the patients in this study were de-identified and managed 
according to the requirements of the Health Records and Information Privacy Act 
2002. 
 Study Funding 
The study received funding through a research grant from the University of Sydney for 
the purchase of the Stata 14 statistics package. No other financial support or funding 
was received.  
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 Statistical Analysis 
Before performing statistical analyses, the data set was inspected and screened for: 
accuracy, the pattern and extent of missing data, outliers and normality. 
The baseline characteristics of this study were reported as medians with ranges for 
continuous variables and frequency with percentages for categorical variables. The 
continuous variables (eg. Units of packed red blood cells transfused) were divided into 
quartiles for statistical analysis. 
  Statistical Methods 
The statistical analysis for this study was performed under the guidance and input of 
the Royal Prince Alfred Hospital statistician, Dr Mario D’Souza. Statistical significance 
for all tests was defined at the conventional level of a p-value less than 0.05. 
  Multivariate analysis 
For each of the multivariate analyses, all variables tested in the univariate analysis 
with a P value less than 0.20 were considered to build the multivariate model (Hosmer 
et al., 2008).  
Stepwise forward selection models were used with the methodology described below. 
A chi-squared statistic value of 0.1 was used for consideration of inclusion into the 
model. As MELD score was considered a confounding factor, it was specifically 
selected into the model for multivariate analysis. Variables that were components of 
the MELD score (serum bilirubin, INR and serum creatinine) were excluded from the 
multivariate selection to avoid collinearity. 
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As each component of blood transfusion was being examined in the analysis, the four 
transfusion variables: packed red blood cells, fresh frozen plasma, platelets and 
cryoprecipitate were also selected into the model. 
From the variables with a chi-squared statistic less than 0.1, the variable that produced 
the greatest increase in the likelihood ratio was added to the model. The chi squared 
statistic values were recalculated for all the remaining variables and this process was 
repeated until all the variables were selected or there were no remaining variables with 
a chi-squared statistic less than 0.1. When the final multivariate models were 
determined for each analysis, all variables within the model were tested to ensure 
substantial multicollinearity was not present. 
In each of the final multivariate models, all the selected variables were evaluated using 
the respective regression analysis. 
  Acute Kidney Injury, Postoperative Dialysis and Infection 
Acute Kidney Injury was defined by as a serum creatinine rise of 0.3 mg/dl (26.52 
umol/l) or a greater than 50% rise above the baseline serum creatinine at 48 hours.   
Logistic regression was used to analyse the binary outcome variables: acute kidney 
injury, postoperative dialysis requirement and infection. 
The patients that had a preoperative dialysis requirement (n=19) were categorised into 
the highest quartile of creatinine and the lowest quartile of creatinine clearance for the 
purposes of analysis. 
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  Duration of Hospital Stay, Intensive Care Unit stay and 
Endotracheal Intubation 
Negative binomial regression was used to analyse the variables: duration of hospital 
stay, duration of intensive care unit stay; and duration of endotracheal intubation. 
  Multicollinearity testing 
As multicollinearity can interfere with the assessment of variable effect on outcomes, 
testing was performed on the variables included in the multivariate model. Collinearity 
was assessed between variables using variance inflation factors, with a cut-off of >10 
used to identify substantial collinearity. Correlation matrixes were also utilised to 
assess correlation between coefficients, with a correlation coefficient of greater than 
0.5 indicating a potential issue. 
 Software Package 
All statistical analyses were performed using Stata SE v14.1 (StataCorp LP, College 
Station, TX). 
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CHAPTER THREE: DEMOGRAPHIC DATA 
 
1  BASELINE PATIENT CHARACTERISTICS 
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 DEMOGRAPHIC DATA 
 Baseline patient characteristics  
The patient and donor characteristics and transplantation variables for this study are 
summarised in the tables below. 
Table 2 displays the number of liver transplantation procedures within each year of the 
study. 
Table 2. Liver transplantation procedures by year 
Year of Transplant 
Number of 
patients N=434 
2002 22 
2003 36 
2004 59 
2005 40 
2006 38 
2007 37 
2008 44 
2009 40 
2010 57 
2011 61 
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The demographic and clinical characteristics for the patients in this study are 
summarised in Table 3.  
Table 3. Demographic and clinical characteristics for the population 
Recipient variables Mean (range) 
Standard 
Deviation 
Age 52.6 (15.3-69.5) 10.1 
Gender     
Male 315 (73%)   
Female 118 (27%)   
BMI 27.4 (16.0-45.5) 5.10 
      
Corrected BMI  26.8 (16.0-45.5) 5.07 
Volume Ascites (mL) 1602.4 (0-14700) 2576.8  
   
Indication for transplantation     
Acute Liver Failure 17 (4%)   
HCC 32 (7%)   
Other 385 (89%)   
 Severity of Liver Disease Mean (range) 
Standard 
Deviation 
CTP score 9.3 (5-15) 2.56 
CTP grade     
A 70 (17%)   
B 137 (32%)   
C 214 (51)   
MELD score 19.5 (6.4-49.8) 9.24 
   
Hepatitis B 56/434 (12.9%)   
Hepatitis C 170/434 (39.2%)   
   
Pulmonary Hypertension     
Yes 11 (2.6%)   
No 414 (97.4%)   
      
Hepatopulmonary Syndrome     
Yes 27 (6.3%)   
No 400 (93.7%)   
   
Preop serum creatinine 86.7 (27-683) 50.5 
Serum bilirubin before OLT 169 (5-1197) 221 
INR before OLT 1.95 (1-12) 1.16 
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Platelet count before OLT 97 (19-753) 74.8 
Hb before OLT 114 (65-169) 23.0 
      
Length of ICU stay 5.0 (1-60) 5.82 
Length of Hospital stay 25.9 (2-292) 22.7 
Duration of endotracheal 
intubation 48.7 hours (4-625) 68.0 
      
Pretransplant location     
Home 255 (62.0%)   
Intensive Care Unit 40 (9.7%)   
Ward 116 (28.2%)   
      
Preoperative endotracheal 
intubation     
Yes 14 (3.3%)   
No 412 (96.7%)   
      
Preoperative Dialysis     
Yes 19 (4.4%)   
No 409 (95.6%)   
      
Previous major abdominal 
surgery     
Yes 69 (16.2%)   
No 358 (83.8%)   
Donor variables Mean (range) 
Standard 
Deviation 
Age 45.1 (8-81) 17.3 
Gender     
Male 232 (53%)   
Female 202 (47%)   
      
Donor Risk Index 1.59 (0.91-3.08) 0.41 
      
Type of donor liver     
DBD 414 (95.4%)   
DCD 18 (4.1%)   
Living 2 (0.5%)   
      
Type of Graft     
Full 348 (85%)   
Split 62 (15%)   
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ABO Compatibility     
Identical 313 (72%)   
Non-identical 121 (73%)   
      
Graft Steatosis     
Not Done 45 (10.37%)   
S0 162 (37.33%)   
S1 - Ma 28 (6.45%)   
S1 - Ma/Mi 58 (13.36%)   
S1 - Mi 67 (15.44%)   
S2 - Ma 13 (3%)   
S2 - Ma/Mi 10 (2.3%)   
S2 - Mi 23 (5.3%)   
S3 - Ma 2 (0.46%)   
S3 - Ma/Mi 3 (0.69%)   
S3 - Mi 23 (5.3%)   
 
Steatosis was defined as follows: S0 – no steatosis (involving <5% of hepatocytes), 
S1 – mild steatosis (involving 5-29% of hepatocytes), S2 – moderate steatosis 
(involving 30-59% of hepatocytes), S3 – severe steatosis (involving ≥60% of 
hepatocytes). Macroscopic (Ma) steatosis was defined as steatosis with fat vacuoles 
larger or equal to the size of the cell nucleus. Microscopic (Mi) steatosis was defined 
as steatosis with fat vacuoles smaller than the size of the cell nucleus. The liver grafts 
containing both macroscopic and microscopic steatosis were indicated as Ma/Mi. 
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The transplantation characteristics and transfusion rates within the study cohort are 
summarised in Table 4. 
Table 4. Transplantation characteristics and transfusion rates within the study 
cohort 
Transplantation 
characteristics Means 
Standard 
Deviation 
Operating time 
5.55 hours (2.00-
20.0) 1.78 
Cold Ischaemic Time 
7.92 hours (1.50-
20.5) 2.19 
Warm Ischaemic Time 
0.82 hours (0.167-
4.22) 0.30 
      
Surgical Technique     
Piggyback 147 (35.8%)   
VVB 1 (0.2%)   
Cross Clamp 263 (64.0%)   
      
Transfusion Units     
Intraoperative     
RBC 6.36 (0-48) 7.11 
FFP 9.82 (0-97)  8.99 
Platelets 1.48 (0-20) 2.22 
Cryoprecipitate 6.09 (0-51) 8.97 
      
ICU (within 48 hours of OLT)     
RBC 1.76 (0-27) 3.41 
FFP 2.09 (0-22) 3.56 
Platelets 1.02 (0-17)  1.78 
Cryoprecipitate 1.31 (0-24)  3.73 
      
Total     
RBC 8.07 (0-48) 8.15 
FFP 11.9 (0-97) 9.82 
Platelets 2.51 (0-27) 3.13 
Cryoprecipitate 7.27 (0-50) 9.81 
      
Transfusion rates(Overall)     
RBC     
Yes 364 (84%)   
No 70 (16%)   
FFP     
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Yes 399 (92%)   
No 35 (8%)   
Platelets     
Yes 310 (71%)   
No 124 (29%)   
Cryoprecipitate     
Yes 221 (51%)   
No 213 (49%)   
      
Volume Cell Saver (mL) 1190.8 (0-29600) 2465.3 
Antifibrinolytic drugs used 229/430 (53%)   
None 201 (47%)   
Aprotinin 121 (28%)   
Tranexamic acid 107 (25%)   
      
Volume Blood loss (mL) 5559.1 (0-50000)  6707.2 
Volume Colloid (mL) 1419.5 (0-13000) 1512.6 
Volume Crystalloid (mL) 4009.4 (0-16000) 2373.6 
Total Volume (mL) 6617.5 (0-36600) 4177.9 
      
Factor VII use      
Intraoperative 33/428 (7.7%)   
ICU 21/399 (5.3%)   
Overall 49/428 (11.45%)   
      
Return to OT (48hr) 61/434 (14%)   
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The one and five year patient survival rates following liver transplantation are shown 
below in Table 5. 
Table 5. Patient Survival Rates following orthotopic liver transplantation 
Time post transplant Survival rate [95% Conf. Int.] 
1 year 0.9171 0.8869    0.9395 
5 years 0.7987 0.7557    0.8350 
 
The one and five year graft survival rates following liver transplantation are shown 
below in Table 6. 
Table 6. Graft survival rates following orthotopic liver transplantation 
Time post transplant Graft Survival rate [95% Conf. Int.] 
1 year 0.9359 0.9079    0.9556 
5 years 0.8769 0.8393    0.9061 
 
The transfusion rates of packed red blood cells, platelets, fresh frozen plasma and 
cryoprecipitate are summarised in Table 7.     
Table 7. Transfusion by year of transplantation 
Year of 
Transplant 
RBC 
Transfusion 
Platelet 
Transfusion 
FFP 
Transfusion 
Cryoprecipitate 
Transfusion 
Any 
Transfusion 
2002-2006 
83% 
(162/195) 
67% 
(130/195) 
90% 
(176/195) 36% (71/195) 
91% 
(178/195) 
2007-2011 
85% 
(202/239) 
75% 
(180/239) 
93% 
(223/239) 63% (150/239) 
95% 
(227/239) 
Total 
84% 
(364/434) 
71% 
(310/434) 
91% 
(399/434) 51% (221/434) 
93% 
(405/434) 
 
The results of the analyses on the effect of blood product transfusion on outcomes 
following liver transplantation are presented in the following Chapters 4 through to 8. 
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 THE ASSOCIATION BETWEEN BLOOD PRODUCT 
ADMINISTRATION AND PATIENT MORTALITY IN LIVER 
TRANSPLANTATION 
 Introduction 
Various factors influence patient mortality after liver transplantation. These include the 
indication for liver transplantation, patient comorbidities prior to transplantation, 
severity of liver disease (MELD score and Child-Pugh score), as well as donor factors, 
donor age and graft factors such as ischaemic time (Adam et al., 2000, Facciuto et al., 
2000, Klinzing et al., 2014).  
The transfusion of blood products is associated with poorer outcomes in other types 
of surgery (Bernard et al., 2009, Koch et al., 2006, Reeves and Murphy, 2008). There 
is debate as to the effect of blood product transfusion in the liver transplantation patient 
cohort. Initial studies reported that packed red blood cell and platelet transfusion were 
associated with an increase in patient mortality (Chin et al., 2014, de Boer et al., 2008, 
Massicotte et al., 2005b), however these were disputed by other studies (Nardo et al., 
2005a, Nixon et al., 2009). 
The aim of this study was to determine whether the transfusion of blood products 
increased all cause patient mortality following orthotopic liver transplantation. The 
mortality rates for patients undergoing orthotopic liver transplantation at Royal Prince 
Alfred Hospital between August 2002 and December 2011 were determined at one 
and five years following liver transplantation. 
 Hypothesis 
The hypothesis of this study was that patients who received perioperative blood 
product transfusion will have an increased all-cause mortality at one and five years 
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following orthotopic liver transplantation compared with patients who did not receive 
perioperative blood product transfusion. 
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 Methods 
 Data Handling 
The recipient variables collected included: age, gender, body mass index, volume of 
ascites, previous major abdominal surgery, preoperative laboratory values (platelet 
count, haemoglobin, fibrinogen, INR, serum creatinine, creatinine clearance), MELD 
score, CTP score, indication for transplantation (acute liver failure/hepatocellular 
carcinoma, other indication), preoperative dialysis requirement, hepatitis B or C 
diagnosis, preoperative admission to ICU, preoperative endotracheal intubation, 
pulmonary hypertension and Hepatopulmonary syndrome. The donor characteristics 
collected were: donor age, ABO type (ABO group identical or non-identical), donor 
graft steatosis, donor risk index (described by Feng et al. (Feng et al., 2006)), 
split/whole graft, gender and DCD (Donation after Cardiac Death)/DBD (Donation after 
Brain Death) status. The transplantation variables collected were: surgical technique, 
graft warm ischaemic time, graft cold ischaemic time, total operative time, “return to 
the operating theatre” within 72 hours of transplantation, antifibrinolytic administration 
(aprotinin/tranexamic acid), packed red blood cell transfusion, platelet transfusion, 
fresh frozen plasma transfusion, cryoprecipitate transfusion, factor VII administration, 
intraoperative crystalloid volume administered, intraoperative colloid volume 
administered, total intraoperative fluid volume administered and intraoperative blood 
loss. 
 Statistical analysis 
The statistical data were presented as the mean ± standard deviation for normally 
distributed data. Data that were not normally distributed were presented as median 
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and interquartile ranges. Categorical data were presented as frequency with 
percentages. 
 Univariate analysis 
The continuous variables were divided into quartiles for analysis to assess for 
variability. A substantial number of patients did not receive perioperative blood 
transfusion and these patients were separated into their own group. The remainder of 
the patients were divided into quartiles for analysis. 
The univariate relationships between blood product transfusion and patient survival 
were evaluated by the Cox proportional hazards model. The Kaplan-Meier analysis 
and the log rank test were used to investigate differences between patient survival 
rates in different blood product transfusion groups. The endpoint was the death of the 
patient. The patients surviving to the end of the follow-up period were censored. The 
survival analysis for patient survival were conducted at 1 and 5-year follow-up intervals 
 Multivariate analysis 
A multivariate Cox regression model was formed utilising the stepwise forward 
selection model described in Section 2.11 of Chapter 2 ( Statistical Methods, page 77). 
Variables with a p-value less than 0.2 on univariate analysis were applied to the 
multivariate model.  
The variables considered for analysis in the multivariate model for one year patient 
survival included: recipient age, MELD score, preoperative admission to the Intensive 
Care Unit, preoperative endotracheal intubation, pulmonary hypertension, 
hepatopulmonary syndrome, donation after cardiac death, graft cold ischaemic time, 
platelet transfusion, and cryoprecipitate transfusion.  
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The final variables included in the multivariate model for one year patient survival 
were: platelet transfusion, packed red blood cell transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, MELD score, recipient age, preoperative 
endotracheal intubation, hepatopulmonary syndrome and pulmonary hypertension. 
The variables considered for analysis in the multivariate model for five year patient 
survival included: recipient age, volume of ascites, preoperative platelet count, 
hepatitis B status, hepatopulmonary syndrome, non-identical ABO graft, donor graft 
steatosis, donor risk index, donation after cardiac death, warm ischaemic time, cold 
ischaemic time, total operating time, antifibrinolytic use (aprotinin and tranexamic 
acid), platelet transfusion, FFP transfusion, cryoprecipitate transfusion, volume of 
intraoperative crystalloid given and total intraoperative blood loss. As cold ischaemic 
time and donation after cardiac death grafts are components of the donor risk index, 
they were excluded from the selection of variables for the multivariate model 
(described within the methods section). The variables selected for multivariate 
analysis for five-year patient survival were platelet transfusion, packed red blood cell 
transfusion, fresh frozen plasma transfusion, cryoprecipitate transfusion, MELD score, 
recipient age, non-identical ABO graft donor, preoperative platelet count, the 
intraoperative volume of crystalloid given and aprotinin use. 
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 Results 
 One Year Patient Survival 
 Univariate Cox regression analysis: one year patient survival 
The results of the univariate analysis are presented in Table 13 (page 122) in the 
appendix. The variables with a p value <0.05 are summarised in Table 8.  
Table 8. Summary table of variables associated with a one year effect on patient 
survival on univariate analysis 
Variables P-value 
Recipient Variables   
Age 0.030 
Preoperative admission to ICU 0.012 
Preoperative endotracheal intubation 0.018 
Transplantation Variables  
Platelet Transfusion 0.027 
Cold Ischaemic Time 0.033 
Cryoprecipitate Transfusion 0.042 
 
The variables with P-values less than 0.2 were utilised for multivariate analysis 
(highlighted in red in Table 13 (page 122)). 
 Kaplan Meier analysis: one year patient survival 
On the univariate Kaplan Meier analysis, the patients who received platelet transfusion 
had a decreased one year survival rate [Figure 2 (p = 0.04)]. Additionally, the patients 
who received cryoprecipitate also had a decreased one year survival [Figure 3 
(p = 0.0437)].  
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Figure 2. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the transfusion of platelets within the perioperative period 
  
Figure 3. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the transfusion of cryoprecipitate within the perioperative period. 
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The transfusion of packed red blood cells (Figure 4) and fresh frozen plasma (Figure 
5) had no association with one year survival following liver transplantation.  
Figure 4. Kaplan-Meier curves representing cumulative one-year patient 
survival in relation to the transfusion of Packed Red Blood Cells within the 
perioperative period. 
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Figure 5. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the transfusion of fresh frozen plasma within the perioperative 
period. 
 
With the aim of improving the exploratory analysis of blood product usage, further 
analysis using quartiles of the transfusion of blood products was performed. There 
was no decrease in patient survival at one year with the transfusion of platelets (Figure 
6), packed red blood cells (Figure 7), fresh frozen plasma (Figure 8), or cryoprecipitate 
(Figure 9).  
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Figure 6. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the number of units of platelets transfused within the perioperative 
period (by quartiles) 
  
Figure 7. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the number of units of Packed Red Blood Cells transfused within the 
perioperative period (by quintiles) 
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Figure 8. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the number of units of fresh frozen plasma transfused within the 
perioperative period (by quintiles) 
  
Figure 9. Kaplan-Meier curves representing cumulative one-year patient survival 
in relation to the number of units of cryoprecipitate transfused within the 
perioperative period (by quartiles) 
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 Multivariate Cox Regression analysis: one year patient 
survival 
The results of the multivariate cox regression for one year patient survival are shown 
in Table 9 (page 101). Perioperative blood transfusion did not have any effect on one 
year patient survival in the multivariate analysis. 
Multivariate analysis identified a number of factors that had a negative effect on patient 
survival following liver transplantation. 
 Age 
The patient’s age at time of liver transplantation was associated with one year survival. 
The patients aged 47 to 53.19 had a decreased one year survival rate compared with 
the patients aged ≤47 (hazard ratio = 5.098, p = 0.019, CI 1.300 - 19.98). The patients 
aged 58.74‐ 70 had decreased one year survival rate compared to patients aged ≤47 
(hazard ratio = 5.479, p = 0.014, CI 1.420 - 21.14).  
 Preoperative Comorbidities 
Preoperative comorbidities of the patient population had a negative effect on patient 
survival following liver transplantation. These included preoperative endotracheal 
intubation and hepatopulmonary syndrome. The patients who were intubated 
preoperatively had a decreased one year survival (hazard ratio = 5.734, p = 0.02, CI 
1.313 - 25.03).   
The patients who had hepatopulmonary syndrome preoperatively had a decreased 
one year survival (hazard ratio = 5.702, p = 0.006, CI 1.644 - 19.77).   
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Table 9. Multivariate analysis for One Year Patient survival. 
Variable Haz. Ratio z P value [95% Conf. Interval] 
Platelet Transfusion 
(0 Units)  1         
1-2 Units 3.670033 1.63 0.103 0.769 17.508 
3-4 Units 4.008271 1.63 0.103 0.756 21.254 
≥ 5 Units 3.308059 1.33 0.183 0.569 19.235 
Packed Cell Transfusion  
(0 Units)  1    
  
1-3 Units 1.438399 0.44 0.66 0.285 7.253 
4-6 Units 0.8524184 -0.16 0.87 0.126 5.785 
7-12 Units 1.466789 0.36 0.719 0.182 11.798 
≥ 13 Units 2.062022 0.61 0.545 0.198 21.470 
Fresh Frozen Plasma 
Transfusion (0 Units)  1    
  
1-6 Units 0.6536143 -0.43 0.67 0.092 4.625 
7-10 Units 0.3493735 -0.8 0.424 0.027 4.604 
11-16 Units 0.1353431 -1.38 0.166 0.008 2.298 
≥17 Units 0.2995319 -0.82 0.413 0.017 5.364 
Cryoprecipitate 
Transfusion  
(0 Units)  1    
  
1-9 Units 2.03E-15 0 1 0 . 
10-19 Units 0.8768985 -0.21 0.835 0.256 3.010 
≥20 Units 0.6952152 -0.52 0.602 0.177 2.730 
MELD Score 
(6-10.99)  1    
  
11-17.99 0.6990994 -0.49 0.625 0.166 2.937 
18-23.99 0.374899 -1.01 0.314 0.056 2.528 
≥24 2.383907 1.08 0.282 0.490 11.589 
Age (≤47)  1    
  
47- 53.19 5.097608 2.34 0.019 1.300 19.983 
53.2- 58.73 0.8444151 -0.21 0.834 0.173 4.116 
58.74- 70 5.478546 2.47 0.014 1.420 21.138 
Preoperative 
Endotracheal 
intubation 5.73411 2.32 0.02 
1.313 25.033 
Hepatopulmonary 
Syndrome 5.702103 2.74 0.006 
1.644 19.772 
Pulmonary 
Hypertension 8.42E-16 0 >0.999 
0 . 
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 Multicollinearity testing 
The results of the multicollinearity and correlation coefficient testing for the variables 
included in the multivariate model for the effect of blood product transfusion on one 
year survival are shown in Table 14 (page 123) and Table 15 (page 124) in the 
appendix. There was no substantial multicollinearity of the variables. 
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 Five Year Patient Survival 
 Univariate Cox regression: five year patient survival 
The results for the univariate cox regression of five year patient survival are presented 
in Table 16 (page 125) in the appendix for Chapter 4. The variables with P-values less 
than 0.2 were considered for multivariate analysis (highlighted within table). 
When univariate analysis was performed, the variables associated (p<0.05) with an 
effect on five year patient survival were: recipient age, preoperative haemoglobin, 
preoperative platelet count, hepatitis B status, hepatopulmonary syndrome, non-
identical ABO group graft, donor graft steatosis, donor risk index, donation after 
cardiac death, total operative time, antifibrinolytic use (tranexamic acid or aprotinin), 
platelet transfusion, fresh frozen plasma transfusion, cryoprecipitate transfusion, 
volume of crystalloid given intraoperatively and total volume of intraoperative blood 
loss.  
Table 10. Summary table of variables associated with a five year effect on patient 
survival on univariate analysis 
Variables P-value 
Recipient Variables   
Age 0.002 
Preoperative haemoglobin 0.005 
Preoperative Platelet Count 0.006 
Hepatopulmonary Syndrome 0.008 
Hepatitis B 0.037 
Donor Variables  
ABO identical/non identical <0.001 
Donor Graft Steatosis 0.013 
DCD/DBD 0.013 
Donor Risk Index 0.037 
Transplantation Variables  
Aprotinin use <0.001 
Tranexamic Acid use <0.001 
Operative Time 0.001 
Cryoprecipitate Transfusion 0.002 
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Total Blood Loss intraoperatively 0.006 
Antifibrinolytic Use 0.011 
Platelet Transfusion 0.012 
FFP Transfusion 0.015 
Volume of Crystalloid given 
intraoperatively 
0.022 
 
 Kaplan Meier analysis: five year patient survival 
The Kaplan Meier survival analysis of the association between blood product 
transfusion and five year patient survival are presented in Figures 10-17. The 
transfusion of fresh frozen plasma (Figure 10, p = 0.026), platelets (Figure 11, p = 
0.015) and cryoprecipitate (Figure 12, p = 0.0017) was associated with a decrease in 
five-year patient survival following liver transplantation. 
Figure 10. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the transfusion of fresh frozen plasma within the perioperative 
period 
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Figure 11. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the transfusion of platelets within the perioperative period 
 
Figure 12. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the transfusion of cryoprecipitate within the perioperative period 
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The transfusion of packed red blood cells was not associated with decreased five year 
patient survival (Figure 13). 
Figure 13. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the transfusion of packed red blood cells within the perioperative 
period 
 
With the aim of improving the exploratory analysis of the effect of blood product usage 
on survival, further analysis was performed using quartiles of blood product 
transfusion. 
The transfusion of platelets was associated with a mixed effect on five year patient 
survival (Figure 14, p = 0.0001). Whilst the transfusion of 1-4 pools of platelets had a 
negative effect on patient survival, transfusion of 5 or more pools of platelets was 
associated with an increase in patient survival.  
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The transfusion of cryoprecipitate was associated with a decrease in five year patient 
survival (Figure 15, p = 0.0085).  
There was no change in five-year patient survival for transfusion of packed red blood 
cells (Figure 16) or fresh frozen plasma (Figure 17). 
Figure 14. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the number of units of platelets transfused within the perioperative 
period (by quartiles) 
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Figure 15. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the number of units of cryoprecipitate transfused within the 
perioperative period (by quartiles) 
Figure 16. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the number of units of packed red blood cells transfused within the 
perioperative period (by quintiles) 
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Figure 17. Kaplan-Meier curves representing cumulative five-year patient survival 
in relation to the number of units of fresh frozen plasma transfused within the 
perioperative period (by quintiles) 
 
 Multivariate Cox Regression 
Multivariate cox regression for five year patient survival was performed and the results 
are summarised in Table 11. 
On multivariate analysis, the patients who received ≥5 units of platelet transfusion 
perioperatively had an increased five year patient survival rate compared with the 
patients who did not receive any perioperative platelet transfusion (hazard ratio 0.335, 
P = 0.009, CI 0.149 - 0.757).  
The patients who received 1 to 6 units of fresh frozen plasma had a decreased five 
year survival rate compared with the patients who did not receive any fresh frozen 
plasma transfusion (hazard ratio: 2.424, P = 0.022, CI 1.134 – 5.183). 
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The multivariate analysis also examined other modifying factors which had an effect 
on survival. The factors that influenced patient survival included: ABO group 
compatibility, preoperative platelet levels, intraoperative fluid therapy and 
antifibrinolytic therapy. 
 ABO group compatibility 
The patients who received a non-identical ABO donor graft had an increased five year 
mortality compared with the patients who received an identical ABO donor graft 
(hazard ratio 1.426, p = 0.038, CI 1.020 - 1.993).  
 Preoperative platelet levels 
Increased preoperative platelet counts in the transplant recipients were associated 
with increased five year survival rates. 
The patients with a preoperative platelet count of >50-100 x 109/L had an increased 
five year survival when compared with the patients who had a preoperative platelet 
count of ≤50 x 109/L (hazard ratio of 0.672, p = 0.046, CI 0.455 - 0.993). The patients 
with a preoperative platelet count of >100 x 109/L had an increased five year survival 
when compared with the patients with a preoperative platelet count of ≤50 x 109/L 
(hazard ratio of 0.496, p = 0.005, CI 0.302 - 0.813).  
 Intraoperative fluid therapy 
Intraoperative crystalloid administration of 3.7L or greater was associated with 
increased five year survival. The patients who received an intraoperative crystalloid 
volume of 3700‐5000mL had an increased five year survival compared with the 
patients who received an intraoperative crystalloid volume of 0‐2000mL (hazard ratio 
= 0.524, p = 0.009, CI 0.323 - 0.849). The patients who received an intraoperative 
crystalloid volume >5000mL had an increased five year survival compared with the 
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patients who received an intraoperative crystalloid volume of 0‐2000mL (hazard ratio 
= 0.449, p = 0.001, CI 0.280 - 0.718). 
 Antifibrinolytic therapy 
The patients who received aprotinin had an increased five year survival (hazard ratio 
= 0.205, p <0.001, CI 0.120 - 0.349).
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Table 11. Multivariate analysis for Five Year Patient survival. 
Variable Haz. Ratio z P value [95% Conf. Interval] 
Platelet Transfusion 
(0 Units)  1         
1-2 Units 1.176585 0.58 0.56 0.681 2.033 
3-4 Units 0.8703267 -0.41 0.681 0.449 1.689 
≥ 5 Units 0.3353253 -2.63 0.009 0.149 0.757 
Packed Cell Transfusion  
(0 Units)  1     
  
1-3 Units 0.9370293 -0.21 0.834 0.510 1.721 
4-6 Units 0.9184042 -0.25 0.801 0.474 1.778 
7-12 Units 1.33393 0.76 0.447 0.635 2.803 
≥ 13 Units 1.486177 0.9 0.37 0.625 3.534 
Fresh Frozen Plasma 
Transfusion (0 Units)  1     
  
1-6 Units 2.423981 2.28 0.022 1.134 5.183 
7-10 Units 2.308432 1.76 0.078 0.909 5.860 
11-16 Units 1.787837 1.16 0.247 0.669 4.777 
≥17 Units 2.014484 1.3 0.192 0.704 5.768 
Cryoprecipitate 
Transfusion  
(0 Units) 1      
  
1-9 Units 0.5429561 -1.52 0.13 0.246 1.196 
10-19 Units 0.9203264 -0.33 0.744 0.559 1.514 
≥20 Units 1.019319 0.07 0.946 0.587 1.771 
MELD Score 
(6-10.99)  1     
  
11-17.99 0.9174603 -0.31 0.754 0.535 1.574 
18-23.99 0.9293354 -0.24 0.809 0.513 1.683 
≥24 0.9690815 -0.1 0.921 0.522 1.801 
Age (≤47)  1       
47- 53.19 0.9433792 -0.24 0.813 0.582 1.529 
53.2- 58.73 1.265893 1.03 0.301 0.810 1.979 
58.74- 70 1.473242 1.67 0.095 0.934 2.323 
Non identical ABO graft 
donor 1.426096 2.08 0.038 
1.020 1.993 
Preoperative Platelet 
Count (≤50 x 109/L)  1     
  
>50 – 100 x 109/L 0.6722033 -1.99 0.046 0.455 0.993 
>100 x 109/L 0.4955786 -2.78 0.005 0.302 0.813 
Intraoperative Crystalloid 
Volume (0-2000mL)  1     
  
2000-3700mL 0.809546 -0.98 0.329 0.530 1.237 
3700-5000mL 0.5236822 -2.62 0.009 0.323 0.849 
>5000mL 0.4485583 -3.34 0.001 0.280 0.718 
Aprotinin use 0.2046973 -5.82 <0.001 0.120 0.349 
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 Multicollinearity  
The results of the multicollinearity and correlation coefficient testing for the variables 
included in the multivariate model for the effect of blood product transfusion on five 
year survival are shown in Table 17 (page 126) and Table 18 (page 127) in the 
appendix. There was no substantial multicollinearity of the variables. 
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 Discussion 
 Factors influencing one-year patient survival  
 Blood product Transfusion 
When the confounding factors for patient illness severity were controlled for in the 
multivariate cox regression analysis, there was no association between blood product 
transfusion and effect on one year patient survival rates. Several factors that 
influenced patient survival were identified and are discussed below. 
 Age 
The survival at one year in patients between 47-53.19 years was decreased by 5.1 
times when compared with the patients aged less than 47 years of age. This is 
consistent with the findings of Chen et al. who reported an association between 
increasing recipient age decreasing patient survival within the liver transplantation 
cohort (Chen et al., 2016). This decreased survival in older patients was attributed to 
preoperative comorbidities and decreased physiological reserve.  
 Patients intubated preoperatively 
The patients who were intubated preoperatively had decreased one year survival. 
Preoperative endotracheal intubation reflects the severity of preoperative liver 
disease. Severe hypoxaemia and physiological derangements associated with 
hepatopulmonary syndrome are a consequence of severe liver failure (Fauconnet et 
al., 2013).  
 Hepatopulmonary Syndrome 
In our cohort, 27 patients with hepatopulmonary syndrome (defined as a partial 
pressure of oxygen of less than 70mmHg on arterial blood gas) had decreased one 
year survival. The mortality hazard ratio of 5.702 was clinically significant. Existing 
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data on patient survival post liver transplantation demonstrated that the presence of 
preoperative hepatopulmonary syndrome had a negative effect on survival (Fritz et al., 
2013). Fallon et al reported a mortality hazard ratio of 2.41 post liver transplantation in 
patients with hepatopulmonary syndrome when they adjusted for MELD score (Fallon 
et al., 2008). The mean MELD score in their population was 13. In contrast, Iyer et al. 
had found no increase in mortality in patients with hepatopulmonary syndrome post 
liver transplantation, however they did not control for MELD score. The mean MELD 
score was 14 in the patient cohort described by Iyer et al, compared to the mean MELD 
score of 19.5 in our population (Iyer et al., 2013). The higher MELD score in our 
patients made comparison to other studies difficult due to the more severe pre-existing 
liver disease. In other studies, the 5 year survival rate post liver transplantation is 
similar in hepatopulmonary syndrome patients compared to those who did not have 
hepatopulmonary syndrome preoperatively. In 80% of the patients with 
hepatopulmonary syndrome, complete resolution following transplantation was 
observed (Cosarderelioglu et al., 2016). 
 Factors influencing five-year patient survival  
When examining five year patient survival post liver transplantation, this study found 
that fresh frozen plasma was associated with a decreased five year survival while 
platelet transfusion was associated with increased five year survival. In contrast to 
other studies (de Boer et al., 2008), we found that the transfusion of packed red blood 
cells did not have a negative effect on 5-year patient survival. Additionally, 
cryoprecipitate transfusion did not have any effect on survival. 
 Platelet transfusion 
This study showed platelet transfusion was associated with increased patient survival 
at five years post liver transplantation. This effect was observed only in the patients 
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who receiving ≥5 units of platelets. This effect is contrary to the findings of De Boer et 
al who reported a decrease in patient survival with platelet transfusion (de Boer et al., 
2008).  
Several mechanisms have been suggested for the effect of platelet transfusion on 
survival. Animal studies indicated that the protective effect of platelet transfusion might 
be mediated by an immunomodulatory effect. Aslam et al. showed that transfusion of 
fresh leukoreduced platelets was associated with an protective immunomodulatory 
effect in a murine model (Aslam et al., 2008). The rejection of donor grafts in the 
murine model was reduced in the cohort transfused with platelets. This was attributed 
to the presence of major histocompatibility complex (MHC) class 1 molecules on the 
surface of platelets. Major histocompatibility complex class 1 molecules contribute to 
transfusion related immunomodulation by inducing apoptosis in recipient CD8+ T cells 
(Contini et al., 2003). Perros et al. demonstrated that the transfusion of platelets 
suppressed the function of dendritic cells (Perros et al., 2015).  
When examining the Kaplan Meier survival analysis graph of five-year patient survival 
(Figure 14, page 107), the increased survival associated with the transfusion of ≥5 
units of platelets occured at the two-year time period post orthotopic liver 
transplantation. This interval was associated with chronic rejection after solid organ 
transplantation. Platelet transfusion may have an effect on chronic rejection by 
suppressing dendritic cell function (Perros et al., 2015). Further studies examining the 
longer-term effect of platelet transfusion on survival following liver transplantation are 
needed. 
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 Fresh frozen plasma transfusion  
The transfusion of fresh frozen plasma was associated with decreased survival at five 
years in the patients who received 1 to 6 units of fresh frozen plasma when compared 
with the patients who received no fresh frozen plasma transfusion. A trend towards 
increased mortality was observed with greater quantities of transfusion of fresh frozen 
plasma. However, these differences were not statistically significant. 
The decreased survival rate associated with fresh frozen plasma transfusion may be 
caused by an increased rate of postoperative infective complications. Although there 
are limited data surrounding infective complications associated with fresh frozen 
plasma in liver transplantation, an association between increased fresh frozen plasma 
transfusion and sepsis has been identified in paediatric burns patients (Jeschke et al., 
2007). 
 Modifying factors 
On multivariate analysis, several factors were found to be associated with patient 
survival at five years; and are discussed below. 
 Non-identical ABO donor Graft 
In this study, there were 313 ABO group identical transplantations and 121 non 
identical ABO group transplantations. These 121 patients included: 115 ABO group 
compatible (but non-identical) transplantations and 6 patients who received an ABO 
group incompatible liver transplant.  
The five-year survival rate was decreased by 1.4 times for those patients who received 
non-identical ABO donor grafts. These findings were in agreement with a study by 
Adam et al. in an analysis of 22089 patients from the European Liver Transplant 
Registry (Adam et al., 2000). Other studies have demonstrated that ABO incompatible 
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donor grafts were associated with biliary complications and antibody mediated 
rejection that caused increased mortality and morbidity (Fusai et al., 2006, Proposito 
et al., 2001, Wiederkehr et al., 2010).  
 Preoperative platelet count 
Multivariate analysis showed that preoperative platelet count was an independent 
predictor of five-year survival. Lower preoperative platelet levels were associated with 
decreased five-year survival in this study. This reflected the severity of preoperative 
liver dysfunction prior to transplantation. Peck-Radosavljevic suggested that 
decreased thrombopoietin associated with worsening liver dysfunction was 
responsible for thrombocytopenia in advanced liver disease (Peck-Radosavljevic, 
2016). 
  Intraoperative crystalloid volume 
The patients who received a large volume of intraoperative crystalloid fluids during 
orthotopic liver transplantation had an increased five-year survival when compared 
with the patients who received lesser volumes of intraoperative crystalloids. A dose 
response relationship was observed with the patients who received increasing 
volumes of intraoperative crystalloid when assessing five-year survival. The patients 
who received 3700mL to 5000mL of intraoperative crystalloid had 47.6% increased 
survival at five years when compared with the patients that received less than two 
litres of intraoperative crystalloid (hazard ratio = 0.524, p = 0.009). This effect was 
increased when assessing the patients that received greater than 5 litres of 
intraoperative crystalloid. These patients had a 55.1% increase in survival at five years 
compared with the patients who received less than 2 litres of intraoperative crystalloid 
(hazard ratio = 0.449, p = 0.001).  
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The effect of intraoperative crystalloid volume on survival will be further investigated 
within the study on effects of transfusion on acute kidney injury (page 163). 
 Antifibrinolytic administration 
The administration of aprotinin during orthotopic liver transplantation was associated 
with increased five year patient survival in this study. The five-year mortality hazard 
ratio of patients was 0.205 in the patients that had received aprotinin. The five year 
patient survival rates were 83.5% for patients who had received aprotinin and 78.6% 
in patients who had received no antifibrinolytic drugs. 
Table 12. Patient Survival at five years after liver transplantation for patients 
receiving aprotinin compared with patients who received no antifibrinolytic 
Survival at 5 years Total Patients Died Survival Rate [95% Conf. Int.] 
No antifibrinolytic 94 38 0.7862 0.7159    0.8410 
Aprotinin 102 20 0.8347 0.7556    0.8900 
 
Aprotinin was used as an antifibrinolytic in our cohort until October 2007. All patients 
after this date received tranexamic where an antifibrinolytic was administered.  
Although improved surgical experience and technique in later years would be thought 
to have been associated with improved outcomes, the improved mortality associated 
with the use of aprotinin was observed in the earlier era of transplantation within our 
cohort (as aprotinin was not used after October 2007 at our centre). The increased 
survival seen with aprotinin use could be attributed to the decreased severity of 
pretransplant liver disease in the early era of transplantation where aprotinin was used. 
In our study, it was evident that the mean severity of liver disease was increased in 
the more recent era of transplantation. Aprotinin was used exclusively in the period 
from January 2002 until June 2006. Within this period, the mean MELD score for the 
cohort was 18.4. As aprotinin was withdrawn from clinical use, tranexamic acid was 
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used exclusively in liver transplantation cases from November 2007 to December 
2011. Within this period, the mean MELD score was 20.4.  
We did not demonstrate an increase in survival in patients who received tranexamic 
acid. This confirms the findings of Massicotte et al. who evaluated the use of aprotinin 
and tranexamic acid in orthotopic liver transplant patients and demonstrated no 
advantage in using either agent when examining the effects on intraoperative blood 
loss, packed red blood cell transfusion requirement, and one year mortality 
(Massicotte et al., 2011). They found that there was no significant difference in 
postoperative creatinine levels or incidence of acute kidney injury. 
A systematic review and meta-analysis of the literature within liver transplantation 
demonstrated that although both aprotinin and tranexamic acid reduced packed red 
cell transfusion requirement, only aprotinin reduced fresh frozen plasma requirement 
(Molenaar et al., 2007). There was no increase in thrombotic complications with the 
use of either fibrinolytic. While aprotinin was associated with decreased fresh frozen 
plasma administration in our study, tranexamic acid was also associated with 
decreased fresh frozen plasma administration. The lower mortality associated with 
administration of aprotinin may be due to the lesser severity of disease in the earlier 
era of transplantation within in cohort.  
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 Conclusion 
Blood product transfusion was not associated with any decrease in survival at one 
year post liver transplantation. At five years, fresh frozen plasma was associated with 
a trend towards decreased survival rates which may be attributed to infective 
complications in the postoperative period. The transfusion of platelets had a trend 
towards increased survival rates at five years post liver transplantation and this may 
be due to long term immunomodulatory effects.  
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 Appendix to Chapter 4 
Table 13. Univariate analysis for One Year Patient survival. 
Variables P-value 
Recipient Variables  
Age 0.030 
Preoperative admission to ICU 0.012 
Preoperative endotracheal intubation 0.018 
Hepatopulmonary Syndrome 0.077 
Preoperative haemoglobin 0.085 
Pulmonary Hypertension 0.165 
MELD Score 0.185 
Preoperative Dialysis 0.220 
Hepatocellular Carcinoma 0.222 
Previous Major Abdominal Surgery 0.229 
Preoperative Creatinine Clearance 0.263 
Hepatitis B 0.388 
CTP Score 0.464 
Corrected BMI 0.499 
Preoperative Platelet Count 0.512 
Preoperative Serum Creatinine 0.529 
All other Indications 0.574 
Acute Liver Failure 0.578 
Recipient Sex 0.595 
BMI 0.661 
Volume of Ascites 0.816 
Hepatitis C 0.932 
Donor Variables  
DCD/DBD 0.074 
Split graft 0.255 
Donor Age 0.358 
Donor Risk Index 0.534 
Donor Graft Steatosis 0.808 
Donor Sex 0.813 
ABO identical/non identical 0.999 
Transplantation Variables  
Platelet Transfusion 0.027 
Cold Ischaemic Time 0.033 
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Cryoprecipitate Transfusion 0.042 
Total fluid volume given intraoperatively 0.204 
Factor VII use 0.256 
RBC Transfusion 0.366 
Antifibrinolytic Use 0.462 
Total Blood Loss intraoperatively 0.513 
FFP Transfusion 0.534 
Warm Ischaemic Time 0.608 
Tranexamic Acid use 0.620 
Surgical technique 0.624 
Return to Operating Theatre within 72 hours 0.638 
Aprotinin use 0.695 
Operative Time 0.728 
Volume of Crystalloid given intraoperatively 0.827 
Volume of Colloid given intraoperatively 0.833 
 
Table 14. Multicollinearity Testing for variables included in multivariate analysis 
for One Year Patient survival. 
Variable Variance Inflation Factor 
Fresh Frozen Plasma Transfusion 8.59 
Packed Red Cell Transfusion 8.44 
MELD Score 6.2 
Recipient Age 4.51 
Cryoprecipitate Transfusion 3.35 
Platelet Transfusion 2.14 
Preoperative endotracheal intubation 1.13 
Hepatopulmonary Syndrome 1.09 
Pulmonary Hypertension 1.05 
  
Mean Variance inflation factor 4.05 
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Table 15. Correlation matrix of coefficients of multivariate Cox model for One Year Patient survival 
Correlation 
Coefficients 
Platelet 
Transfusion 
Packed Red 
Cell 
Transfusion 
Fresh 
Frozen 
Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score Age 
Preoperative 
Endotracheal 
intubation 
Hepatopulmonary 
Syndrome 
Pulmonary 
Hypertension 
Platelet 
Transfusion 1                          
Packed Red Cell 
Transfusion -0.1703 1                        
Fresh Frozen 
Plasma 
Transfusion -0.1295 -0.6561 1                      
Cryoprecipitate 
Transfusion -0.0987 -0.4133 -0.0922 1                    
MELD Score 0.0033 0.1048 -0.2403 -0.2127 1                  
Age 0.0959 0.0312 0.0259 -0.1637 0.1673 1                
Preoperative 
Endotracheal 
intubation 0.072 0.011 -0.0251 -0.0714 -0.4246 0.1118 1              
Hepatopulmonary 
Syndrome 0.0561 0.0115 0.0346 -0.0662 -0.0302 -0.0589 0.1556 1            
Pulmonary 
Hypertension 0 0 0 0 0 0 0 0 1 
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Table 16. Univariate analysis for Five Year Patient survival. 
Variables P-value 
Recipient Variables  
Age 0.002 
Preoperative haemoglobin 0.005 
Preoperative Platelet Count 0.006 
Hepatopulmonary Syndrome 0.008 
Hepatitis B 0.037 
Volume of Ascites 0.161 
Hepatitis C 0.201 
Pulmonary Hypertension 0.216 
Preoperative Dialysis 0.255 
Preoperative admission to ICU 0.266 
Preoperative Serum Creatinine 0.313 
MELD Score 0.318 
All other Indications 0.466 
Previous Major Abdominal Surgery 0.508 
CTP Score 0.599 
Acute Liver Failure 0.604 
BMI 0.619 
Hepatocellular Carcinoma 0.619 
Preoperative Creatinine Clearance 0.754 
Corrected BMI 0.827 
Preoperative endotracheal intubation 0.940 
Recipient Sex 0.972 
Donor Variables  
ABO identical/non identical <0.001 
Donor Graft Steatosis 0.013 
DCD/DBD 0.013 
Donor Risk Index 0.037 
Split graft 0.252 
Donor Age 0.479 
Donor Sex 0.624 
Transplantation Variables  
Aprotinin use <0.001 
Tranexamic Acid use <0.001 
Operative Time 0.001 
Cryoprecipitate Transfusion 0.002 
Total Blood Loss intraoperatively 0.006 
Antifibrinolytic Use 0.011 
Platelet Transfusion 0.012 
FFP Transfusion 0.015 
126 
 
Volume of Crystalloid given 
intraoperatively 
0.022 
Cold Ischaemic Time 0.097 
Warm Ischaemic Time 0.157 
Total intraoperative fluid volume 0.324 
Volume of intraoperative colloid given  0.329 
RBC Transfusion 0.357 
Return to Operating Theatre within 72 
hours 
0.525 
Factor VII use 0.568 
Factor VII use 0.568 
Surgical technique 0.575 
Table 17. Multicollinearity Testing for variables included in multivariate analysis 
for Five Year Patient survival. 
Variable 
Variance Inflation 
Factor 
Fresh Frozen Plasma 
Transfusion 8.66 
Packed Red Cell Transfusion 8.63 
Age 7.62 
MELD Score 6.47 
Intraoperative Crystalloid 
Volume 4.07 
Cryoprecipitate transfusion 3.68 
Preoperative Platelet Count 3.11 
Platelet Transfusion 2.39 
Aprotinin antifibrinolytic use 1.65 
Non identical ABO graft donor 1.47 
  
Mean VIF 4.77 
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Table 18. Correlation matrix of coefficients of multivariate Cox model for Five Year Patient survival. 
Correlation 
Coefficients 
Platelet 
Transfusion 
Packed Red 
Cell 
Transfusion 
Fresh 
Frozen 
Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score 
Non 
identical 
ABO 
graft 
donor Age 
Intraoperative 
Crystalloid 
Volume 
Aprotinin 
use 
Preoperative 
Platelet 
Count 
Platelet 
Transfusion 1                            
Packed Red Cell 
Transfusion -0.0988 1                          
Fresh Frozen 
Plasma 
Transfusion -0.2468 -0.6884 1                        
Cryoprecipitate 
Transfusion -0.208 -0.451 0.1117 1                      
MELD Score -0.0305 0.1088 -0.2198 -0.2751 1                    
Non identical 
ABO graft donor 0.0931 -0.0368 -0.0558 -0.0034 
-
0.1247 1                  
Age 0.0453 -0.0426 0.0368 -0.0352 0.1413 0.0833 1                
Intraoperative 
Crystalloid 
Volume 0.0166 -0.0017 -0.0698 0.005 0.2284 0.0892 0.0776 1              
Aprotinin use -0.0943 -0.1306 0.1071 0.1735 -0.066 0.1388 0.0232 0.1313 1            
Preoperative 
Platelet Count 0.2913 -0.1559 0.0881 0.065 
-
0.0331 -0.0544 0.0844 -0.1262 0.0039 1 
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 THE ASSOCIATION BETWEEN BLOOD PRODUCT 
ADMINISTRATION AND VIABILITY OF LIVER GRAFTS 
FOLLOWING LIVER TRANSPLANTATION 
 Introduction 
De Boer et al. demonstrated an association between red blood cell transfusion and 
decreased graft survival post transplantation (de Boer et al., 2008). The preoperative 
MELD score and donor risk index have been shown to influence graft survival (Bonney 
et al., 2009, Feng et al., 2006). Feng et al and Bonney et al showed that degree of 
liver disease and quality of liver graft were confounding factors in the analysis of blood 
product transfusion effect on graft survival. This study adjusts for these confounders 
by controlling for preoperative MELD score and graft donor risk index. 
The aim of this study was to determine whether blood product transfusion was 
associated with decreased graft survival following orthotopic liver transplantation. The 
association between blood product transfusion and graft survival rates for patients 
undergoing orthotopic liver transplantation at Royal Prince Alfred Hospital between 
August 2002 and December 2011 was evaluated at one and five years post 
transplantation. 
 Hypothesis 
The hypothesis was that patients who received perioperative blood product transfusion 
would have a decreased graft survival at one and five years following orthotopic liver 
transplantation compared with patients who did not receive perioperative blood 
product transfusion. 
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 Methods 
 Statistical methods 
Data handling was performed as described in Chapter 2: General methods section 
2.11 (page 77).  
 Univariate analysis 
To assess for variability, the continuous variables were divided into quartiles for 
analysis. A substantial number of patients did not receive any transfusion (n= 70 for 
packed red cells, n=124 for platelets, n=35 for fresh frozen plasma, n=213 for 
cryoprecipitate). These patients were placed in a separate group and the remainder 
of the patients were divided into quartiles for analysis. 
The univariate relationships between blood product transfusion and graft survival were 
evaluated by the Cox proportional hazards model. The Kaplan-Meier analysis and the 
log rank test were used to evaluate the differences between graft survival rates in 
different blood product transfusion groups. The endpoint was graft failure. The patients 
with liver grafts that survived to the end of the follow-up period were censored. The 
survival analysis for graft survival were conducted at 1 and 5-year follow-up intervals 
 Multivariate analysis 
A multivariate Cox regression model was developed utilising the stepwise forward 
selection model described in section 2.11 of Chapter 2 (Statistical Methods, page 75). 
The variables with a p-value less than 0.2 on univariate analysis were applied to the 
selection process for the multivariate model.  
The parameters for analysis in the multivariate model for one year graft survival 
included preoperative endotracheal intubation requirement, preoperative admission to 
131 
 
ICU, hepatopulmonary syndrome, pulmonary hypertension, preoperative dialysis 
requirement, donor risk index, cold ischaemic time, platelet transfusion, 
cryoprecipitate transfusion and “return to the operating theatre” within 72 hours of 
transplantation. 
The final variables included in the multivariate model for one year graft survival were: 
platelet transfusion, packed red blood cell transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, MELD score, donor risk index, preoperative 
endotracheal intubation and hepatopulmonary syndrome. 
The factors considered for analysis in the multivariate model for five year graft survival 
included: recipient age, hepatopulmonary syndrome, preoperative platelet count, 
hepatitis B/C status, preoperative dialysis requirement, pulmonary hypertension, 
volume of ascites, non-identical ABO graft, donor graft steatosis, donor risk index, 
donation after cardiac death, split graft, antifibrinolytic use (aprotinin and tranexamic 
acid), platelet transfusion, FFP transfusion, cryoprecipitate transfusion, total operative 
time, volume of intraoperative crystalloid given, total intraoperative blood loss and cold 
ischaemic time. As cold ischaemic time and donation after cardiac death grafts were 
components of the donor risk index, they were excluded from the variable selection 
process for the multivariate model (described within the methods section). The final 
variables included in the multivariate model for five-year graft survival were platelet 
transfusion, packed red blood cell transfusion, fresh frozen plasma transfusion, 
cryoprecipitate transfusion, MELD score, donor risk index, non-identical ABO graft 
donor, preoperative platelet count, the intraoperative volume of crystalloid given and 
aprotinin use.  
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 Results 
 Effect of blood product transfusion on one year graft survival 
 Univariate Cox regression: one year graft survival 
The results of the univariate analysis are summarised below in Table 19. The variables 
associated (p<0.05) with an effect on one year graft survival were cold ischaemic time, 
platelet transfusion and cryoprecipitate transfusion. The full results of the univariate 
analysis are presented in Table 23 (page 157) in the appendix. 
Table 19. Summary of variables associated with a one year effect on graft survival 
on univariate analysis 
Variables P-value 
Transplantation Variables   
Cold Ischaemic Time 0.002 
Platelet Transfusion 0.018 
Cryoprecipitate Transfusion 0.024 
 
The variables with P-values less than 0.2 were included in the multivariate analysis 
(highlighted in red in Table 23 (page 157)). 
 
 Kaplan Meier analysis: one year graft survival 
The results of the Kaplan Meier analysis of one year graft survival is presented in the 
figures below. 
On the univariate Kaplan Meier analysis, the transfusion of packed red blood cells 
(Figure 18) and fresh frozen plasma (Figure 19) had no effect on one year graft survival 
following liver transplantation.  
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Figure 18. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the transfusion of Packed Red Blood Cells within the perioperative 
period 
Figure 19. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the transfusion of Fresh Frozen Plasma within the perioperative period  
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The transfusion of platelets was associated with a decreased one year graft survival 
as shown in Figure 20 (p = 0.0271). Additionally, the patients who were transfused 
with cryoprecipitate also had a decreased one year graft survival as demonstrated in 
Figure 21 (p = 0.0254).  
Figure 20. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the transfusion of platelets within the perioperative period 
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Figure 21. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the transfusion of cryoprecipitate within the perioperative period 
 
With the aim of improving the exploratory analysis of blood product usage, further 
analyses using quartiles of blood product transfusion were performed. There was no 
difference in graft survival at one year for transfusion of platelets (Figure 22), packed 
red blood cells (Figure 23), fresh frozen plasma (Figure 24), and cryoprecipitate 
(Figure 25). 
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Figure 22. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the number of units of platelets transfused within the perioperative 
period (by quartiles) 
Figure 23. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the number of units of Packed Red Blood Cells transfused within the 
perioperative period (by quintiles) 
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Figure 24. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the number of units of Fresh Frozen Plasma transfused within the 
perioperative period (by quintiles) 
Figure 25. Kaplan-Meier curves representing cumulative one-year graft survival in 
relation to the number of units of cryoprecipitate transfused within the 
perioperative period (by quartiles) 
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 Multivariate Cox Regression 
Multivariate cox regression for one year graft survival was performed and the results 
are summarised in Table 20.  
Table 20. Multivariate analysis for One Year Graft Survival 
Variable Haz. Ratio z P-value [95% Conf. Interval] 
Platelet Transfusion 
(0 Units)  1         
1-2 Units 2.943647 1.55 0.122 0.750 11.548 
3-4 Units 3.643835 1.7 0.089 0.822 16.143 
≥ 5 Units 4.657998 1.91 0.056 0.960 22.609 
Packed Cell Transfusion  
(0 Units)  1   
   
1-3 Units 0.9094545 -0.13 0.899 0.210 3.933 
4-6 Units 0.5248743 -0.77 0.442 0.101 2.718 
7-12 Units 0.9910163 -0.01 0.992 0.167 5.877 
≥ 13 Units 0.8823077 -0.12 0.903 0.117 6.650 
Fresh Frozen Plasma 
Transfusion (0 Units)  1   
   
1-6 Units 0.6106699 -0.58 0.561 0.116 3.214 
7-10 Units 0.3724109 -0.9 0.369 0.043 3.214 
11-16 Units 0.2373877 -1.15 0.250 0.021 2.749 
≥17 Units 0.6468617 -0.34 0.732 0.054 7.793 
Cryoprecipitate 
Transfusion  
(0 Units)  1   
   
1-9 Units 0.3904645 -0.84 0.400 0.044 3.483 
10-19 Units 0.518098 -1.13 0.257 0.166 1.616 
≥20 Units 0.8783976 -0.22 0.826 0.277 2.782 
MELD Score 
(6-10.99)  1   
   
11-17.99 1.123037 0.19 0.848 0.343 3.674 
18-23.99 0.6172387 -0.63 0.530 0.137 2.778 
≥24 1.462896 0.53 0.594 0.361 5.927 
Donor Risk Index 
(0.906-1.279)  1   
   
1.280-1.524 1.961118 1.17 0.240 0.637 6.035 
1.525-1.845 0.8378968 -0.3 0.764 0.264 2.655 
1.846-3.077 3.048296 2.16 0.031 1.109 8.380 
Preoperative 
Endotracheal intubation 3.328412 1.73 
0.083 0.855 12.952 
Hepatopulmonary 
Syndrome 3.765026 2.39 
0.017 1.268 11.177 
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Perioperative transfusion of any blood product did not decrease one year graft survival 
in the multivariate analysis. 
The multivariate analysis identified the following factors which had an adverse effect 
on graft survival: 
 Quality of Donor Graft 
The quality of donor graft was measured by the donor risk index (the donor risk index 
is further described on page 151). The recipients of grafts with a donor risk index of 
≥1.846 demonstrated an increased one-year graft failure rate with a hazard ratio of 
3.048 (p=0.031, CI 1.11 - 8.38) in comparison to the recipients of grafts with the lowest 
quartile of donor risk index (donor risk index <1.280).  
 Hepatopulmonary Syndrome  
The patients who had hepatopulmonary syndrome also had an increased one-year 
graft failure with a hazard ratio of 3.77 (p=0.017, CI 1.27-11.18). 
 Multicollinearity  
The multicollinearity and correlation coefficient testing demonstrated no substantial 
multicollinearity between the parameters included in the multivariate model for the 
effect of blood product transfusion on one year graft survival. The results are shown 
in Table 24 (page 158) and Table 25 (page 159) in the appendix.  
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 Effect of blood product transfusion on five year graft survival 
 Univariate Cox regression: five year graft survival 
The variables associated with a five year effect on graft survival on univariate analysis 
are summarised below in Table 21. 
The variables (p<0.05) that influenced five year graft survival were recipient age, 
preoperative platelet count, Hepatitis B, preoperative haemoglobin, hepatopulmonary 
syndrome, non-identical ABO group graft, donor graft steatosis, donor risk index, graft 
type (donation after cardiac death vs brain death), total operative time, the use of 
aprotinin & tranexamic acid antifibrinolytics, platelet transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, volume of crystalloid given intraoperatively 
and total intraoperative blood loss.  
Table 21. Univariate analysis: variables associated with graft survival at 5 years 
Variables P-value 
Recipient Variables   
Age 0.011 
Hepatopulmonary Syndrome 0.005 
Preoperative Platelet Count 0.008 
Hepatitis B 0.032 
Preoperative haemoglobin 0.042 
Donor Variables   
ABO identical/non identical 0.000 
Donor Graft Steatosis 0.009 
Donor Risk Index 0.012 
DCD/DBD 0.024 
Transplantation Variables   
Aprotinin use <0.001 
Tranexamic Acid use <0.001 
Cryoprecipitate Transfusion 0.002 
Platelet Transfusion 0.007 
Operative Time 0.011 
Volume of Crystalloid given intraoperatively 0.019 
FFP Transfusion 0.020 
Total Blood Loss intraoperatively 0.024 
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The results of the univariate analysis are presented in Table 26 (page 160) in the 
appendix. The variables with P-values less than 0.2 were applied to the multivariate 
analysis (highlighted in red within the table). 
 Kaplan Meier analysis: five year graft survival 
The Kaplan Meier survival analysis of the effect of blood product transfusion on five 
year graft survival are presented in the figures 26, 27 and 28.  
The transfusion of fresh frozen plasma (p = 0.0325), platelets (p = 0.009) and 
cryoprecipitate (p = 0.0018) were associated with a decrease in five year graft survival 
following liver transplantation. Figures 27 and 28 indicate that the differences in five 
year graft survival associated with platelet and cryoprecipitate transfusion occurred in 
the immediate period following transplantation with almost parallel survival curves 
subsequently. 
Figure 26. Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the transfusion of fresh frozen plasma within the perioperative period 
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Figure 27. Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the transfusion of platelets within the perioperative period 
Figure 28. Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the transfusion of cryoprecipitate within the perioperative period  
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Figure 29. Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the transfusion of Packed Red Blood Cells within the perioperative 
period 
Figure 29 shows that the transfusion of packed red blood cells was not associated with 
decreased five year graft survival. 
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To improve the exploratory analysis of the effect of blood product usage on survival, 
further analyses were performed using quartiles of blood product transfusion. The 
transfusion of platelets was associated with a mixed effect on five year graft survival 
(Figure 30, p = 0.0001). Whilst the transfusion of 1-4 pools of platelets decreased graft 
survival, transfusion of 5 or more pools of platelets was associated with an increase in 
graft survival.  
Figure 30. Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the number of units of platelets transfused within the perioperative 
period (by quartiles) 
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Figure 31.  Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the number of units of cryoprecipitate transfused within the 
perioperative period (by quartiles) 
The transfusion of cryoprecipitate was associated with a decrease in five year graft 
survival (Figure 31, p = 0.0071).  
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The transfusion of packed red blood cells (Figure 32) and fresh frozen plasma (Figure 
33) was not associated with decreased five year graft survival.  
 
Figure 32.  Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the number of units of Packed Red Blood Cells transfused within the 
perioperative period (by quintiles) 
 
  
Figure 33.  Kaplan-Meier curves representing cumulative five-year graft survival in 
relation to the number of units of Fresh Frozen Plasma transfused within the 
perioperative period (by quintiles) 
  
147 
 
 Multivariate Cox Regression for five year graft survival 
Multivariate cox regression for five year graft survival was performed and the results 
are summarised in Table 22. 
On multivariate analysis, the patients who received ≥5 units of perioperative platelet 
transfusion had a decreased five year graft failure rate compared with the patients who 
did not receive any perioperative platelet transfusion (hazard ratio 0.359, P = 0.009, 
CI 0.166 - 0.775).  
The transfusion of packed red blood cells, fresh frozen plasma and cryoprecipitate 
was not associated with five year graft survival. 
The multivariate analysis also examined other modifying factors which had an effect 
on survival. 
 Quality of Donor Graft (Donor Risk Index) 
Poor quality of donor graft was associated with increased one year graft failure rate. 
The patients who received a graft with a donor risk index of ≥1.846 had an increased 
one-year graft failure rate in comparison to the patients who received grafts with a 
donor risk index of <1.280 (hazard ratio = 1.553, p = 0.05, CI 1.0004 - 2.4105).  
 Preoperative platelet levels 
Lower preoperative platelet levels were associated with an increased five year graft 
failure rate. The patients with a preoperative platelet count of >50-100 x 109/L had a 
decreased five year graft failure when compared with the patients with a preoperative 
platelet count of ≤50 x 109/L (hazard ratio of 0.6765, p = 0.044, CI 0.463 - 0.989). The 
patients with a preoperative platelet count of >100 x 109/L had a decreased five year 
graft failure when compared with the patients with a preoperative platelet count of ≤50 
x 109/L (hazard ratio of 0.4967, p = 0.004, CI 0.307 - 0.803).  
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 Antifibrinolytics 
The use of aprotinin was associated with a decreased five year graft failure rate. The 
patients who received aprotinin had a decreased five year graft failure compared with 
the patients who did not (hazard ratio = 0.317, p <0.001, CI 0.197 - 0.510).  
 Intraoperative crystalloid administration 
The administration of larger volumes of intraoperative crystalloid was associated with 
decreased five year graft failure. The patients that received an intraoperative 
crystalloid volume >5000mL had a decreased five year graft failure rate compared with 
the patients who received an intraoperative crystalloid volume of 0‐2000mL (hazard 
ratio = 0.493, p = 0.002, CI 0.313 - 0.778). The patients that received an intraoperative 
crystalloid volume of 3700‐5000mL had a decreased five year graft failure rate 
compared with the patients who received an intraoperative crystalloid volume of 0‐
2000mL (hazard ratio = 0.550, p = 0.011, CI 0.346 - 0.873).
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Table 22. Multivariate analysis for Five Year Graft survival. 
Variable Haz. Ratio z P-Value [95% Conf. Interval] 
Plt Transfusion        0 Units  1         
1-2 Units 1.200441 0.68 0.498 0.708 2.036 
3-4 Units 0.8582965 -0.46 0.643 0.450 1.638 
≥ 5 Units 0.3589389 -2.61 0.009 0.166 0.775 
PRBC Transfusion    0 Units  1       
1-3 Units 0.9919699 -0.03 0.979 0.543 1.812 
4-6 Units 0.8503616 -0.49 0.623 0.445 1.624 
7-12 Units 1.274846 0.65 0.514 0.614 2.646 
≥ 13 Units 1.304109 0.61 0.543 0.555 3.066 
FFP Transfusion       0 Units  1       
1-6 Units 1.983173 1.78 0.075 0.933 4.217 
7-10 Units 1.985907 1.46 0.143 0.792 4.979 
11-16 Units 1.709645 1.08 0.279 0.647 4.518 
≥17 Units 2.179553 1.47 0.142 0.771 6.159 
Cryo Transfusion     0 Units  1       
1-9 Units 0.7051578 -0.9 0.369 0.329 1.510 
10-19 Units 0.9773062 -0.09 0.926 0.603 1.584 
≥20 Units 1.145715 0.49 0.621 0.668 1.965 
MELD Score 
(6-10.99)  1     
  
11-17.99 1.001321 0 0.996 0.593 1.692 
18-23.99 0.9275253 -0.25 0.799 0.708 2.036 
≥24 0.8607684 -0.49 0.627 0.450 1.638 
Donor Risk Index 
(0.906-1.279)  1     
0.166 0.775 
1.280-1.524 1.038737 0.15 0.879   
1.525-1.845 1.300164 1.13 0.259 0.543 1.812 
1.846-3.077 1.55288 1.96 0.05 0.445 1.624 
Non identical ABO graft 
donor 1.357473 1.82 0.069 
0.614 2.646 
Preoperative Platelet 
Count (≤50 x 109/L)  1     
0.555 3.066 
>50 – 100 x 109/L 0.6765155 -2.02 0.044   
>100 x 109/L 0.4966518 -2.85 0.004 0.933 4.217 
Aprotinin use 0.3173929 -4.73 <0.001 0.792 4.979 
Intraoperative Crystalloid 
Volume (0-2000mL)  1     
0.647 4.518 
2000-3700mL 0.7621127 -1.31 0.19 0.771 6.159 
3700-5000mL 0.5497913 -2.54 0.011   
>5000mL 0.4933797 -3.04 0.002 0.329 1.510 
 
Plt = platelet; PRBC = packed red blood cell; FFP = fresh frozen plasma; Cryo = 
cryoprecipitate  
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 Adjustment for possible confounding due to multicollinearity  
The results of the multicollinearity and correlation coefficient testing for the variables 
included in the multivariate model for the effect of blood product transfusion on five 
year graft survival are shown in Table 27 (page 161) and Table 29 (page 163) in the 
appendix.  
As there was multicollinearity in the model, the age variable (VIF>10) was removed 
from the multivariate model before final analysis. The remaining variables were re-
examined for multicollinearity, the results are shown in Table 28 (page 162). With the 
removal of the recipient age variable there was no significant multicollinearity of the 
variables detected. 
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 Discussion 
 Factors affecting one year graft survival 
 Blood product transfusion 
There was no decrease in one year graft survival with transfusion of blood products 
on multivariate analysis. Whilst platelet transfusion and cryoprecipitate transfusion 
showed a trend towards decreased one-year graft survival post liver transplantation in 
the univariate analysis, this was not seen when the preoperative MELD score was 
taken into account in the multivariate analysis. The severity of disease in liver failure 
patients requiring transplantation is an important clinical confounder. The requirement 
for blood product transfusion was associated with increasing coagulopathy in more 
severe liver disease. The higher INR in more severe liver disease was adjusted for 
within the MELD score.  
Donor graft quality and other markers of severity of preoperative liver disease were 
associated with a poorer graft survival. Multivariate analysis of one-year graft survival 
post liver transplantation found that the patients who received a high donor risk index 
graft and the patients who had hepatopulmonary syndrome had an increased graft 
failure rate.  
 Quality of Donor Graft (Donor Risk Index) 
The donor risk index was derived in 2006 by Feng et al, and includes variables such 
as: donor age, cause of donor death, race of donor, donation after cardiac death, 
partial/split liver graft use, donor height, the donor organ location (in regard to local, 
regional or national donors), and cold ischaemic time. A cohort of 20023 patients 
undergoing orthotopic liver transplantation utilising liver grafts from deceased donors 
in the United States of America was used to identify the risk factors associated with 
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increased graft failure. This was validated against subsequent data from 9882 liver 
transplants who had received a deceased donor liver (Feng et al., 2006). 
One of the limitations of the donor risk index was that the original index data was 
derived from patients undergoing orthotopic liver transplantation in the United states 
and had not been validated against a large cohort of transplantations in the Australian 
context. 
The patients who had a donor risk index in the highest quartile of the cohort (greater 
than 1.845) had a threefold increased incidence of graft failure at one year compared 
with the patients with the lowest quartile of donor risk index (donor risk index <1.280). 
Our findings are consistent with other studies that reported an association between 
increased donor risk index and decreased graft survival following orthotopic liver 
transplantation (Bonney et al., 2009, Rosenberger et al., 2014).  
A new index called the organ patient index, which combines the factors of the donor 
risk index and the MELD score, has been created. This has been purported to be more 
predictive of graft survival (Avolio et al., 2008). However, this index has not been 
widely used within other liver transplantation research and the organ patient index has 
not been validated within large patient cohorts. As a result, the organ patient index has 
limited applicability outside the original centre. 
 Hepatopulmonary Syndrome 
The patients who had hepatopulmonary syndrome had an increased one year graft 
failure rate when compared with the patients who did not. A review of the literature 
demonstrated the severity of hepatopulmonary syndrome was associated with poorer 
outcomes post liver transplantation (with decreased one year survival) 
(Cosarderelioglu et al., 2016). 
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 Factors affecting five year graft survival 
 Blood product transfusion 
The multivariate analysis demonstrated that the perioperative transfusion of packed 
red cells, fresh frozen plasma and cryoprecipitate did not increase five year graft failure 
rates following liver transplantation. 
 Perioperative platelet transfusion 
Multivariate analysis demonstrated that the transfusion of ≥5 units of platelets was 
associated with an increased five-year graft survival rate when compared with the 
patients who received no perioperative platelet transfusion. 
When examining the Kaplan-Meier survival curves of the quartiles of platelet 
transfusion plotted against time, the difference in survival was most marked at the 16-
month time period post transplantation. There is a comparatively decreased graft 
failure rate in the patients who received the highest quartile of platelet transfusion at 
this time point. We postulate that the increase in survival with platelet transfusion may 
be due to an immunomodulatory effect on chronic rejection of liver grafts. This is based 
on chronic antibody mediated rejection demonstrated by O’Leary et al in liver grafts at 
a period of one to two years following liver transplantation (O'Leary et al., 2016). 
Antibody mediated rejection has been implicated in chronic graft loss, however the 
effect of platelet transfusion on this immune process has not been examined 
previously in the literature (Wood and Goto, 2012).  
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 Other factors 
Other factors found to influence five year graft survival are described below. 
 Quality of Donor Graft (Donor Risk Index) 
Poor quality donor grafts were associated with an increased five year graft failure rate. 
Our findings are consistent with the literature, where an association between 
increased donor risk index and decreased graft survival following orthotopic liver 
transplantation has been established (Bonney et al., 2009, Rosenberger et al., 2014). 
 Preoperative platelet count 
Increased five year graft failure rates were associated with lower preoperative platelet 
counts. This reflected the severity of preoperative liver dysfunction prior to 
transplantation. Peck-Radosavljevic et al showed that decreased thrombopoietin 
associated with more severe liver dysfunction was responsible for thrombocytopenia 
in advanced liver disease (Peck-Radosavljevic, 2016). 
 Antifibrinolytic administration 
The administration of aprotinin was associated with increased five year graft survival. 
The anti-inflammatory properties of aprotinin may contribute to improved graft survival 
rates. Ortmann et al postulated that these anti-inflammatory effects are mediated by 
the reduction of cytokine release and leukocyte activation (Ortmann et al., 2013).  
 Intraoperative crystalloid volume 
Increasing volumes of intraoperative crystalloid administration were associated with 
increased five year graft survival. A dose response relationship was observed with the 
recipients who received large volumes of intraoperative crystalloids when assessing 
five-year graft survival. The recipients who received 3700mL to 5000mL of 
intraoperative crystalloid had a decreased hazard ratio for graft failure at five years 
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post transplantation (hazard ratio = 0.550) when compared with the patients that 
received less than two litres of intraoperative crystalloid. This effect was increased in 
patients who received greater than 5 litres of intraoperative crystalloid. These patients 
had a five year graft survival hazard ratio 0.493 when compared with the patients that 
received less than 2 litres of intraoperative crystalloid. 
Intraoperative fluid management during liver transplantation is a complex interplay 
between the competing aims of maintaining low central venous pressure) to reduce 
blood loss) and maintaining intravascular volume to support organ and graft perfusion. 
We speculate that the association between increased intraoperative crystalloid 
administration and increased graft survival may be related to improved graft perfusion 
secondary to the maintenance of increased intraoperative intravascular volume. It is 
difficult to recommend increased crystalloid volume administration routinely based on 
these results, as fluid overload and increased bleeding may result. Further prospective 
studies are required to clarify the association between increased intraoperative 
crystalloid administration and improved graft survival rates. A less restrictive fluid 
administration regimen within liver transplantation may be recommended if this 
association is confirmed in prospective studies. 
The effect of intraoperative crystalloid on graft survival will be further discussed within 
the study on effects of transfusion on acute kidney injury (page 165). 
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 Conclusion 
In contrast to previous studies by de Boer et al. and Pereboom et al. (de Boer et al., 
2008, Pereboom et al., 2009), the transfusion of blood products was not associated 
with any decrease in graft survival following liver transplantation. We adjusted for the 
effects of graft quality in our graft survival analysis, whereas the studies by de Boer et 
al. and Pereboom et al. did not. This difference in statistical methodology may account 
for the difference in results. Heterogeneity between study populations may also have 
contributed to the difference in findings. The patients in our cohort had a higher 
preoperative MELD score (mean MELD = 19.5) in comparison to the transplant cohort 
studied by De Boer et al. (mean MELD = 16). The transfusion of platelets had a trend 
towards increased graft survival rates at five years post liver transplantation and this 
may be attributed to long term immunomodulatory effects. 
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 Appendix to Chapter 5 
 One year graft survival 
 
Table 23. Univariate analysis for One Year Graft survival. 
Variables P-value 
Recipient Variables   
Preoperative endotracheal intubation 0.052 
Preoperative admission to ICU 0.068 
Hepatopulmonary Syndrome 0.077 
Pulmonary Hypertension 0.110 
Preoperative haemoglobin 0.123 
Preoperative Dialysis 0.152 
MELD Score 0.235 
Hepatitis B 0.343 
Volume of Ascites 0.345 
Age 0.372 
Hepatocellular Carcinoma 0.378 
Hepatitis C 0.401 
Preoperative Serum Creatinine 0.454 
Previous Major Abdominal Surgery 0.458 
Preoperative Creatinine Clearance 0.602 
Recipient Sex 0.653 
CTP Score 0.658 
Acute Liver Failure 0.857 
Corrected BMI 0.867 
Preoperative Platelet Count 0.904 
BMI 0.981 
Donor Variables  
Donor Risk Index 0.093 
DCD/DBD 0.423 
Donor Age 0.539 
Split graft 0.684 
Donor Sex 0.809 
Donor Graft Steatosis 0.991 
ABO identical/non identical 0.992 
Transplantation Variables  
Cold Ischaemic Time 0.002 
Platelet Transfusion 0.018 
Cryoprecipitate Transfusion 0.024 
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Return to Operating Theatre within 72 
hours 
0.139 
Total fluid volume given intraoperatively 0.219 
Antifibrinolytic Use 0.296 
Factor VII use 0.366 
Operative Time 0.430 
Aprotinin use 0.476 
RBC Transfusion 0.477 
FFP Transfusion 0.623 
Total Blood Loss intraoperatively 0.678 
Volume of Crystalloid given 
intraoperatively 
0.788 
Warm Ischaemic Time 0.848 
Tranexamic Acid use 0.855 
Surgical technique 0.906 
Volume of Colloid given intraoperatively 0.968 
 
 
Table 24. Multicollinearity Testing for One Year Graft Survival 
Variable Variance Inflation Factor 
FFP Transfusion 8.51 
Packed Cell Transfusion 8.17 
MELD score 6.3 
Donor Risk Index 4.68 
Cryoprecipitate Transfusion 3.3 
Platelet Transfusion 2.13 
Preoperative Endotracheal intubation 1.11 
Hepatopulmonary Syndrome 1.08 
  
Mean VIF 4.41 
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Table 25. Correlation matrix of coefficients of Cox model for One Year Graft Survival 
     
 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
FFP 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
score 
Donor 
Risk 
Index 
Preoperative 
Endotracheal 
intubation 
Hepatopulmonary 
Syndrome 
Platelet 
Transfusion 1                        
Packed Cell 
Transfusion -0.1423 1                      
FFP Transfusion -0.1286 -0.7054 1                    
Cryoprecipitate 
Transfusion -0.1117 -0.4734 0.0468 1                  
MELD score -0.0095 0.1118 -0.2484 -0.2126 1                
Donor Risk Index 0.1252 0.0448 0.0378 -0.2031 0.0285 1              
Preoperative 
Endotracheal 
intubation -0.0192 -0.0593 0.0751 -0.0287 -0.3988 -0.0501 1            
Hepatopulmonary 
Syndrome 0.0425 0.005 0.0414 -0.028 -0.0592 -0.0461 0.1432 1 
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 Five year graft survival 
Table 26. Univariate analysis for Five Year Graft survival. 
Variables P-value 
Recipient Variables   
Age 0.011 
Hepatopulmonary Syndrome 0.005 
Preoperative Platelet Count 0.008 
Hepatitis B 0.032 
Preoperative haemoglobin 0.042 
Preoperative Dialysis 0.150 
Pulmonary Hypertension 0.161 
Hepatitis C 0.170 
Volume of Ascites 0.184 
Preoperative Serum Creatinine 0.301 
Previous Major Abdominal Surgery 0.355 
MELD Score 0.389 
CTP Score 0.454 
Preoperative admission to ICU 0.456 
BMI 0.637 
All other Indications 0.654 
Preoperative Creatinine Clearance 0.726 
Hepatocellular Carcinoma 0.746 
Acute Liver Failure 0.769 
Preoperative endotracheal intubation 0.904 
Recipient Sex 0.928 
Corrected BMI 0.932 
Donor Variables  
ABO identical/non identical <0.001 
Donor Graft Steatosis 0.009 
Donor Risk Index 0.012 
DCD/DBD 0.024 
Split graft 0.117 
Donor Age 0.212 
Donor Sex 0.582 
Transplantation Variables  
Aprotinin use <0.001 
Tranexamic Acid use <0.001 
Cryoprecipitate Transfusion 0.002 
Platelet Transfusion 0.007 
Operative Time 0.011 
Volume of Crystalloid given 
intraoperatively 
0.019 
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FFP Transfusion 0.020 
Total Blood Loss intraoperatively 0.024 
Antifibrinolytic Use 0.055 
Cold Ischaemic Time 0.060 
Warm Ischaemic Time 0.244 
RBC Transfusion 0.274 
Total fluid volume given intraoperatively 0.286 
Volume of Colloid given intraoperatively 0.321 
Surgical technique 0.730 
Factor VII use 0.779 
Return to Operating Theatre within 72 
hours 
0.011 
 
Table 27. Multicollinearity Testing for variables included in multivariate analysis 
for Five Year Graft survival. 
Variable 
Variance Inflation 
Factor 
Age 14.78 
Donor Risk Index 13.93 
FFP Transfusion 8.61 
Packed Cell Transfusion 8.52 
MELD score 6.83 
Volume of Intraoperative 
Crystalloid 4.19 
Cryoprecipitate Transfusion 3.66 
Preoperative Platelet count 3.19 
Platelet Transfusion 2.41 
Aprotinin use 1.65 
Non identical ABO group 1.49 
  
Mean VIF 6.29 
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Table 28. Multicollinearity Testing for variables included in multivariate analysis 
for Five Year Graft survival (after removal of Age variable from model). 
Variable 
Variance Inflation 
Factor 
FFP Transfusion 8.61 
Packed Cell Transfusion 8.52 
Donor Risk Index 7.33 
MELD score 6.65 
Volume of Intraoperative 
Crystalloid 3.71 
Cryoprecipitate Transfusion 3.65 
Preoperative Platelet count 3.18 
Platelet Transfusion 2.41 
Aprotinin Use 1.62 
Non identical ABO group 1.49 
  
Mean Variance Inflation Factor 4.72 
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Table 29. Correlation matrix of coefficients of multivariate cox model for five-year graft survival 
Correlation 
Coefficients 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
FFP 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
score 
Donor 
Risk 
Index 
Non 
identical 
ABO 
group 
Aprotini
n Use 
Volume of 
Intraoperative 
Crystalloid 
Preoperative 
Platelet count 
Platelet 
Transfusion 1                            
Packed Cell 
Transfusion -0.0997 1                          
FFP Transfusion -0.2587 -0.6851 1                        
Cryoprecipitate 
Transfusion -0.1923 -0.4685 0.1271 1                      
MELD score -0.0501 0.1224 -0.2228 -0.2742 1                    
Donor Risk 
Index 0.0727 0.0187 -0.0212 -0.0846 0.028 1                  
Non identical 
ABO group 0.0963 -0.0318 -0.0759 0.0069 
-
0.1347 
-
0.0031 1                
Aprotinin Use -0.0959 -0.1451 0.1276 0.1943 
-
0.0943 0.0832 0.1443 1              
Volume of 
Intraoperative 
Crystalloid -0.0131 0.0133 -0.07 -0.0187 0.2715 0.0722 0.064 0.1285 1            
Preoperative 
Platelet count 0.2844 -0.1408 0.0637 0.0799 -0.061 0.0565 -0.0665 0.0051 -0.1629 1 
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 THE ASSOCIATION BETWEEN BLOOD PRODUCT 
ADMINISTRATION AND ACUTE KIDNEY INJURY AND 
INCIDENCE OF POSTOPERATIVE DIALYSIS IN LIVER 
TRANSPLANTATION 
 Introduction 
The incidence of acute kidney injury following orthotopic liver transplantation is 12-
64% (de Haan et al., 2017, Karapanagiotou et al., 2014, Rahman et al., 2017). It is 
associated with increased mortality and morbidity. Renal replacement therapy in the 
postoperative period occurs in 8-17% of patients following liver transplantation 
(Suleymanlar et al., 2011). The predisposing factors for acute kidney injury following 
liver transplantation include the administration of calcineurin inhibitors, postoperative 
sepsis, and severity of liver dysfunction (Gainza et al., 2002).  
The aim of this study was to determine whether the transfusion of blood products was 
associated with an increase in acute kidney injury following orthotopic liver 
transplantation. Acute kidney injury was assessed by examining postoperative 
creatinine levels at 48 hours post liver transplantation. In this study, acute kidney injury 
was defined by the Acute Kidney Injury Network (AKIN) Stage 1 criteria: a 50% 
increase in the baseline serum creatinine level or a 26.5 µmol/L absolute increase in 
the serum creatinine level at 48 hours post liver transplantation (Lopes and Jorge, 
2013a).  
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 Definition of Acute Kidney Injury 
The varied definitions of acute kidney injury have made it difficult to compare clinical 
studies. However, the development of standardised definitions has enabled the 
comparison of research data. These criteria include the RIFLE (Risk, Injury, Failure, 
Loss, End-Stage), AKIN (Acute Kidney Injury Network) and KDIGO (Kidney Disease: 
Improving Global Outcomes) criteria.  
Table 30. Criteria for Acute Kidney Injury 
Classification Criteria for Acute Kidney Injury 
RIFLE Rise in Serum Creatinine ≥50 % within 7 days  
AKIN Rise in Serum Creatinine ≥26.5 µmol/L or ≥50 % within 48 hours 
KDIGO Rise in Serum Creatinine ≥26.5 µmol/L within 48 h or ≥50 % within 7 days 
 
This study utilised the AKIN criteria to define acute kidney injury. The AKIN criteria 
and KDIGO criteria have a similar sensitivity for identifying patients with acute kidney 
injury in liver transplantation (Erdost et al., 2016). The heterogeneity of criteria used in 
the literature to define patients with acute kidney injury is a barrier in comparing results 
from different institutions.  
The AKIN criteria are more sensitive at identifying patients with acute kidney injury 
than the RIFLE criteria (Jiang et al., 2011, Lopes and Jorge, 2013a, Xiong et al., 2015). 
The AKIN criteria was introduced in 2007 to address several shortcomings of the 
RIFLE criteria. The AKIN criteria utilise two measurements of serum creatinine in a 
48-hour period. Acute kidney injury is defined by a 50% increase in the baseline serum 
creatinine level or a 26.5 µmol/L absolute increase in the serum creatinine level. A rise 
in serum creatinine of 26.5 µmol/L or greater was associated with a fourfold increase 
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in hospital mortality (Zhou et al., 2016).  The 48-hour time interval for assessing acute 
kidney injury makes the AKIN criteria more specific for perioperative effects compared 
with the RIFLE criteria. The use of an absolute serum creatinine rise makes the AKIN 
criteria more sensitive for detecting acute kidney injury, especially in patients with a 
high baseline serum creatinine level (Lopes and Jorge, 2013a). This is significant in 
patients with underlying renal dysfunction prior to orthotopic liver transplantation, eg. 
patients with hepatorenal syndrome. 
Prior to the AKIN criteria, the RIFLE criteria used as the standardised method for 
defining acute kidney injury in patients (Bellomo et al., 2004). The RIFLE criteria 
utilised a percentage rise in baseline serum creatinine, decrease in glomerular filtration 
rate or a decrease in urine output to define acute kidney injury. These changes were 
assessed within 7 days post-surgery. There were several limitations associated with 
the RIFLE criteria. As serum creatinine was used to definite end stage acute kidney 
injury, the percentage increase in serum creatinine was reached at a later stage for 
patients with a high baseline creatinine (eg. patients with existing kidney disease). 
Consequently, the RIFLE criteria were less sensitive in identifying patients with acute 
kidney injury. The production of endogenous creatinine is influenced by age, diet, 
muscle mass and gender. This has important implications for the assessment of acute 
kidney injury patients in patients with end stage liver disease who are often cachectic. 
As the increase in serum creatinine, decrease in glomerular filtration rate or decrease 
in urine output were measured across a duration of 7 days (compared to the 48 hours 
in the AKIN critera), the RIFLE criteria were less specific to perioperative physiological 
disturbances that predisposed patients to acute kidney injury and could be influenced 
by other factors (such as diuretic use and contrast induced nephropathy) in the 
postoperative period (Lopes and Jorge, 2013b). 
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A hybrid classification of acute kidney injury was proposed by the KDIGO group 
(Kidney Disease: Improving Global Outcomes) in 2012. This classification utilises 
features of both the AKIN and RIFLE criteria for defining acute kidney injury. The 
definition of acute kidney injury according to the KDIGO criteria include an increase in 
serum creatinine by an absolute value of 26.5 µmol/L within 48 hours, a ≥50% rise 
within 7 days, or a urine output less than 0.5mL/kg/hour for 6 hours. 
Standardisation of definitions for acute kidney injury enable better comparison of 
experiences between research groups. The KDIGO classification attempts to refine 
the RIFLE and AKIN criteria. However, few studies have evaluated it in the liver 
transplantation setting. Novel markers of acute kidney injury are being assessed for 
defining early acute kidney injury. One such marker is cystatin-C, a cysteine protease 
inhibitor filtered freely by the glomerulus. Although cystatin-C shows promise in 
predicting acute kidney injury and associated mortality, it has not been validated in the 
critically ill or the liver transplant population (Zhou et al., 2016). 
 Hypothesis 
 Primary Hypothesis 
The primary hypothesis of this study was that the patients who received perioperative 
blood product transfusion have an increased incidence of acute kidney injury following 
orthotopic liver transplantation compared with patients who did not receive 
perioperative blood product transfusion. 
 Secondary Hypothesis 
The secondary hypothesis of this study was that the patients receiving perioperative 
blood product transfusion have an increased incidence of postoperative dialysis 
following orthotopic liver transplantation compared with patients who did not receive 
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perioperative blood transfusion. Postoperative dialysis is an indicator of more severe 
renal dysfunction following liver transplantation and is clinically important.   
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 Methods  
Data collection and management was performed as described in Section 2.11 of 
Chapter 2 ( Statistical Methods, page 77). 
 Statistical methods 
For the statistical analysis of the effects of blood product transfusion on acute kidney 
injury and incidence of postoperative dialysis, the patients who were dialysed 
preoperatively were excluded. 
 Methods for univariate analysis 
The univariate analysis of the relationship between the transfusion of blood products 
and acute kidney injury was evaluated by logistic regression. The continuous variables 
were divided into quartiles to assess for variability. A substantial number of patients 
did not receive any transfusion (n=70 for packed red cells, n=124 for platelets, n=35 
for fresh frozen plasma, n=213 for cryoprecipitate). These patients were placed in a 
separate group and the remainder of the patients were divided into quartiles for 
analysis. 
 Methods for multivariate analysis 
A multivariate logistic regression model was developed utilising the stepwise forward 
selection model described in Chapter 2 (Section 2.11.1 -  Statistical Methods, page 
77). In the analysis of acute kidney injury following liver transplantation, the variables 
with a p-value less than 0.2 in the univariate analysis (highlighted within Table 35) 
were selected for multivariate analysis. These included recipient body mass index, 
corrected body mass index (defined in section 2.7.9.2, page 72), volume of ascites, 
preoperative platelet count, MELD score, Child Turcotte Pugh score, hepatocellular 
carcinoma, pulmonary hypertension, donor sex, return to operating theatre within 72 
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hours of transplant, antifibrinolytic use (including aprotinin and tranexamic acid use), 
packed red blood cell transfusion, platelet transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, recombinant factor VII use, volume of colloid 
and crystalloid given intraoperatively; and total intraoperative blood loss.  
In the analysis of the incidence of postoperative dialysis following liver transplantation, 
variables with a p-value less than 0.2 in the univariate analysis (highlighted within 
Table 33) were selected for the multivariate model. 
The recipient MELD score was selected over the Child Turcotte Pugh score in the 
multivariate analysis because it is used to prioritise recipients for liver transplantation 
and is more objective. Preoperative creatinine was removed from the final model prior 
to the final analysis to avoid collinearity as it is a component of the MELD score.  
The variables included in the multivariate model for acute kidney injury post 
transplantation were: platelet transfusion, packed red blood cell transfusion, fresh 
frozen plasma transfusion, cryoprecipitate transfusion, MELD score, corrected body 
mass index, intraoperative blood loss, volume of intraoperative crystalloid 
administered, the use of antifibrinolytics (aprotinin and tranexamic acid) and 
pulmonary hypertension. 
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 Results 
 The association between blood product administration and 
postoperative Acute Kidney Injury 
Univariate and multivariate analyses were performed to determine the association 
between blood product administration and acute kidney injury. 
 Univariate Logistic regression 
The results of the univariate logistic regression analysis are summarised in Table 31. 
Table 31. Variables selected from univariate analysis for multivariate model 
Variables P-value 
Recipient Variables   
CTP Score <0.001 
BMI <0.001 
MELD Score <0.001 
Corrected BMI 0.001 
Preoperative Platelet Count 0.003 
Pulmonary Hypertension 0.028 
Hepatocellular Carcinoma 0.128 
Volume of Ascites 0.153 
Donor Variables  
Donor Sex 0.056 
Transplantation Variables  
Platelet Transfusion <0.001 
RBC Transfusion <0.001 
FFP Transfusion <0.001 
Total intraoperative Blood Loss  <0.001 
Cryoprecipitate Transfusion <0.001 
Antifibrinolytic Use 0.001 
Factor VII use 0.030 
Volume of Crystalloid given intraoperatively 0.031 
Return to Operating Theatre within 72 hours 0.053 
Tranexamic Acid use 0.060 
Aprotinin use 0.120 
Volume of Colloid given intraoperatively 0.149 
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From the univariate analysis, the factors associated with acute kidney injury (p<0.05) 
were: recipient body mass index, corrected recipient body mass index (volume of 
ascites removed from the pre transplant weight), preoperative platelet count, MELD 
score, Child Turcotte Pugh score, pulmonary hypertension, antibrinolytic use, packed 
red blood cell transfusion, platelet transfusion, fresh frozen plasma transfusion, 
cryoprecipitate transfusion, the use of recombinant factor VII, the volume of crystalloid 
given intraoperatively and the total intraoperative blood loss.  
The results of the univariate analysis are presented in Table 35 (page 186) in the 
appendix to Chapter 6.  
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 Multivariate Logistic Regression 
The results of the multivariate logistic regression for acute kidney injury are shown in 
Table 32. 
Table 32. Multivariate analysis for Acute Kidney Injury. 
Acute Kidney Injury Odds Ratio z P value [95% Conf. Interval] 
Plt Transfusion                   0 Units 1         
1-2 Units 2.172583 2.05 0.041 1.034 4.566 
3-4 Units 1.099614 0.21 0.831 0.459 2.636 
≥ 5 Units 1.790747 1.19 0.234 0.686 4.676 
PRBC Transfusion               0 Units 1       
1-3 Units 1.806985 1.2 0.231 0.686 4.761 
4-6 Units 2.875852 2 0.046 1.020 8.112 
7-12 Units 5.386086 2.74 0.006 1.619 17.924 
≥ 13 Units 1.90559 0.91 0.361 0.478 7.600 
FFP Transfusion                  0 Units 1       
1-6 Units 1.790233 0.86 0.392 0.472 6.793 
7-10 Units 1.386197 0.41 0.684 0.287 6.686 
11-16 Units 1.296562 0.3 0.765 0.237 7.102 
≥17 Units 1.67404 0.55 0.581 0.269 10.409 
Cryo Transfusion                 0 Units 1       
1-9 Units 0.8275631 -0.32 0.751 0.257 2.661 
10-19 Units 0.8395455 -0.47 0.636 0.407 1.731 
≥20 Units 1.865967 1.3 0.192 0.730 4.767 
MELD Score                     (6-10.99) 1       
11-17.99 0.9765991 -0.06 0.953 0.444 2.147 
18-23.99 0.8222082 -0.44 0.66 0.344 1.967 
≥24 0.8973594 -0.23 0.818 0.357 2.259 
Corrected BMI                      <20 1       
20 - <25 1.372579 0.55 0.584 0.442 4.260 
25 - <30 2.130551 1.31 0.191 0.686 6.615 
≥30 4.505334 2.5 0.013 1.382 14.683 
Intraoperative Blood Loss 
(<1700mL) 1     
  
1700-3399mL 1.12387 0.31 0.753 0.543 2.328 
3400- 6900mL 1.970989 1.69 0.09 0.899 4.323 
>6900mL 1.750172 1.15 0.25 0.674 4.546 
Intraoperative Crystalloid 
Volume           (0-2000mL) 1     
  
2000-3700mL 0.9995128 0 0.999 0.497 2.010 
3700-5000mL 0.668229 -1.05 0.295 0.314 1.421 
>5000mL 0.5283505 -1.8 0.072 0.264 1.059 
Antifibrinolytic use 1       
Aprotinin 1.531585 1.38 0.168 0.835 2.809 
Tranexamic Acid 0.8588153 -0.46 0.648 0.446 1.652 
Pulmonary Hypertension 3.662592 1.37 0.17 0.573 23.430 
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On the multivariate analysis, blood product transfusion and recipient body mass index 
were associated with an increased incidence of acute kidney injury. 
 Multicollinearity  
The multicollinearity and correlation coefficient testing were performed for the 
parameters included in the multivariate model for the effect of blood product 
transfusion on acute kidney injury. Although the variance inflation factor for fresh 
frozen plasma was greater than 10, it was not significantly correlated with other 
variables within the model as all the values within the correlation matrix were less than 
0.5. The results are shown in Table 36 (page 174) and Table 37  (page 187) in the 
appendix to Chapter 6. 
 Platelet transfusion 
The transfusion of platelets was associated with increased acute kidney injury 
following liver transplantation. The patients who received 1-2 units of platelets had an 
increased incidence of acute kidney injury compared with the patients who did not 
receive any platelet transfusion (odds ratio = 2.17, p = 0.041, CI 1.034 - 4.566).  
 Packed red blood cell transfusion 
The transfusion of packed red blood cells (4-12 units) was also associated with 
increased acute kidney injury following orthotopic liver transplantation. The patients 
who received 4-6 units of packed red blood cells had an increased incidence of acute 
kidney injury compared with the patients who did not receive any packed red blood 
cell transfusion (odds ratio = 2.876, p = 0.046, CI 1.020 - 8.112). An increased 
incidence of acute kidney injury was also demonstrated in patients who received 7-12 
units of packed red blood cells compared with those who did not receive any packed 
red blood cell transfusion (odds ratio = 5.386, p = 0.006, CI 1.619 - 17.92).  
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 Cryoprecipitate and Fresh Frozen Plasma transfusion 
The transfusion of fresh frozen plasma and cryoprecipitate was not associated with 
increased acute kidney injury following liver transplantation. 
 Body mass index and acute kidney injury 
Obesity in liver transplant recipients was associated with increased acute kidney injury 
post liver transplantation. Patients with a corrected body mass index of ≥30 had a 
higher incidence of acute kidney injury compared with those with a corrected body 
mass index <20 (odds ratio = 4.505, p = 0.013, CI 1.382 - 14.68).  
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 Postoperative Dialysis  
 Univariate Logistic regression for incidence of postoperative 
dialysis 
The variables (p-value <0.2) selected for the multivariate analysis are summarised in 
Table 33. The variables were: volume of ascites, preoperative serum creatinine, 
preoperative creatinine clearance, MELD score, Child Turcotte Pugh score, indication 
for transplant (acute liver failure, hepatocellular carcinoma), hepatitis C status, 
preoperative admission to the intensive care unit, preoperative endotracheal 
intubation, pulmonary hypertension, donor age, non-identical ABO graft, split graft, 
surgical technique, cold ischaemic time, operative time, “return to the operating 
theatre” within 72 hours, packed red blood cell transfusion, platelet transfusion, 
cryoprecipitate transfusion, recombinant factor VII use, volume of crystalloid given 
intraoperatively. 
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Table 33. Variables selected from univariate analysis for multivariate model 
selection 
Recipient Variables   
MELD Score <0.001 
Preoperative admission to ICU <0.001 
Preoperative endotracheal intubation <0.001 
Preoperative Creatinine Clearance <0.001 
Preoperative Serum Creatinine <0.001 
CTP Score 0.037 
Pulmonary Hypertension 0.067 
Volume of Ascites 0.072 
Hepatitis C 0.110 
Acute Liver Failure 0.110 
Hepatocellular Carcinoma 0.190 
Donor Variables  
Split graft 0.015 
ABO identical/non identical 0.104 
Donor Age 0.107 
Transplantation Variables  
FFP Transfusion <0.001 
Surgical technique 0.168 
Total Blood Loss intraoperatively 0.000 
Platelet Transfusion 0.002 
Volume of Crystalloid given 
intraoperatively 
0.003 
Cryoprecipitate Transfusion 0.005 
Factor VII use 0.005 
RBC Transfusion 0.006 
Return to Operating Theatre within 72 
hours 
0.023 
Cold Ischaemic Time 0.023 
Operative Time 0.057 
 
The details of the univariate analysis are presented in Table 43 (page 205) in the 
appendix. 
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 Multivariate Logistic Regression for postoperative dialysis  
The results of the multivariate logistic regression for postoperative dialysis are shown 
in Table 34. 
Table 34. Multivariate analysis for postoperative dialysis. 
Postoperative Dialysis Odds Ratio z P value [95% Conf. Interval] 
Platelet Transfusion                        0 Units 1         
1-2 Units 2.435604 0.98 0.325 0.413 14.357 
3-4 Units 1.306619 0.28 0.777 0.205 8.323 
≥ 5 Units 4.52165 1.5 0.134 0.629 32.489 
Packed Cell Transfusion                  0 Units 1       
1-3 Units 1       
4-6 Units 4.670734 1.06 0.29 0.269 81.029 
7-12 Units 11.42121 1.54 0.125 0.510 255.820 
≥ 13 Units 14.06228 1.57 0.118 0.513 385.204 
FFP Transfusion                               0 Units 1       
1-6 Units 1       
7-10 Units 5.522523 1.18 0.239 0.321 95.096 
11-16 Units 2.031488 0.9 0.37 0.431 9.576 
≥17 Units 0.887767 -0.18 0.856 0.246 3.201 
1-6 Units 1       
Cryoprecipitate Transfusion          0 Units 1       
1-9 Units 0.631346 -0.46 0.647 0.088 4.526 
10-19 Units 0.403842 -1.31 0.189 0.104 1.565 
≥20 Units 0.368569 -1.29 0.197 0.081 1.679 
MELD Score                                      6-10.99 1       
11-17.99 0.39733 -0.91 0.363 0.054 2.908 
18-23.99 0.457708 -0.76 0.447 0.061 3.427 
≥24 1.17228 0.16 0.871 0.173 7.939 
Preoperative Endotracheal intubation 9.782093 2.58 0.01 1.734 55.175 
Intraoperative Blood Loss        (<1700mL) 1       
1700-3399mL 0.668854 -0.38 0.705 0.084 5.353 
3400- 6900mL 3.647549 1.42 0.156 0.611 21.769 
>6900mL 7.803459 2.04 0.042 1.082 56.284 
Intraoperative Crystalloid Volume  
                                                    (0-2000mL) 1     
  
2000-3700mL 0.908138 -0.17 0.865 0.300 2.747 
3700-5000mL 0.777289 -0.4 0.692 0.224 2.700 
>5000mL 0.098836 -2.97 0.003 0.021 0.456 
Cold Ischaemic Time                (<6.5 hours) 1       
6.5-7.84 hours 2.703351 1.17 0.24 0.514 14.215 
7.85 – 9.14 hours 2.764596 1.25 0.212 0.561 13.628 
≥9.15 hours 4.867974 1.93 0.054 0.972 24.384 
Pulmonary Hypertension 4.050669 1.51 0.13 0.662 24.787 
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The variables with significant p-values that were selected for final multivariate model 
for postoperative dialysis were: platelet transfusion, packed red blood cell transfusion, 
fresh frozen plasma transfusion, cryoprecipitate transfusion, MELD score, 
preoperative endotracheal intubation, preoperative creatinine, intraoperative blood 
loss, intraoperative crystalloid volume, graft cold ischaemic time and pulmonary 
hypertension.  
 Multicollinearity  
The multicollinearity and correlation coefficient testing were performed for the 
parameters included in the multivariate model for the effect of blood product 
transfusion on postoperative dialysis. Although the variance inflation factor for fresh 
frozen plasma was greater than 10, it was not significantly correlated with any other 
variable within the model as all the values within the correlation matrix were less than 
0.5. The results are shown in Table 39 (page 190) and Table 40 (page 191) in the 
appendix.  
181 
 
 The effects of blood product transfusion on postoperative 
dialysis  
The transfusion of blood products was not associated with increased postoperative 
dialysis on multivariate analysis. However, multivariate analysis identified preoperative 
endotracheal intubation and intraoperative blood loss as factors associated with an 
increased incidence of postoperative dialysis. The administration of >5 litres of 
crystalloid was associated with decreased postoperative dialysis. 
 Intraoperative blood loss 
The patients who had an intraoperative blood loss of greater than 6900mL had 
increased postoperative dialysis compared with the patients with an intraoperative 
blood loss of less than 1700mL (odds ratio = 7.803, p = 0.042, CI 1.082 – 56.28).  
 Intraoperative crystalloid administration 
Large crystalloid volume (>5 litres) administered during the intraoperative period was 
associated with decreased postoperative dialysis. The patients who received greater 
than 5000mL of intraoperative crystalloid had decreased postoperative dialysis 
compared with those who received a volume of 2000mL or less (odds ratio = 0.09884, 
p = 0.003, CI 0. 02144 - 0. 4556).  
 Preoperative endotracheal intubation 
The patients who were intubated preoperatively had an increased incidence of 
postoperative dialysis (odds ratio = 9.782, p = 0.01, CI 1.734- 55.18).  
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 Discussion 
 Postoperative Acute Kidney Injury  
The incidence of acute kidney injury (as defined by Acute Kidney Injury Network 
(AKIN) criteria) was 50.69% (220 of 434 patients) in this cohort of patients. This is 
similar to the study by Hilmi et al who reported a 52% incidence of acute kidney injury, 
using the KDIGO criteria (Hilmi et al., 2015). Karapanagiotou et al recorded a 52% 
incidence of acute kidney injury in patients who had undergone orthotopic liver 
transplantation as defined by the AKIN criteria (Karapanagiotou et al., 2014). 
 Effect of blood product transfusion on incidence of acute kidney 
injury 
An association between blood product transfusion and acute kidney injury was 
identified, although it is difficult to attribute a cause & effect relationship between blood 
product transfusion and acute kidney injury due to the severity of underlying liver 
disease. 
 Platelet Transfusion 
Multivariate analysis demonstrated that platelet transfusion was associated with 
postoperative acute kidney injury. This was observed in the patients who received 1-
2 units of platelets compared with the patients that received no platelet transfusion. 
No dose response relationship was observed in the larger quantities of platelet 
transfusion. Hilmi et al reported an association with platelet transfusion with 
postoperative acute kidney injury in liver transplant patients with univariate analysis. 
However after multivariate analysis this effect was not seen (Hilmi et al., 2015). 
Karapanagiotou et al found an association between acute kidney injury and higher 
transfusion rates of platelets, packed red blood cells and fresh frozen plasma 
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(Karapanagiotou et al., 2014). It is difficult to compare their data with our study as 
Karapanagiotou et al did not perform a multivariate analysis to control for confounding 
factors.  
 Packed Red Blood Cell transfusion 
Multivariate analysis demonstrated an association between packed red blood cell 
transfusion and increased incidence of acute kidney injury post orthotopic liver 
transplantation. These was seen with transfusion of 4-6 units of packed red blood cells 
and 7-12 units of packed red blood cells. The higher odds ratio associated with 7-12 
units of packed cells suggested a dose relationship. However, in the patients who 
received 13 or more units of packed red blood cell transfusion (largest transfusion 
group) there was no association with acute kidney injury (p = 0.361). A trend towards 
increased incidence of acute kidney injury was associated with increased 
intraoperative blood loss. However, this was not statistically significant within the 
multivariate analysis. These findings support those of Hilmi et al, who found an 
association with packed red blood cell transfusion with postoperative acute kidney 
injury in liver transplant patients on univariate analysis. However after multivariate 
analysis, this association was not present (Hilmi et al., 2015). 
 Other factors associated with acute kidney injury 
The multivariate analysis found that recipient body mass index, intraoperative 
crystalloid administration, intraoperative blood loss and preoperative intubation were 
also associated with acute kidney injury. 
 Body Mass Index 
The patients in this study with a corrected body mass index ≥30 had an increased 
incidence of acute kidney injury post orthotopic liver transplantation. These results are 
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in agreement with the findings of Hilmi et al who found that the patients with a body 
weight >100kg had an increased incidence of acute kidney injury following liver 
transplantation (Hilmi et al., 2015).  
 Intraoperative crystalloid administration 
The use of intraoperative crystalloid administered during liver transplantation was 
associated with a trend towards decreased acute kidney injury, particularly at volumes 
greater than 5 litres. The patients who received greater than 5 litres crystalloid during 
orthotopic liver transplantation had a decreased incidence of postoperative dialysis 
(odds ratio = 0.0988).  
 Intraoperative Blood loss 
The patients who had a large intraoperative blood volume loss had a significantly 
increased incidence of postoperative dialysis. This is reflected in the patients in the 
largest quartile of blood loss (greater than 6900mL) who had a 7.8 times higher 
incidence of postoperative dialysis than the group of patients who had less than 
1700mL of blood loss. In this cohort, the transfusion of blood products (platelets, 
packed red blood cells, fresh frozen plasma and cryoprecipitate) were not associated 
with increased postoperative dialysis. A possible mechanism for the increase in the 
incidence in postoperative dialysis is renal hypoperfusion associated with blood loss. 
 Preoperative endotracheal intubation 
In the multivariate analysis, the patients who were intubated prior to liver 
transplantation had an increased incidence of postoperative dialysis (odds ratio = 
9.78). This is likely due to increased disease severity reflected by hepatopulmonary 
syndrome and associated portal hypertension or hepatorenal syndrome. 
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 Conclusion 
 Acute Kidney Injury 
This study showed that platelet and packed red blood cell transfusion was associated 
with a trend towards increased acute kidney injury following liver transplantation. This 
association was stronger with packed red blood cell transfusion. Although these 
effects may be secondary to blood loss, no causal relationship can be concluded. 
These findings are in agreement with those of Hilmi et al. (Hilmi et al., 2015). While 
Hilmi et al. identified an association between postoperative acute kidney injury 
following liver transplantation and transfusion of packed red blood cells and fresh 
frozen plasma, the effect was only observed on univariate analysis. 
Acute kidney injury in the postoperative period may influence the dose and timing of 
nephrotoxic immunosuppressive medications such as tacrolimus and hence may 
influence graft survival.  
 Incidence of postoperative dialysis 
The transfusion of blood products did not increase the incidence of postoperative 
dialysis in patients undergoing orthotopic liver transplantation. Severity of preoperative 
disease (preoperative endotracheal intubation) and complexity of surgery 
intraoperative blood loss) were associated with increased postoperative dialysis. 
Increased crystalloid volume administration (greater than 5 litres) was associated with 
decreased postoperative dialysis. Further prospective studies utilising goal directed 
and liberal fluid strategies are required to clarify the association between fluid therapy 
and the need for postoperative dialysis.  
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 Appendix to Chapter 6 
Table 35. Univariate analysis for Acute Kidney Injury. 
Variables P-value 
Recipient Variables   
CTP Score <0.001 
BMI <0.001 
MELD Score <0.001 
Corrected BMI 0.001 
Preoperative Platelet Count 0.003 
Pulmonary Hypertension 0.028 
Hepatocellular Carcinoma 0.128 
Volume of Ascites 0.153 
All other Indications 0.247 
Previous Major Abdominal Surgery 0.266 
Preoperative Creatinine Clearance 0.416 
Preoperative Serum Creatinine 0.419 
Preoperative admission to ICU 0.591 
Recipient Sex 0.694 
Age 0.714 
Preoperative endotracheal intubation 0.752 
Acute Liver Failure 0.798 
Hepatopulmonary Syndrome 0.866 
Hepatitis C 0.904 
Hepatitis B 0.955 
Donor Variables  
Donor Sex 0.056 
Donor Age 0.246 
Split graft 0.264 
DCD/DBD 0.349 
ABO identical/non identical 0.451 
Donor Graft Steatosis 0.713 
Transplantation Variables  
Platelet Transfusion <0.001 
RBC Transfusion <0.001 
FFP Transfusion <0.001 
Total intraoperative Blood Loss  <0.001 
Cryoprecipitate Transfusion <0.001 
Antifibrinolytic Use 0.001 
Factor VII use 0.030 
Volume of Crystalloid given 
intraoperatively 
0.031 
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Return to Operating Theatre within 72 
hours 
0.053 
Tranexamic Acid use 0.060 
Aprotinin use 0.120 
Volume of Colloid given intraoperatively 0.149 
Total fluid volume given intraoperatively 0.416 
Operative Time 0.430 
Warm Ischaemic Time 0.433 
Cold Ischaemic Time 0.656 
Surgical technique 0.775 
 
Table 36. Multicollinearity Testing for variables included in multivariate analysis 
for Acute Kidney Injury. 
Variable Variance Inflation Factor 
Fresh Frozen Plasma Transfusion 10.6 
Body Mass Index 9.58 
Packed Cell Transfusion 9.11 
MELD Score 7.1 
Intraoperative Blood Loss 5.06 
Intraoperative Crystalloid Volume 3.68 
Cryoprecipitate Transfusion 3.38 
Antifibrinolytic use 2.42 
Platelet Transfusion 2.28 
Pulmonary Hypertension 1.06 
  
Mean Variance Inflation Factor 5.43 
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Table 37. Correlation matrix of coefficients of multivariate logistic regression model for Acute Kidney Injury. 
 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh 
Frozen 
Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score 
Body 
Mass 
Index 
Intraoperative 
Blood Loss 
Intraoperative 
Crystalloid 
Volume 
Antifibrinolytic 
use 
Pulmonary 
Hypertension 
Platelet 
Transfusion 1                   
Packed Cell 
Transfusion -0.1543 1                 
Fresh Frozen 
Plasma 
Transfusion -0.1603 -0.4632 1               
Cryoprecipitate 
Transfusion -0.0847 -0.3787 0.0272 1             
MELD Score 0.0079 -0.0192 -0.2376 -0.153 1           
Body Mass 
Index -0.0663 0.1443 -0.0451 0.0243 -0.0162 1         
Intraoperative 
Blood Loss 0.0922 -0.2616 -0.4319 -0.114 0.1158 -0.151 1       
Intraoperative 
Crystalloid 
Volume -0.0957 -0.0755 0.0778 0.0967 0.2099 0.0106 -0.1671 1     
Antifibrinolytic 
use -0.0839 -0.0556 -0.1251 -0.0721 0.0048 -0.1447 0.1807 0.0105 1   
Pulmonary 
Hypertension 0.0058 -0.0889 0.0363 0.0534 -0.0179 -0.0299 0.0318 0.0345 0.0387 1 
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Table 38. Univariate analysis for postoperative dialysis  
Recipient Variables   
MELD Score <0.001 
Preoperative admission to ICU <0.001 
Preoperative endotracheal intubation <0.001 
Preoperative Creatinine Clearance <0.001 
Preoperative Serum Creatinine <0.001 
CTP Score 0.037 
Pulmonary Hypertension 0.067 
Volume of Ascites 0.072 
Hepatitis C 0.110 
Acute Liver Failure 0.110 
Hepatocellular Carcinoma 0.190 
Hepatopulmonary Syndrome 0.221 
BMI 0.251 
Corrected BMI 0.280 
Hepatitis B 0.357 
Recipient Sex 0.552 
Preoperative Platelet Count 0.802 
Previous Major Abdominal Surgery 0.861 
Age 0.889 
All other Indications 0.957 
Donor Variables  
Split graft 0.015 
ABO identical/non identical 0.104 
Donor Age 0.107 
Donor Graft Steatosis 0.249 
Donor Sex 0.416 
DCD/DBD 0.605 
Donor Risk Index 0.934 
Transplantation Variables  
FFP Transfusion <0.001 
Surgical technique 0.168 
Total Blood Loss intraoperatively 0.000 
Platelet Transfusion 0.002 
Volume of Crystalloid given 
intraoperatively 
0.003 
Cryoprecipitate Transfusion 0.005 
Factor VII use 0.005 
RBC Transfusion 0.006 
Return to Operating Theatre within 72 
hours 
0.023 
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Cold Ischaemic Time 0.023 
Operative Time 0.057 
Warm Ischaemic Time 0.487 
Tranexamic Acid use 0.570 
Volume of Colloid given intraoperatively 0.618 
Aprotinin use 0.701 
Total fluid volume given intraoperatively 0.797 
Antifibrinolytic Use 0.953 
 
Table 39. Multicollinearity Testing for variables included in multivariate analysis 
for postoperative dialysis. 
Variable Variance Inflation Factor 
Fresh Frozen Plasma Transfusion 10.37 
Packed Cell Transfusion 8.94 
Cold Ischaemic Time 8.32 
MELD Score 6.67 
Total intraoperative Blood Loss 4.68 
Volume of intraoperative crystalloid 3.61 
Cryoprecipitate Transfusion 3.44 
Platelet Transfusion 2.26 
Preoperative endotracheal intubation 1.1 
Pulmonary Hypertension 1.05 
  
Mean Variance Inflation Factor 5.04 
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Table 40. Correlation matrix of coefficients of multivariate logistic regression model for postoperative dialysis. 
 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh Frozen 
Plasma 
Transfusion 
Cryoprecipitate 
Transfusion MELD Score 
Preoperative 
endotracheal 
intubation 
Intraoperative 
Blood Loss 
Intraoperative 
Crystalloid 
Volume 
Cold 
Ischaemic 
Time  
Pulmonary 
Hypertension 
Platelet 
Transfusion 1                   
Packed Cell 
Transfusion -0.0961 1                 
Fresh Frozen 
Plasma 
Transfusion 0.0201 -0.4215 1               
Cryoprecipitate 
Transfusion -0.1578 -0.4625 -0.048 1             
MELD Score 0.0853 0.0772 -0.2333 -0.2733 1           
Preoperative 
endotracheal 
intubation 0.0387 -0.1096 -0.0451 0.1094 -0.1745 1         
Intraoperative 
Blood Loss 0.0168 -0.3861 -0.3892 0.0886 0.1544 0.152 1       
Intraoperative 
Crystalloid 
Volume -0.1037 0.0311 -0.0934 -0.0562 0.2453 0.0079 -0.0001 1     
Cold Ischaemic 
Time -0.1545 -0.0281 -0.1776 0.0849 -0.1001 -0.0422 0.1574 0.0124 1   
Pulmonary 
Hypertension 0.0714 -0.1642 0.0872 0.09 0.0184 0.0866 0.0744 0.0846 0.124 1 
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 THE ASSOCIATION BETWEEN BLOOD PRODUCT 
ADMINISTRATION AND THE INCIDENCE OF POSTOPERATIVE 
INFECTION FOLLOWING LIVER TRANSPLANTATION 
 Introduction 
Postoperative infection is an important cause of graft failure and mortality following 
liver transplantation (Avkan-Oguz et al., 2013). The preoperative severity of disease, 
transfusion of packed red cells, prolonged operative time, prolonged hospital 
admission and prolonged intensive care unit stay have been identified as risk factors 
for postoperative infection in liver transplantation (Kim, 2014, Nemes et al., 2005). Li 
et al reported a bacterial infection rate of 14.01% in the 3 months following liver 
transplantation (Li et al., 2012c). 
The aim of this study was to determine whether the transfusion of blood products was 
associated with an increase in postoperative infection following orthotopic liver 
transplantation. Postoperative infection was assessed in the 3-month period following 
liver transplantation. 
 Hypothesis 
The hypothesis of this study was that the patients who received perioperative blood 
product transfusion would have an increased incidence of postoperative infection 
following orthotopic liver transplantation compared with the patients who did not 
receive perioperative blood product transfusion. 
  
194 
 
 Methods 
Data collection and management was performed as described in Section 2.11 of 
Chapter 2 ( Statistical Methods, page 77). Infection was defined as any infective 
complication reported within the 3-month period following liver transplantation. The 
parameters used to define an episode of infection included: antibiotic treatment, blood 
culture with bacterial growth, fungal culture treated with antifungal agents, and coding 
for infective complications or the term “sepsis” within the medical records. 
 Statistical methods 
 Univariate analysis 
The univariate relationships between the transfusion of blood products and 
postoperative infection were evaluated by logistic regression. The continuous 
variables were divided into quartiles to assess for variability. There were a substantial 
number of patients who did not receive any transfusion (n=70 for packed red cells, 
n=124 for platelets, n=35 for fresh frozen plasma, n=213 for cryoprecipitate). These 
patients were placed in a separate group and the remainder of the patients were 
divided into quartiles for analysis. 
 Multivariate analysis 
A multivariate logistic regression model was developed utilising the stepwise forward 
selection model described in the Chapter 2 (Section 2.11.1 -  Statistical Methods, page 
77). For the analysis of infection following liver transplantation, the variables with a p-
value less than 0.2 in the univariate analysis (highlighted within Table 43) were applied 
to the selection process for the multivariate model. These included: the recipient body 
mass index, preoperative creatinine clearance, Child Turcotte Pugh score, 
preoperative dialysis requirement, Donation after Cardiac Death Vs Donation after 
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Brain Death, “return to the operating theatre” within 72 hours, aprotinin use, 
tranexamic acid use, packed red blood cell transfusion, platelet transfusion, fresh 
frozen plasma transfusion, factor VII use, and total intraoperative blood loss. 
 Results 
Infective complications in the postoperative period occurred in 162 of 434 patients 
(37%) and infection was identified as the cause of death in 13 patients in our cohort. 
 Univariate Logistic regression 
The variables with a p-value <0.2 were used in the multivariate selection process. The 
results are summarised in the table below. 
Table 41. Summary of variables selected from univariate analysis for multivariate 
model selection for postoperative infection 
Variables P-value 
Recipient Variables   
CTP Score 0.030 
Preoperative Creatinine Clearance 0.115 
BMI 0.124 
Preoperative Dialysis 0.174 
Donor Variables  
DCD/DBD 0.162 
Transplantation Variables  
Platelet Transfusion 0.001 
Aprotinin use 0.009 
Return to Operating Theatre within 72 
hours 
0.009 
FFP Transfusion 0.021 
Tranexamic Acid use 0.107 
Factor VII use 0.146 
RBC Transfusion 0.161 
Total intraoperative Blood Loss  0.167 
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The variables associated with postoperative infection (p<0.05) on the univariate 
analysis were: “return to the operating theatre” within 72 hours, aprotinin use, platelet 
transfusion, and FFP transfusion. 
The results of the univariate analysis are presented in Table 43 (page 205) in the 
appendix.  
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 Multivariate Logistic Regression 
The results of the multivariate logistic regression for postoperative infection are shown 
in Table 42. 
Table 42. Multivariate analysis for postoperative infection. 
Infection 
Odds 
Ratio z P value [95% Conf. Interval] 
Platelet Transfusion 
                           (0 Units) 1     
1-2 Units 3.742931 3.56 <0.001 1.810 7.742 
3-4 Units 2.521081 2.18 0.029 1.097 5.793 
≥ 5 Units 2.501926 2 0.045 1.020 6.134 
Packed Cell Transfusion  
(0 Units) 1       
1-3 Units 0.729425 -0.69 0.493 0.296 1.797 
4-6 Units 0.883886 -0.26 0.794 0.349 2.236 
7-12 Units 2.199998 1.46 0.145 0.761 6.358 
≥ 13 Units 2.480776 1.48 0.138 0.747 8.243 
Fresh Frozen Plasma 
Transfusion (0 Units) 1       
1-6 Units 1.656874 0.94 0.349 0.576 4.765 
7-10 Units 1.167474 0.23 0.816 0.318 4.290 
11-16 Units 0.91312 -0.13 0.9 0.222 3.763 
≥17 Units 1.598067 0.61 0.541 0.355 7.190 
Cryoprecipitate 
Transfusion      (0 Units) 1       
1-9 Units 1.454612 0.71 0.476 0.519 4.074 
10-19 Units 0.368292 -2.82 0.005 0.184 0.738 
≥20 Units 0.579544 -1.26 0.207 0.248 1.353 
MELD Score     (6-10.99) 1       
11-17.99 1.021752 0.06 0.954 0.492 2.122 
18-23.99 1.106513 0.25 0.805 0.495 2.472 
≥24 0.776865 -0.6 0.546 0.342 1.762 
Return to OT (within 72 
hours) 1.446828 1.19 0.236 
0.786 2.664 
Antifibrinolytic use        
Aprotinin  1.240434 0.78 0.433 0.723 2.127 
Tranexamic Acid 0.506668 -2.1 0.035 0.269 0.954 
BMI                            <20 1       
20-30 2.180517 1.32 0.188 0.684 6.956 
>30 3.887858 2.2 0.028 1.157 13.069 
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These variables were subjected to the selection process described within Chapter 2.11 
(page 77). The variables included in the multivariate model for postoperative infection 
were: platelet transfusion, packed red blood cell transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, MELD score, “return to operating theatre” 
within 72 hours, antifibrinolytic use (aprotinin & tranexamic acid), and recipient body 
mass index.  
 Multicollinearity  
The multicollinearity and correlation coefficient testing demonstrated no significant 
multicollinearity between the parameters included in the multivariate model for the 
effect of blood product transfusion on postoperative infection. The results are shown 
in Table 44 (page 206) and Table 45 (page 207) in the appendix of Chapter 7. 
 Platelet Transfusion 
The transfusion of platelets was associated with increased incidence of postoperative 
infection in liver transplant recipients. The 310 patients who received platelet 
transfusion had increased incidence of postoperative infection compared with the 124 
patients who did not receive any platelet transfusion. The odds ratio for 121 patients 
who received 1-2 units of platelets was 3.743 for developing postoperative infection, 
compared with the patients who did not receive platelet transfusion in the perioperative 
period (p <0.001, CI 1.810 – 7.742). The odds ratio for 84 patients who received 3-4 
units of platelets was 2.521 for developing postoperative infection, when compared 
with patients who did not receive platelet transfusion in the perioperative period (p = 
0.029, CI 1.097 – 5.793). In the 70 patients who received 5 or more units of platelets 
the odds ratio for developing postoperative infection was 2.502, when compared with 
patients who received no platelet transfusion in the perioperative period (p=0.045, CI 
1.020 - 6.134). 
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 Cryoprecipitate Transfusion 
The 92 patients who received 10-19 units of cryoprecipitate transfusion in the 
perioperative period had a lower incidence of postoperative infection compared with 
the 213 patients who received no cryoprecipitate transfusion (odds ratio = 0.368, P = 
0.005, CI 0.1838 – 0.7379). 
 Antifibrinolytic agents 
The 107 patients who received tranexamic acid had a 49.3% lower incidence of 
postoperative infection compared with the 201 patients who received no antifibrinolytic 
(odds ratio = 0.5067, P = 0.035, CI 0.2690 – 0.9542). 
 Body Mass Index 
The 142 patients with a body mass index of >30 had an increased incidence of 
postoperative infection compared with the 19 patients with a body mass index less 
than 20 (odds ratio 3.888, P = 0.028, CI 1.157 – 13.07). 
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 Discussion 
 Effects of platelet transfusion on infection 
The transfusion of platelets was associated with increased incidence of infection in the 
postoperative period in our cohort. This association was observed in patients who 
received platelet transfusion in the perioperative period when compared with the 
patients who did not receive any platelets. 
An increased incidence of transfusion related infection has been associated with 
platelet transfusion. Platelets are stored between 20-24 degrees Celsius for up to five 
days, and therefore are more prone to bacterial contamination. The incidence of 
bacterial contamination of platelet products has been described in the range of 1 in 
750 to 1 in 1000 platelet units (Corash, 2011). Patients undergoing liver transplantation 
commonly receive multiple transfusions of platelet products which increase the 
exposure to potentially contaminated products. A number of factors increase the 
susceptibility of patients undergoing liver transplantation to infective complications. 
The liver recipients receive immunosuppressive medications to prevent graft rejection. 
Immunosuppression increases infective complications (Moini et al., 2015). Platelets 
suppress T cell mediated immunity which further increases the incidence of infective 
complications (Kapur and Semple, 2016). No specific incidences of platelet bacterial 
contamination were identified within this study and so it is uncertain whether the 
increased incidence of infection associated with platelet transfusion was related to 
bacterial contamination in this study. It is likely that the infective events are related to 
immunosuppression, however it is difficult to state a conclusive mechanism behind 
this finding. 
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 Effects of cryoprecipitate transfusion on infection 
The transfusion of cryoprecipitate products was not associated with an increased 
incidence of infection in the postoperative period. The patients who received 10-19 
units of cryoprecipitate had a decreased incidence of postoperative infective 
complications when compared with the patients who received no cryoprecipitate 
transfusion. As this finding was isolated to one quartile and no dose related effect was 
found in the patients that received 20 or more units of cryoprecipitate, no causative 
effect could be concluded.  
 Effects of fresh frozen plasma transfusion on infection 
This study found no association between transfusion of fresh frozen plasma and 
increased incidence of postoperative infection following liver transplantation. 
Whilst there is a lack of data investigating the association between fresh frozen plasma 
transfusion and postoperative infections in liver transplant recipients, there is a single 
study that identified an increased incidence of fungal infections with fresh frozen 
plasma transfusion. Briegel et al. identified an association between the transfusion of 
fresh frozen plasma and increased incidence of systemic fungal infections following 
liver transplantation (Briegel et al., 1995). In contrast to the study by Briegel et al, our 
analysis examined overall infection rather than specifically investigating fungal 
infections. Due to the different types of infection being examined, it is difficult to 
compare results. 
 Effects of packed red blood cell transfusion on infection 
This study found no association between the transfusion of packed red blood cells and 
increased incidence of postoperative infection following liver transplantation.  
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This is in contrast to the findings of Benson et al., which described a dose related 
association between packed red blood cell transfusion and infective complications 
following liver transplantation (Benson et al., 2011a). While this study controlled for 
MELD score, the study by Benson et al. did not control for MELD score as a 
confounding factor in their multivariate analysis. While their patients received packed 
red cells less than 10 days old, our patients received packed cells with varying duration 
of storage. This is due to the local blood bank guidelines in dispensing products with 
the shortest expiry date. The patient characteristics of the study by Benson et al 
differed to ours. In the study by Benson et al. the median MELD score was 25 and the 
main aetiology of disease was cirrhosis secondary to hepatitis C (49% of the cohort). 
In this cohort, the median MELD score was 17 and 32.5% of patients had cirrhosis 
secondary to hepatitis C. The differences in statistical methodology, age of packed red 
blood cells and baseline patient characteristics may account for the differences in 
findings between our study and those of Benson et al. 
 Effects of tranexamic acid administration on infection 
While there was an association in this study between tranexamic acid administration 
and decreased incidence of postoperative infection, the administration of aprotinin was 
not associated with decreased incidence of postoperative infection. While it is possible 
that the association between tranexamic acid use and decreased incidence of 
postoperative infection may be related to decreased blood product transfusion, this 
study did not find a statistically significant decrease in transfusion requirements with 
the administration of antifibrinolytics. Additionally, whilst tranexamic acid has been 
associated with decreased packed red blood cell transfusion requirements (Molenaar 
et al., 2007), packed red blood cell transfusion was not associated with increased 
postoperative infection in this study. The association between tranexamic acid 
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administration and decreased infection is difficult to explain and warrants further 
investigation. 
 Effects of Body Mass Index on infection 
Obesity has been associated with increased postoperative infective complications in 
general surgery patients (Tjeertes et al., 2015). Our study demonstrated an 
association between obese patients (BMI >30) and infective complications following 
liver transplantation. The reasons for this are likely due to increased intraoperative 
blood loss and a longer duration of operative time. Longer operative time has been 
associated with increased infective complications in other surgical cohorts (Kurmann 
et al., 2011, Mullen et al., 2008, Mullen et al., 2009), as well as in liver transplantation 
(Hernandez et al., 2015). 
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 Conclusion 
Platelet transfusion was associated with increased incidence of infective complications 
in the postoperative period following orthotopic liver transplantation. The transfusion 
of packed cells, cryoprecipitate and fresh frozen plasma was not associated with an 
increase in infective complications in the postoperative period following liver 
transplantation. 
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Table 43. Univariate analysis for postoperative infection. 
Variables P-value 
Recipient Variables   
CTP Score 0.030 
Preoperative Creatinine Clearance 0.115 
BMI 0.124 
Preoperative Dialysis 0.174 
MELD Score 0.206 
Corrected BMI 0.291 
All other Indications 0.296 
Preoperative admission to ICU 0.308 
Previous Major Abdominal Surgery 0.325 
Preoperative endotracheal intubation 0.327 
Preoperative Platelet Count 0.403 
Hepatopulmonary Syndrome 0.434 
Hepatocellular Carcinoma 0.455 
Preoperative Serum Creatinine 0.472 
Acute Liver Failure 0.484 
Volume of Ascites 0.490 
Pulmonary Hypertension 0.577 
Age 0.648 
Hepatitis C 0.926 
Recipient Sex 0.974 
Hepatitis B 0.977 
Donor Variables  
DCD/DBD 0.162 
Donor Risk Index 0.246 
ABO identical/non identical 0.631 
Split graft 0.806 
Donor Graft Steatosis 0.855 
Donor Age 0.882 
Donor Sex 0.936 
Transplantation Variables  
Platelet Transfusion 0.001 
Aprotinin use 0.009 
Return to Operating Theatre within 72 
hours 
0.009 
FFP Transfusion 0.021 
Tranexamic Acid use 0.107 
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Factor VII use 0.146 
RBC Transfusion 0.161 
Total Blood Loss intraoperatively 0.167 
Volume of Crystalloid given 
intraoperatively 
0.354 
Antifibrinolytic Use 0.395 
Operative Time 0.433 
Total fluid volume given intraoperatively 0.454 
Surgical technique 0.542 
Volume of Colloid given intraoperatively 0.552 
Cold Ischaemic Time 0.686 
Warm Ischaemic Time 0.722 
Cryoprecipitate Transfusion 0.922 
 
Table 44. Multicollinearity Testing for variables included in multivariate analysis 
for postoperative infection 
Variable Variance Inflation Factor 
Fresh Frozen Plasma Transfusion 8.62 
Packed Cell Transfusion 8.45 
MELD Score 6.68 
Body Mass Index 6.26 
Cryoprecipitate Transfusion 3.31 
Antifibrinolytic use 2.38 
Platelet Transfusion 2.24 
Return to Operating Theatre within 72 hours 1.23 
  
Mean Variance inflation factor 4.9 
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Table 45. Correlation matrix of coefficients of multivariate logistic regression model for postoperative infection. 
Correlation 
Coefficients 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh Frozen Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score 
Return to 
Operating Theatre 
within 72 hours 
Antifibrinolytic 
use 
Body Mass 
Index 
Platelet 
Transfusion 1        
Packed Cell 
Transfusion -0.0889 1       
Fresh Frozen 
Plasma 
Transfusion -0.0952 -0.6517 1      
Cryoprecipitate 
Transfusion -0.1572 -0.4721 -0.0084 1     
MELD Score 0.0269 0.0406 -0.2321 -0.1424 1    
Return to 
Operating 
Theatre within 
72 hours 0.0343 -0.0745 -0.0146 -0.0328 0.0628 1   
Antifibrinolytic 
use -0.1043 0.0043 -0.1006 -0.0171 -0.0189 -0.0944 1  
Body Mass 
Index -0.0609 0.1163 -0.1259 -0.0711 -0.0163 0.0971 -0.1165 1 
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 THE ASSOCIATION BETWEEN BLOOD PRODUCT 
TRANSFUSION AND DURATION OF ENDOTRACHEAL 
INTUBATION, DURATION OF INTENSIVE CARE UNIT STAY 
AND DURATION OF HOSPITAL STAY 
 Introduction 
Platelet transfusion is associated with increased duration of intensive care unit stay 
and increased duration of mechanical ventilation. This effect is independent of 
preoperative platelet count (Fayed et al., 2014). Prolonged duration of mechanical 
ventilation is also associated with increased duration of intensive care unit stay and 
duration of hospital stay in liver transplant patients (Nafiu et al., 2017). Nardo et al. 
found that packed red blood cell transfusion was not associated with an increase in 
hospital or intensive care unit stay in liver transplant recipients (Nardo et al., 2005b).  
The aim of this study was to determine whether the transfusion of blood products was 
associated with an increased duration of endotracheal intubation, duration of intensive 
care unit stay and duration of hospital stay following orthotopic liver transplantation. 
Hospital length of stay, intensive care unit length of stay and duration of endotracheal 
intubation data for patients undergoing liver transplantation at Royal Prince Alfred 
Hospital between August 2002 and December 2011 were analysed. 
 Hypothesis 
The hypothesis of this study was that the patients who received perioperative blood 
product transfusion would have an increased duration of endotracheal intubation, 
increased duration of intensive care unit stay and increased duration of hospital stay 
following orthotopic liver transplantation compared with the patients who did not 
receive perioperative blood product transfusion. 
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 Methods 
Data collection and management was performed as described in Section 2.11 of 
Chapter 2 ( Statistical Methods, page 77). The duration of endotracheal intubation was 
measured in hours from the time of intubation to the time of extubation following liver 
transplantation. The duration of intensive care unit stay was measured in days from 
date of intensive care unit admission to intensive care unit discharge. The duration of 
hospital stay was measured in days from date of hospital admission to hospital 
discharge. 
 Univariate analysis 
The univariate relationships between the transfusion of blood products and duration 
of hospital and intensive care unit stay were evaluated by negative binomial 
regression. The continuous variables were divided into quartiles to assess for 
variability. There were a substantial number of patients who did not receive any 
transfusion (n=70 for packed red cells, n=124 for platelets, n=35 for fresh frozen 
plasma, n=213 for cryoprecipitate). These patients were placed in a separate group 
and the remainder of the patients were divided into quartiles to aid comparison of the 
data. 
 Multivariate analysis 
A multivariate logistic regression model was developed utilising the stepwise forward 
selection model described in Chapter 2 (Section 2.11.1 -  Statistical Methods, page 
77). For the analysis of duration of hospital and intensive care unit stay following liver 
transplantation, the variables with a p-value less than 0.2 in the univariate analysis 
(highlighted within Table 54 and Table 57) were applied to the selection process for 
the multivariate model.  
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The variables included in the selection process for the multivariate model for duration 
of hospital stay were: recipient age, recipient sex, recipient body mass index, corrected 
recipient body mass index, volume of ascites, preoperative platelet count, preoperative 
serum creatinine, preoperative creatinine clearance, MELD score, CTP score, 
transplant indications other than acute liver failure, hepatocellular carcinoma, 
preoperative dialysis requirement, hepatitis C status, preoperative endotracheal 
intubation requirement, donor age, donor graft steatosis, donation after brain death, 
warm ischaemic time, cold ischaemic time, antifibrinolytic use (tranexamic acid and 
aprotinin), blood product transfusion (packed red blood cells, platelets, fresh frozen 
plasma, cryoprecipitate), volume of intraoperative colloid given, total intraoperative 
fluid volume administered and total intraoperative blood loss. 
The variables included in the selection process for the multivariate model for the 
duration of intensive care unit stay were recipient age, recipient body mass index (and 
corrected body mass index), preoperative platelet count, preoperative serum 
creatinine (and creatinine clearance), MELD score, CTP score, indication of liver 
transplantation, preoperative dialysis requirement, hepatitis C status, requirement for 
preoperative admission to the intensive care unit, preoperative endotracheal 
intubation, pulmonary hypertension, hepatopulmonary syndrome, donor graft 
steatosis, non-identical ABO graft, donor risk index, surgical technique, warm 
ischaemic time, cold ischaemic time, operative time, “return to the operating theatre” 
within 72 hours of transplantation, antifibrinolytic use (aprotinin and tranexamic acid), 
factor VII use, packed red blood cell transfusion, platelet transfusion, fresh frozen 
plasma transfusion, cryoprecipitate transfusion and total volume of intraoperative 
blood loss. 
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 Results 
The summary characteristics of the duration of intubation, duration of intensive care 
unit stay and duration of hospital stay are displayed in Table 46.  
Table 46. Characteristics of duration of intensive care unit stay, hospital stay and 
duration of intubation 
  Median (IQR) Mean (SD) 
Duration of intubation 27 hours (21-49) 48.6 hours (68.0) 
Duration of ICU Stay 3 days (2-6) 4.98 days (5.82) 
Duration of Hospital Stay 20 days (15-30) 25.9 days (22.7) 
 
 Effects of blood product administration on duration of 
postoperative endotracheal intubation 
 Univariate negative binomial regression 
Negative binomial regression was used to analyse the recipient, donor and 
transplantation variables. The variables associated (p<0.05) with an effect on the 
duration of endotracheal intubation on univariate analysis are summarised in Table 
47. These were: preoperative endotracheal intubation, preoperative admission to the 
intensive care unit, recipient MELD score, transplant indication, preoperative serum 
creatinine, preoperative dialysis, hepatitis B status, hepatitis C status, corrected 
recipient body mass index, recipient age, recipient gender, CTP score, pulmonary 
hypertension, preoperative creatinine clearance, graft from a non-identical ABO donor, 
donor age, donor risk index, split liver graft, total intraoperative blood loss, cold 
ischaemic time, “return to the operating theatre” within 72 hours of transplantation, 
volume of crystalloid administered intraoperatively, antifibrinolytic use (tranexamic 
acid and aprotinin), blood product transfusion (packed red blood cells, platelets, fresh 
frozen plasma, cryoprecipitate), Factor VII use,  volume of intraoperative colloid given, 
total intraoperative fluid volume administered and warm ischaemic time. 
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Table 47. Univariate analysis: Variables associated with duration of intubation  
Variables P-value 
Recipient Variables   
Preoperative endotracheal intubation <0.001 
Preoperative admission to ICU <0.001 
MELD Score <0.001 
Acute Liver Failure <0.001 
Preoperative Serum Creatinine <0.001 
Preoperative Dialysis <0.001 
Hepatitis C <0.001 
Corrected BMI <0.001 
Age <0.001 
Recipient Sex <0.001 
CTP Score <0.001 
All other Indications <0.001 
Pulmonary Hypertension <0.001 
Hepatitis B <0.001 
BMI 0.001 
Preoperative Creatinine Clearance 0.047 
Donor Variables   
ABO identical/non identical <0.001 
Donor Age 0.065 
Donor Risk Index 0.032 
Split graft 0.033 
Transplantation Variables   
Platelet Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
Cryoprecipitate Transfusion <0.001 
Cold Ischaemic Time <0.001 
Return to Operating Theatre within 72 
hours 
<0.001 
FFP Transfusion <0.001 
RBC Transfusion <0.001 
Volume of Crystalloid given 
intraoperatively 
<0.001 
Antifibrinolytic Use <0.001 
Total fluid volume given intraoperatively 0.001 
Tranexamic Acid use 0.009 
Surgical technique 0.017 
Factor VII use 0.027 
Warm Ischaemic Time 0.028 
Aprotinin use 0.028 
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The details of the full univariate analysis are presented in Table 60 (page 245) in the 
appendix. The variables with a p-value less than 0.2 in the univariate analysis 
(highlighted within Table 60) were applied to the multivariate model selection process 
described in Section 2.11.1 (page 77). 
 Multivariate negative binomial Regression 
The results of the multivariate negative binomial regression for duration of intubation 
are shown in Table 48. 
Table 48. Multivariate analysis for duration of endotracheal intubation. 
Duration of 
Endotracheal 
intubation 
Incidence 
Rate 
Ratio z P value [95% Conf. Interval] 
Platelet 
Transfusion 
(0 Units)  1         
1-2 Units 1.364009 2.81 0.005 1.098 1.694 
3-4 Units 1.034534 0.27 0.79 0.806 1.328 
≥ 5 Units 1.178854 1.18 0.238 0.897 1.550 
Packed Cell 
Transfusion  
(0 Units)  1     
  
1-3 Units 0.81936 -1.5 0.135 0.631 1.064 
4-6 Units 0.982654 -0.12 0.902 0.744 1.297 
7-12 Units 1.027382 0.16 0.869 0.744 1.418 
≥ 13 Units 0.992189 -0.04 0.969 0.672 1.466 
Fresh Frozen 
Plasma Transfusion 
(0 Units)  1     
  
1-6 Units 1.450235 2.48 0.013 1.081 1.945 
7-10 Units 1.320771 1.49 0.136 0.916 1.903 
11-16 Units 1.19954 0.88 0.379 0.800 1.799 
≥17 Units 1.806733 2.64 0.008 1.164 2.804 
Cryoprecipitate 
Transfusion  
(0 Units)  1     
  
1-9 Units 0.858156 -0.93 0.351 0.622 1.183 
10-19 Units 0.873685 -1.26 0.209 0.708 1.078 
≥20 Units 0.944313 -0.42 0.672 0.724 1.232 
MELD Score  1       
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(6-10.99) 
11-17.99 1.022626 0.2 0.839 0.824 1.269 
18-23.99 0.963985 -0.3 0.766 0.757 1.227 
≥24 1.138296 0.96 0.338 0.873 1.483 
Preoperative 
Endotracheal 
intubation 2.322595 4.13 <0.001 
1.557 3.465 
Pulmonary 
Hypertension 2.22674 3.72 <0.001 
1.460 3.397 
Return to OT 
(within 72 hours) 1.561366 4.71 <0.001 
1.297 1.879 
Cold Ischaemic 
Time (hours) (<6.5)  1     
  
6.5-7.84 1.102936 0.99 0.324 0.908 1.340 
7.85-9.14 1.09648 0.92 0.359 0.900 1.335 
≥9.15 1.376327 3 0.003 1.117 1.695 
Non identical ABO 
graft donor 1.284556 3.14 0.002 
1.099 1.502 
Hepatitis C 1.001579 0.02 0.984 0.855 1.174 
Intraoperative 
Blood Loss 
(<1700mL)  1     
  
1700-3399mL 0.996166 -0.04 0.97 0.813 1.221 
3400- 6900mL 1.26219 2.05 0.041 1.010 1.577 
>6900mL 1.204918 1.32 0.186 0.914 1.589 
Male graft donor 1.057839 0.78 0.436 0.918 1.219 
Age (≤47)         
47- 53.19 0.908166 -0.95 0.343 0.744 1.108 
53.2- 58.73 0.985597 -0.15 0.883 0.812 1.197 
58.74- 70 1.290499 2.51 0.012 1.058 1.575 
Hepatitis B 1.15025 1.32 0.186 0.935 1.416 
Female Gender 1.189772 2.03 0.042 1.006 1.407 
Warm Ischaemic 
Time (<0.63 hours)       
  
0.63 - 0.77 hours 1.095153 0.91 0.365 0.900 1.333 
0.78 - 0.9 hours 1.134927 1.23 0.219 0.928 1.389 
>0.9 hours 1.228592 2.13 0.033 1.017 1.485 
Intraoperative 
Crystalloid Volume 
(0-2000mL)  1     
  
2000-3700mL 0.7534 -2.83 0.005 0.619 0.917 
3700-5000mL 0.747961 -2.72 0.006 0.607 0.922 
>5000mL 0.842746 -1.72 0.085 0.694 1.024 
 
The variables selected for the final multivariate model for duration of endotracheal 
intubation were: platelet transfusion, packed red blood cell transfusion, fresh frozen 
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plasma transfusion, cryoprecipitate transfusion, MELD score, requirement for 
preoperative endotracheal intubation, pulmonary hypertension, “return to the 
operating theatre” within 72 hours of liver transplantation, cold ischaemic time, non-
identical ABO graft donor, Hepatitis C status, total volume of intraoperative blood loss, 
graft donor gender, recipient age, hepatitis B status, recipient gender, warm ischaemic 
time, and volume of intraoperative crystalloid administered.  
 Multicollinearity  
The multicollinearity and correlation coefficient testing demonstrated no substantial 
multicollinearity between the parameters included in the multivariate model for the 
effect of blood product transfusion on duration of intubation. The results are shown in 
Table 61 (page 247) and Table 62 (page 248) in the appendix. 
 Platelet transfusion 
One hundred and twenty-one patients who received a transfusion of 1-2 units of 
platelets had an increased duration of endotracheal intubation compared with the 124 
patients who received no platelet transfusion. The incidence rate ratio was 1.364 (P = 
0.005, CI 1.098 – 1.694). The transfusion of 3 or more units of platelets did not have 
a statistically significant association with increased duration of endotracheal 
intubation. 
 Fresh Frozen plasma transfusion 
Eighty-two patients who received a transfusion of 1-6 units of fresh frozen plasma had 
an increased duration of endotracheal intubation compared with the 35 patients who 
received no fresh frozen plasma transfusion. The incidence rate ratio was 1.450 (P = 
0.013, CI 1.081 – 1.945). Additionally, the 94 patients who received a transfusion of 
17 or more units of fresh frozen plasma had an increased duration of endotracheal 
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intubation compared with the patients who received no fresh frozen plasma 
transfusion. The incidence rate ratio was 1.807 (P = 0.008, CI 1.164 – 2.804). The 
patients who received 7-16 units of fresh frozen plasma did not have a statistically 
significant association with increased duration of endotracheal intubation. 
 Preoperative endotracheal intubation 
As the 14 patients who were intubated preoperatively had an increased duration of 
endotracheal intubation compared with the 420 patients who did not (incidence rate 
ratio: 2.323, P <0.001, CI 1.557 – 3.465), it is a clinical confounding factor and was 
adjusted for within the multivariate analysis. 
 Pulmonary Hypertension 
Eleven patients who had pulmonary hypertension had an increased duration of 
endotracheal intubation compared with the 423 patients who did not. The incidence 
rate ratio was 2.227 (P <0.001, CI 1.460 – 3.397). 
 Return to operating theatre 
The 61 patients who “returned to the operating theatre” within 72 hours of liver 
transplantation had an increased duration of endotracheal intubation compared with 
the 373 patients who did not. The incidence rate ratio was 1.561 (P<0.001, CI 1.297 – 
1.879). 
 Cold Ischaemic time 
The 105 patients who received a graft with a cold ischaemic time of 9.15 hours or 
greater had an increased duration of endotracheal intubation compared with the 105 
patients who received a graft with a cold ischaemic time of less than 6.5 hours. The 
incidence rate ratio was 1.376 (P = 0.003, CI 1.117-1.695). 
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 Non-Identical ABO donor graft 
The 121 patients who received a non-identical ABO donor graft had an increased 
duration of endotracheal intubation compared with the 313 patients who received an 
identical ABO graft. The incidence rate ratio was 1.285 (P=0.002, CI 1.099 – 1.502). 
 Intraoperative blood loss 
The 102 patients who received an intraoperative blood loss of 3400-6900mL had an 
increased duration of endotracheal intubation compared with the 100 patients who had 
an intraoperative blood loss of less than 1700mL. The incidence rate ratio was 1.262 
(P = 0.041, CI 1.010 – 1.577). 
 Recipient age 
The 109 patients who were aged 58.74 – 70 had an increased duration of endotracheal 
intubation compared with the 108 patients aged 47 or less. The incidence rate ratio 
was 1.290 (P = 0.012, CI 1.058 – 1.575). 
 Recipient gender 
The 118 female transplant recipients had an increased duration of endotracheal 
intubation compared to the 315 male patients. The incidence rate ratio was 1.190 (P 
= 0.042, CI 1.006 – 1.407). 
 Warm ischaemic time 
The 118 patients who received a liver graft with a warm ischaemic time of greater than 
0.9 hours had an increased duration of endotracheal intubation compared with the 102 
patients who received a graft with a warm ischaemic time of less than 0.63 hours. The 
incidence rate ratio was 1.229 (P = 0.033, CI 1.017 – 1.485). 
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 Intraoperative crystalloid volume 
The 107 patients who received 2000-3700mL of intraoperative crystalloid had a 
decreased duration of endotracheal intubation compared with the 103 patients who 
received less than 2000mL of intraoperative crystalloid. The incidence rate ratio was 
0.753 (P=0.005, CI 0.619 – 0.917). The 79 patients who received 3700 – 5000mL of 
intraoperative crystalloid had a decreased duration of endotracheal intubation. The 
incidence rate ratio was 0.748 (P=0.006, CI 0.607 – 0.922). 
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 Effect of blood product transfusion on duration of Intensive 
Care Unit Stay 
 Incidence of transfusion in the postoperative period in 
intensive care 
The incidence of blood product transfusion in the intensive care unit within the initial 
48-hour period post liver transplantation is summarised in Table 49 below. 
Table 49. Summary table of incidence of blood product transfusion in the 
postoperative period within the intensive care unit 
Blood product 
Transfused in 
ICU 
(within 48hr) 
Mean Transfusion 
(units) 
Median 
transfusion 
(units) 
Interquartile 
range 
(units) 
Packed Red Blood 
Cells 
41.10% 
(161/399) 1.76 0 0-2 
Platelets 
42.11% 
(168/399) 1.01 0 0-1 
Fresh Frozen 
Plasma 
39.60% 
(158/399) 2.09 0 0-3 
Cryoprecipitate 
14.29% 
(57/399) 1.31 0 0-0 
 
 Univariate negative binomial regression 
A negative binomial regression was used to analyse the recipient, donor and 
transplantation variables. The variables associated with duration of intensive care unit 
stay on univariate analysis are summarised in Table 50.  
Table 50. Variables associated with duration of intensive care unit stay following 
liver transplantation on univariate analysis. 
Variables P-value 
Recipient Variables   
MELD Score <0.001 
Preoperative endotracheal intubation <0.001 
Preoperative admission to ICU <0.001 
Preoperative Serum Creatinine <0.001 
Hepatopulmonary Syndrome <0.001 
Acute Liver Failure <0.001 
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CTP Score <0.001 
Hepatitis C 0.001 
Pulmonary Hypertension 0.005 
Age 0.017 
All other Indications 0.047 
Donor Variables   
Donor Graft Steatosis <0.001 
Transplantation Variables   
Cryoprecipitate Transfusion <0.001 
Platelet Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
Tranexamic Acid use <0.001 
Return to Operating Theatre within 72 
hours 
<0.001 
Operative Time <0.001 
RBC Transfusion <0.001 
FFP Transfusion 0.002 
Warm Ischaemic Time 0.011 
Antifibrinolytic Use 0.020 
Aprotinin use 0.021 
Cold Ischaemic Time 0.034 
 
The complete results of the univariate analysis for duration of intensive care unit stay 
are presented in Table 57 in the appendix. Using univariate analysis, it was found that 
the factors that influenced (p<0.05) duration of intensive care unit stay were: recipient 
age, CTP score, indication for liver transplantation, hepatitis C status, requirement for 
preoperative admission to the intensive care unit, preoperative endotracheal 
intubation, pulmonary hypertension, hepatopulmonary syndrome, donor graft 
steatosis, warm ischaemic time, cold ischaemic time, operative time, “return to the 
operating theatre” within 72 hours of transplantation, antifibrinolytic use (aprotinin and 
tranexamic acid), packed red blood cell transfusion, platelet transfusion, fresh frozen 
plasma transfusion, cryoprecipitate transfusion and total volume of intraoperative 
blood loss. 
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 Multivariate negative binomial regression 
The results of the multivariate negative binomial regression for duration of intensive 
care unit stay are shown in Table 51. 
Table 51. Multivariate analysis for duration of intensive care unit stay. 
Duration of 
Intensive Care 
Unit Stay 
Incidence 
Rate 
Ratio z 
P 
value 
[95% 
Conf. Interval] 
Platelet 
Transfusion 
(0 Units) 1         
1-2 Units 1.255804 1.74 0.082 0.972 1.623 
3-4 Units 1.081676 0.52 0.602 0.805 1.453 
≥ 5 Units 1.186532 1.07 0.282 0.869 1.621 
Packed Cell 
Transfusion  
(0 Units) 1     
1-3 Units 0.862724 -0.94 0.345 0.635 1.172 
4-6 Units 1.101054 0.61 0.544 0.807 1.503 
7-12 Units 1.288668 1.39 0.165 0.901 1.844 
≥ 13 Units 1.283217 1.19 0.235 0.850 1.937 
Fresh Frozen 
Plasma Transfusion 
(0 Units) 1     
1-6 Units 0.988726 -0.06 0.949 0.700 1.397 
7-10 Units 0.897137 -0.51 0.613 0.589 1.367 
11-16 Units 0.762121 -1.16 0.247 0.481 1.207 
≥17 Units 0.945412 -0.23 0.821 0.582 1.537 
Cryoprecipitate 
Transfusion  
(0 Units) 1     
1-9 Units 1.049967 0.28 0.781 0.745 1.480 
10-19 Units 1.168153 1.33 0.183 0.929 1.469 
≥20 Units 1.364475 2.25 0.025 1.041 1.789 
MELD Score 
(6-10.99) 1     
11-17.99 1.033832 0.27 0.786 0.813 1.315 
18-23.99 0.903754 -0.72 0.472 0.686 1.191 
≥24 1.051853 0.35 0.725 0.794 1.393 
Hepatopulmonary 
Syndrome 1.937194 4.67 <0.001 
1.467 2.558 
Return to OT 
(within 72 hours) 1.40843 3.43 0.001 
1.158 1.713 
Steatosis 1.590962 3.31 0.001 1.208 2.095 
223 
 
Preoperative 
Endotracheal 
intubation 2.38356 4.21 <0.001 
1.591 3.571 
Age (≤47) 1     
47- 53.19 1.029414 0.26 0.793 0.829 1.279 
53.2- 58.73 1.104901 0.9 0.368 0.889 1.373 
58.74- 70 1.207206 1.71 0.087 0.973 1.498 
Warm Ischaemic 
Time (<0.63 hours) 1     
0.63 - 0.77 hours 1.128161 1.1 0.271 0.910 1.398 
0.78 - 0.9 hours 1.194781 1.54 0.124 0.952 1.499 
>0.9 hours 1.251132 2.08 0.037 1.013 1.545 
Pulmonary 
Hypertension 1.566043 2.11 0.035 
1.033 2.374 
Preoperative 
Creatinine (<60 
µmol/L) 1     
60-74 µmol/L 0.814655 -1.88 0.06 0.658 1.009 
75-96 µmol/L 0.724718 -2.91 0.004 0.584 0.900 
>96 µmol/L 0.800992 -2.02 0.043 0.646 0.993 
Donor Risk Index 
(0.906-1.279) 1     
1.280-1.524 1.085649 0.75 0.455 0.875 1.347 
1.525-1.845 1.170279 1.47 0.142 0.949 1.444 
1.846-3.077 1.197985 1.65 0.1 0.966 1.485 
Operative Time  
               (<4 hours) 1     
4 - <5 hours 1.027295 0.16 0.876 0.733 1.440 
5 - <6 hours 1.305867 1.64 0.101 0.949 1.797 
≥6 hours 1.312954 1.66 0.096 0.953 1.809 
Hepatitis C 0.878234 -1.53 0.126 0.744 1.037 
Preoperative 
Platelet Count  
           (≤50 x 109/L) 1     
>50 – 100 x 109/L 0.889943 -1.15 0.251 0.729 1.086 
>100 x 109/L 0.808456 -1.79 0.074 0.640 1.021 
 
The variables selected for the multivariate model for duration of intensive care unit 
stay were platelet transfusion, packed red blood cell transfusion, fresh frozen plasma 
transfusion, cryoprecipitate transfusion, MELD score, hepatopulmonary syndrome, 
“return to the operating theatre” within 72 hours of liver transplantation, donor graft 
steatosis, preoperative endotracheal intubation, patient age, donor graft warm 
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ischaemic time, pulmonary hypertension, preoperative serum creatinine, donor risk 
index, operative time, hepatitis C, and preoperative platelet count. 
 Multicollinearity  
The multicollinearity and correlation coefficient testing demonstrated no substantial 
multicollinearity between the parameters included in the multivariate model for the 
effect of blood product transfusion on duration of intensive care unit stay. The results 
are shown in Table 58 (page 243) and Table 59 (page 244) in the appendix. 
 Blood product transfusion 
The transfusion of cryoprecipitate was associated with an increased duration of 
intensive care unit stay. Seventy-three patients who were transfused ≥20 units of 
cryoprecipitate had an increased duration of intensive care unit stay compared with 
the 213 patients who did not receive any cryoprecipitate transfusion. The incidence 
rate ratio was 1.364 (P = 0.025, CI 1.041 – 1.789).  
The transfusion of platelets, packed red blood cells and fresh frozen plasma did not 
increase the duration of intensive care unit stay. 
 Other factors with an effect on duration of intensive care 
unit stay 
On the multivariate analysis, other factors which had an effect on the duration of 
intensive care unit stay following liver transplantation were hepatopulmonary 
syndrome, “return to the operating theatre” within 72 hours of transplantation, graft 
steatosis, preoperative endotracheal intubation, graft warm ischaemic time, pulmonary 
hypertension and preoperative serum creatinine level. 
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 Preoperative endotracheal intubation 
Fourteen patients who were intubated preoperatively had an increased duration of 
intensive care unit stay compared with the 420 patients who were not. The incidence 
rate ratio was 2.384 (P <0.001, CI 1.591 – 3.571). 
 Hepatopulmonary Syndrome  
Twenty-seven patients who had hepatopulmonary syndrome had an increased 
duration of intensive care unit stay compared with the 407 patients who did not. The 
incidence rate ratio was 1.937 (P < 0.001, CI 1.467 – 2.558). 
 Pulmonary Hypertension 
Eleven patients with pulmonary hypertension had an increased duration of intensive 
care unit stay compared to the 423 patients who did not. The incidence rate ratio was 
1.566 (P=0.035, CI 1.033 – 2.374). 
 Preoperative serum creatinine level 
One hundred and six patients with a preoperative serum creatinine level of 75-96 
μmol/L had a decreased duration of intensive care unit stay compared with the 101 
patients with a preoperative serum creatinine level of <60 μmol/L. The incidence rate 
ratio was 0.7247 (P=0.004, CI 0.5836 – 0.9000). Additionally, the 115 patients with a 
preoperative serum creatinine level of greater than 96 μmol/L had a decreased 
duration of intensive care unit stay compared with the patients with a preoperative 
serum creatinine level of <60 μmol/L. The incidence rate ratio was 0.8010 (P=0.043, 
CI 0.6461 – 0.9930). 
 Return to operating theatre within 72 hours 
Sixty-one patients who returned to the operating theatre within 72 hours of liver 
transplantation had an increased duration of intensive care unit stay compared with 
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the 373 patients who did not. The incidence rate ratio was 1.408 (P=0.001, CI 1.158 – 
1.713).  
 Graft warm ischaemic time 
One hundred and eighteen patients who received a graft with a warm ischaemic time 
of greater than 0.9 hours had an increased duration of intensive care unit stay 
compared to the 102 patients who received a graft with a warm ischaemic time of less 
than 0.63 hours. The incidence rate ratio was 1.251 (P=0.037, CI 1.013 – 1.544). 
 Liver Steatosis 
Twenty-eight patients who received a liver graft with greater than 30% macroscopic 
steatosis had an increased duration of intensive care unit stay compared with the 406 
patients who received a liver graft with less than 30% macroscopic steatosis. The 
incidence rate ratio was 1.591 (P = 0.001, CI 1.208 – 2.095). 
 Duration of Hospital Stay 
 Univariate negative binomial regression 
Negative binomial regression was used to analyse the recipient, donor and 
transplantation variables. The results of the univariate analysis are presented in Table 
54 (page 238) in the appendix. On univariate analysis, the variables associated with 
an effect on the duration of hospital stay (p<0.05) were: recipient age, recipient body 
mass index (and corrected body mass index), volume of ascites, preoperative platelet 
count, preoperative serum creatinine and creatinine clearance, MELD score, CTP 
score, indications for liver transplant other than acute liver failure, hepatocellular 
carcinoma diagnosis, hepatitis C status, donation after brain death, antifibrinolytic use, 
transfusion of all blood product types (packed red blood cells, platelets, fresh frozen 
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plasma, and cryoprecipitate), total volume of intraoperative fluid administered and total 
intraoperative blood loss. 
Table 52. Summary table of variables associated with an effect on duration of 
hospital stay following liver transplantation on univariate analysis 
Variables P-value 
Recipient Variables   
MELD Score <0.001 
Preoperative Serum Creatinine <0.001 
Hepatitis C 0.001 
CTP Score 0.001 
BMI 0.001 
Preoperative Creatinine Clearance 0.002 
Hepatocellular Carcinoma 0.002 
Preoperative Platelet Count 0.007 
Age 0.015 
Corrected BMI 0.016 
All other Indications 0.030 
Volume of Ascites 0.034 
Donor Variables   
Donor Age 0.137 
DCD/DBD 0.049 
Transplantation Variables   
Platelet Transfusion <0.001 
RBC Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
FFP Transfusion 0.007 
Cryoprecipitate Transfusion 0.010 
Antifibrinolytic Use 0.010 
Total fluid volume given intraoperatively 0.014 
 
 Multivariate negative binomial regression 
The results of the multivariate negative binomial regression for duration of hospital 
stay are shown below in Table 53. 
The variables included in the multivariate model for analysis of the effect of 
perioperative blood transfusion on duration of hospital stay were: platelet transfusion, 
packed red blood cell transfusion, fresh frozen plasma transfusion, cryoprecipitate 
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transfusion, MELD score, Hepatitis C status, acute liver failure as a cause of 
transplantation, recipient age, recipient body mass index (adjusted  for ascites), 
preoperative serum creatinine levels, donation after brain death, donor age, graft 
steatosis, antifibrinolytic use and the total volume of intraoperative blood loss.  
Table 53. Multivariate analysis for duration of hospital stay. 
Duration of 
Hospital Stay 
Incidence 
Rate 
Ratio z P value [95% Conf. Interval] 
Platelet 
Transfusion 
(0 Units)  1         
1-2 Units 1.167236 1.65 0.1 0.971 1.403 
3-4 Units 0.973689 -0.24 0.811 0.783 1.212 
≥ 5 Units 1.209994 1.59 0.111 0.957 1.530 
Packed Cell 
Transfusion  
(0 Units) 1     
1-3 Units 1.009241 0.08 0.936 0.806 1.264 
4-6 Units 0.964473 -0.3 0.761 0.764 1.218 
7-12 Units 1.076777 0.53 0.596 0.819 1.416 
≥ 13 Units 0.840596 -1.09 0.277 0.615 1.149 
Fresh Frozen 
Plasma 
Transfusion (0 
Units) 1     
1-6 Units 1.068818 0.5 0.615 0.825 1.385 
7-10 Units 1.028222 0.17 0.868 0.741 1.428 
11-16 Units 1.060244 0.32 0.751 0.739 1.521 
≥17 Units 1.481652 2.03 0.042 1.014 2.165 
Cryoprecipitate 
Transfusion  
(0 Units) 1     
1-9 Units 0.972872 -0.21 0.836 0.749 1.263 
10-19 Units 0.980758 -0.21 0.835 0.817 1.178 
≥20 Units 1.238927 1.85 0.064 0.988 1.554 
MELD Score 
(6-10.99) 1     
11-17.99 1.287881 2.71 0.007 1.073 1.546 
18-23.99 1.175136 1.53 0.126 0.956 1.445 
≥24 1.195938 1.61 0.108 0.961 1.488 
Hepatitis C 0.871561 -2.2 0.028 0.771 0.985 
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Acute Liver 
Failure 1.394742 3.56 <0.001 
1.161 1.675 
Age (≤47) 1     
47- 53.19 0.970466 -0.35 0.723 0.822 1.146 
53.2- 58.73 1.145605 1.64 0.101 0.974 1.348 
58.74- 70 1.258765 2.67 0.008 1.063 1.490 
Corrected BMI 
(<20) 1     
20 - <25 0.875114 -1.02 0.306 0.678 1.130 
25 - <30 0.782385 -1.86 0.063 0.604 1.013 
≥30 0.859915 -1.12 0.261 0.661 1.119 
Preoperative 
Creatinine (<60 
µmol/L) 1     
60-74 µmol/L 0.873305 -1.63 0.102 0.742 1.027 
75-96 µmol/L 0.810471 -2.43 0.015 0.684 0.960 
>96 µmol/L 0.89143 -1.33 0.182 0.753 1.055 
Donation after 
Cardiac Death 1     
Donation after 
Brain Death 1.474781 2.47 0.013 
1.084 2.007 
Donor Age  
                   (≤30) 1     
31-46 0.865862 -1.8 0.072 0.740 1.013 
47-58 0.841219 -2.07 0.038 0.714 0.991 
≥59 0.844925 -1.98 0.047 0.715 0.998 
Steatosis 1.230196 1.77 0.076 0.978 1.547 
Antifibrinolytic 
use 1     
Aprotinin  1.08667 1.14 0.255 0.942 1.254 
Tranexamic 
Acid 0.942449 -0.73 0.465 
0.804 1.105 
Intraoperative 
Blood Loss 
(<1700mL) 1     
1700-3399mL 1.020556 0.23 0.815 0.861 1.210 
3400- 6900mL 1.158733 1.53 0.125 0.960 1.399 
>6900mL 1.057725 0.49 0.627 0.843 1.327 
  
230 
 
 Multicollinearity  
The multicollinearity and correlation coefficient testing demonstrated no substantial 
multicollinearity between the parameters included in the multivariate model for the 
effect of blood product transfusion on duration of hospital stay. The results are shown 
in Table 55 (page 240) and Table 56 (page 241) in the appendix. 
 Blood product transfusion 
 Fresh frozen plasma transfusion 
The transfusion of large volumes of fresh frozen plasma was associated with 
increased duration of hospital of stay. The 94 patients who received a transfusion of 
≥17 units of fresh frozen plasma had an increased duration of hospital stay compared 
with the 35 patients who received no fresh frozen plasma transfusion. The incidence 
rate ratio was 1.482 (p = 0.042, CI 1.014 – 2.165). 
 Other blood product transfusion 
There was no association between the transfusion of packed red blood cells, platelets 
and cryoprecipitate on the duration of hospital stay on multivariate analysis. 
 Other factors with an effect on duration of hospital stay 
On the multivariate analysis, the factors that were identified as having an effect on the 
duration of hospital stay following liver transplantation included the recipient MELD 
score, hepatitis C status, acute liver failure as an indication for transplantation, 
recipient age, preoperative serum creatinine, type of graft and donor age. 
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 Degree of preoperative disease severity (Model for End 
Stage Liver Disease Score) 
One hundred and forty-seven patients who had a MELD score of 11-17.99 had an 
increased duration of hospital stay compared with the 76 patients who had a MELD 
score <11. The incidence rate ratio was 1.288 (P = 0.007, CI 1.073 -  1.546).  
 Hepatitis C 
One hundred and seventy patients who had a positive Hepatitis C status had a 
decreased duration of hospital stay compared with the 264 patients who did not. The 
incidence rate ratio was 0.8716 (P = 0.028, CI 0.7710 – 0.9853). 
 Acute liver failure 
Seventeen patients who received a liver transplantation due to acute liver failure had 
an increased duration of hospital stay compared with the patients who did not. The 
incidence rate ratio was 1.395 (P = <0.001, CI 1.161 – 1.675). 
 Recipient Age 
One hundred and nine patients who were aged 58.74-70 had an increased duration of 
hospital stay compared with the 108 patients that were aged 47 years old or younger. 
The incidence rate ratio was 1.259 (P = 0.008, CI 1.063 – 1.490). 
 Preoperative serum creatinine 
One hundred and six patients who had a preoperative serum creatinine between 75-
96 µmol/L had a decreased duration of hospital stay compared with the 101 patients 
with a preoperative serum creatinine less than 60 µmol/L. The incidence rate ratio was 
0.8104 (P = 0.015, CI 0.6841 - 0.9602). 
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 Type of graft (Donation after cardiac death/Donation after 
brain death) 
Four hundred and fourteen patients receiving a donation after brain death liver graft 
had an increased duration of hospital stay compared with the 18 patients receiving a 
donation after cardiac death liver graft. The incidence rate ratio was 1.475 (P = 0.013, 
CI 1.084 – 2.007). 
 Donor age 
One hundred and eight recipients of liver grafts from a donor aged from 47-58 had a 
decreased duration of hospital stay compared with the 103 patients receiving a graft 
from a donor aged 30 years or younger. The incidence rate ratio was 0.8412 (P = 
0.038, CI 0.7142 - 0.9908). Additionally, the 109 patients receiving a liver graft from a 
donor aged 59 years or older had a decreased duration of hospital stay compared with 
the patients receiving a graft from a donor aged 30 years or younger. The incidence 
rate ratio was 0.8449 (P = 0.047, CI 0.7153 – 0.9979). 
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 Discussion 
The duration of hospital and intensive care unit stay are interrelated indicating that 
there are common causal factors (Kramer and Zimmerman, 2011). The prolonged 
length of stay in the intensive care unit is a measure of morbidity and is associated 
with increased long term mortality and resource utilisation (Williams et al., 2010). 
As MELD score is known to be associated with longer duration of intensive care unit 
stay within liver transplantation patients (Oberkofler et al., 2010), our study controlled 
for MELD score as a confounding factor for prolonged duration of hospital and 
intensive care unit study. Multivariate analysis found that MELD score was not 
associated prolonged duration of intensive care unit stay. This study did find a weak 
association between MELD score and duration of hospital stay, with liver transplant 
recipients with a MELD score of 11-17.99 having an increased duration of hospital 
stay (incidence rate ratio = 1.29, p = 0.007). Klinzing et al. found that a MELD score 
greater than 25 was associated with a prolonged duration of intensive care unit stay 
more than 4 days (odds ratio = 4.12) and a prolonged duration of hospital stay greater 
than 37 days (odds ratio = 13.0) (Klinzing et al., 2014). In contrast to the findings of 
Klinzing et al., this study did not find an increased duration of hospital stay in the 
patients with a MELD score ≥24 (p = 0.11). The difference between this study and 
those of Klinzing et al. can be explained by the difference in sample size. The study 
by Klinzing et al. contained 56 patients, compared with the 434 patients in this study. 
Small sample size studies may over-estimate the degree of statistical association 
(Hackshaw, 2008). 
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 Blood product transfusion 
 Duration of intubation 
On multivariate analysis, the transfusion of platelets (1-2 pooled units, incidence rate 
ratio: 1.364, P = 0.005) and fresh frozen plasma (1-6 units, p=0.013; ≥17 units, 
p=0.008) was associated with a prolonged duration of endotracheal intubation. There 
was no association between packed red cell transfusion and cryoprecipitate 
transfusion and increased duration of endotracheal intubation. 
It is not possible to attribute the association between platelet and fresh frozen plasma 
transfusion to a causative effect in this retrospective study. These effects may be 
related to an increased incidence of acute lung injury, though further studies clarifying 
the link between blood product transfusion and the mechanisms behind prolonged 
duration of endotracheal intubation are required. Acute lung injury was not examined 
within our study as the data required to define acute lung injury was not available. 
However, transfusion related acute lung injury following liver transplantation has been 
described in other studies. Pereboom et al. described an association between platelet 
transfusion and increased mortality following liver transplantation due to acute lung 
injury (Pereboom et al., 2009). Platelet and fresh frozen plasma transfusion in liver 
transplant recipients has also been associated with transfusion associated acute lung 
injury in a study of 525 patients by Benson et al. (Benson et al., 2011b).  
 Duration of Intensive care unit stay 
On multivariate analysis, the transfusion of cryoprecipitate (≥20 units) was associated 
with an increased duration of intensive care unit stay following liver transplantation 
(incidence rate ratio = 1.36, p = 0.025). There was no relationship between the 
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transfusion of other blood products (packed red cells, platelets or fresh frozen plasma) 
and duration of intensive care unit stay.  
The literature surrounding the transfusion of cryoprecipitate and duration of hospital or 
intensive care unit stay in liver transplantation is lacking. Fibrinogen concentrates are 
used instead of cryoprecipitate in the majority of Europe, which may explain the lack 
of data evaluating cryoprecipitate transfusion in liver transplantation (Franchini and 
Lippi, 2012). Sabate et al. in a small study (n=99) of liver transplantation patients, 
examined the effects of fibrinogen concentrates. They found no association between 
fibrinogen concentrate administration and adverse outcomes (including increased 
duration of intensive care unit stay or duration of hospital stay) (Sabate et al., 2016). 
Fibrinogen concentrates were not available in Australia until 2010 and were not utilised 
in the patients included in this study. 
There was no association between decreased packed red blood cell transfusion and 
decreased length of intensive care unit stay in our study. Bulatao et al. identified an 
association between decreased packed red blood cell transfusion volumes and the 
ability to avoid intensive care unit admission in a study of 1296 liver transplantation 
patients (Bulatao et al., 2014). Although our findings are in contrast to those of Bulatao 
et al., there were fewer patients (n=434) in our cohort. 
It is noteworthy that although transfusion of platelets and fresh frozen plasma was 
associated with an increased duration of intubation, they were not shown to be 
associated with an increased duration of intensive care unit stay in this study. A 
prolonged duration of intubation would be expected to result in a prolonged duration 
of intensive care unit stay. A possible explanation for this finding is that although 
platelet and fresh frozen plasma transfusion was associated with increased duration 
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of endotracheal intubation (median of 27 hours), other factors may have had a more 
significant influence on the overall duration of intensive care unit stay (median of 3 
days). 
 Duration of Hospital stay 
On multivariate analysis, the transfusion of fresh frozen plasma was associated with 
increased duration of hospital of stay (incidence rate ratio: 1.482, p = 0.042). There 
was no association between the transfusion of other blood products (packed red cells, 
platelets or cryoprecipitate) and duration of hospital stay. 
In general intensive care unit patients, the transfusion of fresh frozen plasma has been 
associated with increased incidence of transfusion related acute lung injury (Dara et 
al., 2005). However, Dara identified no association between the transfusion of fresh 
frozen plasma and increased duration of intensive care unit stay or duration of hospital 
stay. This study did not evaluate the incidence of acute lung injury following liver 
transplantation as the data required to define acute lung injury was not available. 
Future research in this area could clarify potential associations between fresh frozen 
plasma transfusion and acute lung injury. 
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 Conclusion 
 Duration of endotracheal intubation 
The transfusion of platelets (1-2 pooled units, p = 0.005) was associated with an 
increased duration of endotracheal intubation compared with the patients who 
received no platelet transfusion.  Fresh frozen plasma transfusion (1-6 units, p=0.013; 
≥17 units, p=0.008) was also associated with increased duration of endotracheal 
intubation. The transfusion of packed red blood cells and cryoprecipitate had no 
association with increased duration of endotracheal intubation. 
 Duration of intensive care unit stay 
The transfusion of large volumes of cryoprecipitate (≥20 units) was associated with 
increased duration of intensive care unit stay following liver transplantation. The 
transfusion of packed red blood cells, platelets and fresh frozen plasma was not 
associated with an increase in duration of intensive care unit stay. The association 
between cryoprecipitate transfusion and increased length of intensive care unit stay 
was weak, and other variables representing pre-existing disease severity had a 
stronger association with increased duration of intensive care unit stay.  
 Duration of hospital stay 
The transfusion of large volumes of fresh frozen plasma (≥17 units) was associated 
with an increased duration of hospital stay following liver transplantation. The 
transfusion of packed red blood cells, platelets and cryoprecipitate was not associated 
with an increase in duration of hospital stay. The association between fresh frozen 
plasma transfusion and increased length of hospital stay was weak, and other 
variables representing disease severity and patient factors had a stronger association 
with increased duration of hospital stay. 
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 Appendix to Chapter 8 
Table 54. Univariate analysis for duration of hospital stay. 
Variables P-value 
Recipient Variables   
MELD Score <0.001 
Preoperative Serum Creatinine <0.001 
Hepatitis C 0.001 
CTP Score 0.001 
BMI 0.001 
Preoperative Creatinine Clearance 0.002 
Hepatocellular Carcinoma 0.002 
Preoperative Platelet Count 0.007 
Age 0.015 
Corrected BMI 0.016 
All other Indications 0.030 
Volume of Ascites 0.034 
Preoperative Dialysis 0.055 
Recipient Sex 0.056 
Preoperative endotracheal intubation 0.080 
Hepatopulmonary Syndrome 0.216 
Pulmonary Hypertension 0.228 
Hepatitis B 0.367 
Preoperative admission to ICU 0.488 
Previous Major Abdominal Surgery 0.597 
Acute Liver Failure 0.721 
Donor Variables   
Donor Age 0.137 
DCD/DBD 0.049 
Donor Graft Steatosis 0.127 
ABO identical/non identical 0.470 
Donor Sex 0.531 
Donor Risk Index 0.601 
Split graft 0.784 
Transplantation Variables   
Platelet Transfusion <0.001 
RBC Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
FFP Transfusion 0.007 
Cryoprecipitate Transfusion 0.010 
Antifibrinolytic Use 0.010 
Total fluid volume given intraoperatively 0.014 
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Warm Ischaemic Time 0.096 
Aprotinin use 0.104 
Volume of Colloid given intraoperatively 0.174 
Cold Ischaemic Time 0.182 
Tranexamic Acid use 0.183 
Return to Operating Theatre within 72 
hours 
0.354 
Volume of Crystalloid given 
intraoperatively 
0.412 
Operative Time 0.644 
Surgical technique 0.658 
Factor VII use 0.832 
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Table 55. Multicollinearity Testing for variables included in multivariate analysis 
for duration of hospital stay. 
Variable Variance Inflation Factor (VIF) 1/VIF 
Packed Cell Transfusion  4.39 0.227678 
Fresh Frozen Plasma 
Transfusion 4.28 0.233851 
Intraoperative Blood 
Loss 2.79 0.357833 
Cryoprecipitate 
Transfusion 2.35 0.425829 
MELD Score 1.63 0.615232 
Platelet Transfusion 1.48 0.675254 
Antifibrinolytic use 1.24 0.806244 
Preoperative 
Creatinine 1.24 0.806307 
Age 1.14 0.87604 
Donor Age 1.14 0.876704 
Corrected BMI 1.12 0.891196 
Donation after Brain 
Death 1.09 0.919438 
Hepatitis C 1.06 0.943824 
Steatosis 1.06 0.943836 
Acute Liver Failure 1.03 0.968695 
Mean Variance Inflation 
Factor 1.8  
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Table 56. Correlation matrix of coefficients of multivariate logistic regression model for duration of hospital stay. 
Correlation 
Coefficients 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh Frozen 
Plasma 
Transfusion 
Cryoprecipitate 
Transfusion MELD Score Hepatitis C 
Acute Liver 
Failure Age 
Corrected 
BMI 
Preoperative 
Creatinine 
Donation after 
Brain Death Donor Age Steatosis 
Anti-
fibrinolytic 
use 
Intra-
operative 
Blood Loss 
Platelet Transfusion 1               
Packed Cell 
Transfusion -0.1965 1              
Fresh Frozen Plasma 
Transfusion -0.1662 -0.4452 1             
Cryoprecipitate 
Transfusion -0.085 -0.3867 0.0534 1            
MELD Score -0.0291 0.0167 -0.1817 -0.2354 1           
Hepatitis C 0.0051 0.0234 0.0494 -0.0832 0.0581 1          
Acute Liver Failure -0.0517 -0.0093 0.0508 0.0979 -0.0479 -0.0864 1         
Age 0.0901 -0.0613 0.0704 -0.0498 0.2307 0.0008 0.0217 1        
Corrected BMI -0.1039 0.1126 -0.0152 0.0115 -0.0614 -0.145 0.0166 -0.1046 1       
Preoperative 
Creatinine 0.1039 -0.1016 -0.0603 0.0821 -0.3142 0.0651 0.0154 -0.06 -0.007 1      
Donation after Brain 
Death -0.0614 -0.0168 0.0237 0.0866 -0.1038 -0.0382 0.03 0.0697 0.054 -0.0005 1     
Donor Age 0.0983 -0.079 -0.1175 0.0303 -0.101 0.0048 0.0136 -0.1834 -0.1172 0.0797 -0.1598 1    
Steatosis 0.0496 0.1231 -0.1147 -0.1301 -0.0082 -0.0059 0.0074 -0.0246 0.0626 -0.0569 0.0538 -0.0212 1   
Antifibrinolytic use -0.0078 0.0648 -0.169 -0.225 -0.0212 -0.0177 -0.0903 -0.0349 -0.1334 0.0135 0.1262 0.0115 0.0477 1  
Intraoperative 
Blood Loss 0.1159 -0.2657 -0.4285 -0.1188 0.1267 -0.0043 -0.0849 -0.0173 -0.1238 0.0205 -0.0233 0.1213 -0.0138 0.104 1 
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Table 57. Univariate analysis for duration of intensive care unit stay. 
Variables P-value 
Recipient Variables   
MELD Score <0.001 
Preoperative endotracheal intubation <0.001 
Preoperative admission to ICU <0.001 
Preoperative Serum Creatinine <0.001 
Hepatopulmonary Syndrome <0.001 
Acute Liver Failure <0.001 
CTP Score <0.001 
Hepatitis C 0.001 
Pulmonary Hypertension 0.005 
Age 0.017 
All other Indications 0.047 
Preoperative Dialysis 0.050 
BMI 0.054 
Preoperative Platelet Count 0.104 
Preoperative Creatinine Clearance 0.117 
Corrected BMI 0.173 
Previous Major Abdominal Surgery 0.308 
Recipient Sex 0.319 
Hepatocellular Carcinoma 0.330 
Hepatitis B 0.389 
Volume of Ascites 0.874 
Donor Variables  
Donor Graft Steatosis <0.001 
ABO identical/non identical 0.069 
Donor Risk Index 0.082 
Donor Sex 0.236 
Split graft 0.350 
DCD/DBD 0.539 
Donor Age 0.579 
Transplantation Variables  
Cryoprecipitate Transfusion <0.001 
Platelet Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
Tranexamic Acid use <0.001 
Return to Operating Theatre within 72 
hours 
<0.001 
Operative Time <0.001 
RBC Transfusion <0.001 
FFP Transfusion 0.002 
Warm Ischaemic Time 0.011 
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Antifibrinolytic Use 0.020 
Aprotinin use 0.021 
Cold Ischaemic Time 0.034 
Surgical technique 0.146 
Factor VII use 0.162 
Volume of Crystalloid given 
intraoperatively 
0.218 
Total fluid volume given intraoperatively 0.421 
Volume of Colloid given intraoperatively 0.663 
 
 
Table 58. Multicollinearity Testing for variables included in multivariate analysis 
for duration of intensive care unit stay. 
Variable Variance Inflation Factor (VIF) 
Packed Cell 
Transfusion 4.34 
Fresh Frozen 
Plasma Transfusion 3.75 
Cryoprecipitate 
Transfusion 2.34 
Platelet 
Transfusion 1.74 
MELD Score 1.5 
Operative Time 1.28 
Preoperative 
Platelet Count 1.28 
Age 1.15 
Hepatitis C 1.15 
Preoperative 
Creatinine 1.14 
Preoperative 
Endotracheal 
intubation 1.12 
Return to OT 
(within 72 hours) 1.09 
Warm Ischaemic 
Time 1.08 
Steatosis 1.07 
Donor Risk Index 1.05 
Pulmonary 
Hypertension 1.05 
Hepatopulmonary 
Syndrome 1.04 
Mean Variance 
Inflation Factor 1.6 
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Table 59. Correlation matrix of coefficients of multivariate logistic regression model for duration of intensive care unit stay. 
Correlation Coefficients 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh Frozen Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score 
Hepatopulmonary 
Syndrome 
Return to OT 
(within 72 hours) Steatosis 
Preoperative 
Endotracheal 
intubation Age 
Warm 
Ischaemic 
Time 
Pulmonary 
Hypertension 
Preoperative 
Creatinine 
Donor Risk 
Index 
Operative 
Time 
Hepatitis 
C 
Preoperative 
Platelet Count 
Platelet Transfusion 1                                          
Packed Cell Transfusion -0.1986 1                                        
Fresh Frozen Plasma 
Transfusion -0.148 -0.6405 1                                      
Cryoprecipitate 
Transfusion -0.1085 -0.417 0.0318 1                                    
MELD Score 0.0396 0.0536 -0.1785 -0.2262 1                                  
Hepatopulmonary 
Syndrome -0.0397 0.0089 0.0233 0.0057 
-
0.053 1                                
Return to OT (within 72 
hours) -0.0504 -0.1179 0.0105 -0.0137 
0.035
9 0.048 1                              
Steatosis 0.0624 0.1046 -0.1616 -0.1235 
0.000
2 0.0246 -0.0142 1                   
Preoperative 
Endotracheal intubation -0.009 -0.0279 -0.0046 0.0096 
-
0.200
6 0.0407 -0.0445 
0.074
2 1                          
Age 0.0341 -0.0458 0.0394 0.0104 
0.240
8 -0.0611 -0.0019 
-
0.017
4 0.0625 1                        
Warm Ischaemic Time -0.0465 0.1049 -0.0786 -0.0112 
0.059
1 0.0259 0.0079 
0.039
7 0.0167 
0.01
58 1                      
Pulmonary 
Hypertension 0.0438 -0.0993 0.0551 0.0499 
-
0.046
7 -0.117 -0.0727 
0.037
4 0.0356 
-
0.00
96 -0.0105 1                    
Preoperative Creatinine -0.0369 -0.0393 -0.0227 -0.0266 
-
0.166
9 0.0013 0.0326 
-
0.018
6 0.0445 
-
0.17
87 0.0425 -0.0442 1                  
Donor Risk Index 0.1128 0.0436 -0.0611 -0.0776 
0.014
4 -0.0405 0.0043 
-
0.019
8 -0.018 
-
0.10
28 0.062 0.0669 -0.0253 1                
Operative Time 0.0485 0.0771 -0.211 -0.176 
0.022
4 -0.0386 0.0757 0.032 0.0476 
-
0.10
37 -0.2107 0.0395 -0.0547 0.0243 1              
Hepatitis C 0.0235 0.0124 0.0634 -0.0849 
0.070
8 -0.0433 0.0011 
-
0.018
4 0.0867 
0.01
85 -0.0307 -0.0397 0.0155 0.0671 
-
0.0081 1   
Preoperative Platelet 
Count 0.2231 -0.113 0.099 0.0612 
0.080
8 -0.1146 -0.0763 
-
0.080
4 -0.0716 
0.10
31 -0.0366 0.0371 -0.0387 0.0501 0.0235 0.2991 1 
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Table 60. Univariate analysis for duration of endotracheal intubation. 
Variables P-value 
Recipient Variables   
Preoperative endotracheal intubation <0.001 
Preoperative admission to ICU <0.001 
MELD Score <0.001 
Acute Liver Failure <0.001 
Preoperative Serum Creatinine <0.001 
Preoperative Dialysis <0.001 
Hepatitis C <0.001 
Corrected BMI <0.001 
Age <0.001 
Recipient Sex <0.001 
CTP Score <0.001 
All other Indications <0.001 
Pulmonary Hypertension <0.001 
Hepatitis B <0.001 
BMI 0.001 
Preoperative Creatinine Clearance 0.047 
Hepatocellular Carcinoma 0.131 
Preoperative Platelet Count 0.600 
Hepatopulmonary Syndrome 0.666 
Volume of Ascites 0.734 
Previous Major Abdominal Surgery 0.953 
Donor Variables  
ABO identical/non identical <0.001 
Donor Age 0.065 
Donor Risk Index 0.032 
Split graft 0.033 
Donor Sex 0.120 
Donor Graft Steatosis 0.281 
DCD/DBD 0.490 
Transplantation Variables  
Platelet Transfusion <0.001 
Total Blood Loss intraoperatively <0.001 
Cryoprecipitate Transfusion <0.001 
Cold Ischaemic Time <0.001 
Return to Operating Theatre within 72 
hours 
<0.001 
FFP Transfusion <0.001 
RBC Transfusion <0.001 
Volume of Crystalloid given 
intraoperatively 
<0.001 
Antifibrinolytic Use <0.001 
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Total fluid volume given intraoperatively 0.001 
Tranexamic Acid use 0.009 
Surgical technique 0.017 
Factor VII use 0.027 
Warm Ischaemic Time 0.028 
Aprotinin use 0.028 
Operative Time 0.227 
Volume of Colloid given intraoperatively 0.467 
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Table 61. Multicollinearity Testing for variables included in multivariate analysis 
for duration of endotracheal intubation. 
Variable 
Variance Inflation Factor 
(VIF) 
Packed Cell Transfusion 4.64 
Fresh Frozen Plasma Transfusion 4.5 
Intraoperative Blood Loss 2.88 
Cryoprecipitate Transfusion 2.26 
Platelet Transfusion 1.75 
MELD Score 1.67 
Intraoperative Crystalloid Volume 1.19 
Recipient Gender 1.18 
Preoperative Endotracheal 
intubation 1.17 
Cold Ischaemic Time 1.16 
Hepatitis C 1.12 
Return to OT (within 72 hours) 1.11 
Age 1.1 
Non identical ABO graft donor 1.1 
Donor Gender 1.09 
Warm Ischaemic Time 1.05 
Pulmonary Hypertension 1.05 
Mean Variance Inflation Factor 1.77 
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Table 62. Correlation matrix of coefficients of multivariate logistic regression model for duration of endotracheal intubation. 
Correlation Coefficients 
Platelet 
Transfusion 
Packed Cell 
Transfusion 
Fresh Frozen Plasma 
Transfusion 
Cryoprecipitate 
Transfusion 
MELD 
Score 
Preoperative 
Endotracheal intubation 
Pulmonary 
Hypertension 
Return to OT 
(within 72 hours) 
Cold 
Ischaemic 
Time 
Hepa-
titis C 
Non identical ABO 
graft donor 
Intraoperative 
Blood Loss 
Donor 
Gender 
Warm 
Ischaemic 
Time 
Recipient 
Gender Age 
Intraoperative 
Crystalloid Volume 
Platelet Transfusion 1                                          
Packed Cell Transfusion -0.209 1                                        
Fresh Frozen Plasma 
Transfusion 
-
0.1981 -0.4105 1                                      
Cryoprecipitate 
Transfusion 
-
0.1632 -0.3411 -0.0056 1                                    
MELD Score 0.0156 -0.0323 -0.2007 -0.2318 1                                  
Preoperative 
Endotracheal intubation 0.0207 -0.0692 -0.0089 0.0317 
-
0.14
89 1                                
Pulmonary Hypertension 0.0318 -0.117 0.034 0.0606 
-
0.04
38 0.0348 1                              
Return to OT (within 72 
hours) 
-
0.0299 -0.1714 -0.0592 0.0108 
0.08
88 -0.0721 -0.0533 1                   
Cold Ischaemic Time -0.009 0.0091 -0.2001 0.0411 
-
0.11 -0.1041 0.0776 0.0269 1                          
Hepatitis C 
-
0.0731 0.0171 0.0966 -0.0743 
0.06
4 0.0985 -0.0482 0.024 -0.0092 1                        
Non identical ABO graft 
donor 0.1239 0.0235 -0.0194 -0.079 
-
0.05
35 -0.1043 0.0711 0.0051 0.0393 
-
0.03
77 1                      
Intraoperative Blood 
Loss 0.127 -0.2957 -0.4322 -0.0703 
0.11
74 0.066 0.0314 0.1785 0.1285 
-
0.03
27 -0.0739 1                    
Donor Gender 0.1223 -0.0388 -0.1291 0 
0.03
72 -0.018 0.0838 0.0416 -0.0076 
-
0.04
02 0.0561 0.1332 1                  
Warm Ischaemic Time 
-
0.0392 0.1135 -0.1168 -0.0554 
0.06
37 -0.0086 -0.0194 0.0287 0.0116 
-
0.05
77 -0.0353 0.0563 
0.00
58 1                
Recipient Gender 
-
0.0797 -0.0497 0.1598 -0.001 
-
0.04
04 -0.119 -0.0106 0.0174 0.0772 
0.22
17 -0.0582 -0.0322 
-
0.18
68 0.0238 1              
Age 0.0373 -0.0244 0.043 -0.0756 
0.19
63 0.053 -0.013 -0.0175 -0.1032 
0.00
52 0.0904 -0.0293 
0.06
27 0.0099 
0.077
6 1   
Intraoperative 
Crystalloid Volume 
-
0.0671 -0.0786 0.0656 0.071 
0.22
4 0.0717 0.0838 0.036 -0.0335 
0.11
13 0.0692 -0.1353 
0.02
61 -0.1377 
-
0.070
1 
0.02
84 1 
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 CONCLUSION 
 Introduction 
This study was a retrospective analysis of 434 liver transplant recipients at Royal 
Prince Alfred Hospital from 2002 to 2011. It aimed to investigate the association 
between perioperative transfusion of blood products (intraoperative and up to 48 hours 
post-operatively) and outcomes following liver transplantation. The primary outcome 
measures were patient and graft survival rates at one and five years following liver 
transplantation. The secondary outcome measures were: (a) incidence of 
postoperative acute kidney injury and incidence of postoperative dialysis, (b) incidence 
of postoperative infective complications, (c) duration of mechanical ventilation, (d) 
duration of intensive care unit stay, and (e) duration of hospital stay following liver 
transplantation.  
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 Principal Findings 
 The association between perioperative blood product 
transfusion and patient survival and graft survival following liver 
transplantation 
The principal findings of this study were that perioperative platelet transfusion of five 
or more pooled units was associated with a decreased five-year patient mortality 
(hazard ratio 0.335, P = 0.009, CI 0.149 - 0.757) and decreased five-year graft failure 
(hazard ratio 0.359, P = 0.009, CI 0.166 - 0.775) compared with the patients who 
received no perioperative platelet transfusion following liver transplantation. 
Perioperative fresh frozen plasma transfusion of 1 to 6 units was associated with 
increased five-year patient mortality (hazard ratio: 2.424, P = 0.022, CI 1.134 – 5.183) 
compared with the patients who received no perioperative fresh frozen plasma 
transfusion. The perioperative transfusion of cryoprecipitate and packed red blood 
cells was not associated with increased patient mortality or graft failure at five years 
following liver transplantation. 
Perioperative blood product transfusion of packed red blood cells, platelets, fresh 
frozen plasma or cryoprecipitate was not associated with increased patient mortality 
or graft failure at one year following liver transplantation.  
 The effect of perioperative blood product transfusion on acute 
kidney injury and dialysis following liver transplantation 
 Acute Kidney Injury 
This study found that perioperative platelet transfusion of 1-2 units was associated 
with increased incidence of acute kidney injury (odds ratio = 2.17, p = 0.041, CI 1.034 
- 4.566) compared with the patients who did not receive any platelet transfusion. 
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Perioperative packed red blood cell transfusion of 4 to 12 units was also associated 
with increased incidence of acute kidney injury. Further analysis of the data showed 
that the patients who received 4-6 units of packed red blood cells had an increased 
incidence of acute kidney injury compared with the patients who did not receive any 
packed red blood cell transfusion (odds ratio = 2.876, p = 0.046, CI 1.020 - 8.112). 
The patients who received 7-12 units of packed red blood cell transfusion had an 
increased incidence of acute kidney injury compared with the patients who did not 
receive any packed red blood cell transfusion (odds ratio = 5.386, p = 0.006, CI 1.619 
- 17.92). The association with increased acute kidney injury was stronger with packed 
red blood cell transfusion; although these effects may be secondary to blood loss and 
no causal relationship could be concluded. There was no increase in the incidence of 
acute kidney injury following liver transplantation with the transfusion of fresh frozen 
plasma or cryoprecipitate. 
 Dialysis 
Perioperative blood product transfusion of packed red blood cells, platelets, fresh 
frozen plasma or cryoprecipitate was not associated with increased incidence of 
postoperative dialysis following liver transplantation. 
 Infection 
The perioperative transfusion of platelets was strongly associated with increased 
incidence of infection in the postoperative period in our cohort. In the multivariate 
analysis, all the patients who received platelets had an increased incidence of 
postoperative infection with an odds ratio of at least 2.5 times compared with the 
patients who did not. 
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The perioperative transfusion of cryoprecipitate was associated with a lower incidence 
of postoperative infection compared with the patients who received no cryoprecipitate 
transfusion (odds ratio = 0.368, P = 0.005, CI 0.1838 – 0.7379). 
Perioperative transfusion of packed red blood cells and fresh frozen plasma was not 
associated with an increase in postoperative infection following orthotopic liver 
transplantation. 
 Duration of endotracheal intubation 
The transfusion of platelets (1-2 pooled units, p = 0.005) was associated with an 
increased duration of endotracheal intubation compared with the patients who 
received no platelet transfusion.  Fresh frozen plasma transfusion (1-6 units, p=0.013; 
≥17 units, p=0.008) was also associated with increased duration of endotracheal 
intubation. The transfusion of packed red blood cells and cryoprecipitate had no 
association with increased duration of endotracheal intubation. 
 Duration of Intensive care unit stay 
The transfusion of large volumes of cryoprecipitate (≥20 units) was associated with 
increased duration of intensive care unit stay following liver transplantation. The 
transfusion of packed red blood cells, platelets and fresh frozen plasma was not 
associated with an increase in duration of intensive care unit stay. The association 
between cryoprecipitate transfusion and increased length of intensive care unit stay 
was weak, and other variables representing pre-existing disease severity had a 
stronger association with increased duration of intensive care unit stay.  
 Duration of Hospital stay 
The transfusion of large volumes of fresh frozen plasma (≥17 units) was associated 
with an increased duration of hospital stay following liver transplantation. The 
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transfusion of packed red blood cells, platelets and cryoprecipitate was not associated 
with an increase in duration of hospital stay. The association between fresh frozen 
plasma transfusion and increased length of hospital stay was weak, and other 
variables representing disease severity and patient factors had a stronger association 
with increased duration of hospital stay. 
The investigation of perioperative blood product transfusion effects is complicated by 
a number of confounding factors. The patients who have more severe preoperative 
liver dysfunction may have a greater transfusion requirement due to reduced ability of 
the recipient liver to synthesis coagulation factors. The quality of the graft (quantified 
by the donor risk index) is also a confounder for graft failure in the postoperative 
period. Within our multivariate analysis, the MELD score was used to control for the 
potential confounding of the patients with more severe liver disease receiving more 
blood product transfusion. The MELD score is an objective measure of pre-transplant 
liver disease severity and is widely used in other studies. The donor risk index as 
described by Feng et al. was utilised to control for graft quality in the analysis of graft 
failure as it has been identified as being a predictor of graft failure (Feng et al., 2006). 
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 Strengths and limitations of study 
 Strengths  
 Analysis of overall transfusion data 
One of the strengths of this study was that perioperative transfusion in both the 
intraoperative period and the first 48 hours in intensive care were included in the 
analysis. This is in contrast to previous studies (Cacciarelli et al., 1999, de Boer et al., 
2008, Massicotte et al., 2005b, Pereboom et al., 2009, Rana et al., 2013), which 
considered only intraoperative transfusion.  
Analysing transfusion data from only the intraoperative period has a number of 
limitations. If a more conservative transfusion approach during the intraoperative 
period is undertaken, increased blood product transfusion may occur during the 
immediate postoperative period. When assessing the association of blood product 
transfusion with outcomes following liver transplantation, the studies which focus 
solely on intraoperative transfusion may lead to inaccurate conclusions when 
compared to a study which considers overall transfusion in the perioperative period. 
 Adjustment for confounding factors 
The use of multivariate analysis to control for confounding factors is a strength of this 
study. A number of other studies examining the association of blood product 
transfusion on outcomes have identified positive findings on univariate analysis which 
subsequently were negated on multivariate analysis (Cacciarelli et al., 1999, Chin et 
al., 2014). 
The main confounding factor in the analysis of the effect of blood product transfusion 
on survival was that patients with more severe liver disease required more blood 
product transfusion. In this study, the MELD score was correlated with increased 
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transfusion requirements. We controlled for the severity of pre-existing liver disease 
by adjusting for MELD score within the multivariate analyses. The MELD score was 
used as it is an objective means to stratify liver disease severity.  
The quality of the liver graft, represented by the donor risk index, was adjusted for 
within the multivariate analysis of blood product transfusion on patient and graft 
survival. The donor risk index as described by Feng et al. represents an objective 
means to stratify liver graft quality. We chose to control for donor risk index in the graft 
survival analysis as graft quality has been demonstrated to be an important 
confounding variable (Avolio et al., 2008, Feng et al., 2006). 
 Duration of follow-up data 
The other strength of this study was that the patients in this study had follow-up data 
collected to five years. This has allowed analysis of longer term effects of blood 
product transfusion on outcomes following liver transplantation. A significant finding of 
this study (ie. the association between platelet transfusion and increased five year 
patient and graft survival) was evident only on analysis of the five year data. 
 Limitations  
 Retrospective data 
As this study was a retrospective analysis, there are many inherent limitations. As the 
study is retrospective, the questions examined are limited to those to which the data 
are amenable. It is difficult to establish cause and effect relationships between 
perioperative blood product transfusion and effects identified in this retrospective 
study. However, a randomised control trial which has a control arm withholding blood 
product transfusion would not be possible. Furthermore, this is a large study with 
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multiple confounding factors. As such it relies heavily on statistical methods and 
inherent limitations of statistical analysis. 
 Statistical analysis 
There is considerable debate as to the cut-off value to use when assessing for 
multicollinearity within statistical analysis. For the multicollinearity testing performed in 
this thesis, a conventional variance inflation factor cut-off value of 10 was used as a 
screening tool to identify substantial problems with collinearity within the multivariable 
analysis (Hair et al., 2013). When using the conventional variance inflation factor cut-
off value of 10, there is a higher chance of missing collinearity when compared to using 
a more conservative lower cut-off value. Considering this limitation, we used the 
variance inflation factors and correlation coefficient matrices as a screening tool to 
avoid serious collinearity and further comments about collinearity were not made. 
The study of the association between blood product transfusion and outcomes in liver 
transplantation required exploratory data analysis. For this analysis, continuous data 
such as the units of packed red blood cells, platelets, fresh frozen plasma and 
cryoprecipitate were divided into quartiles (as is the convention for exploratory data 
analysis) (Hosmer et al., 2008). The resulting groupings of transfusion quantity may 
differ with other studies. This may make drawing conclusions as to the transfusion 
thresholds difficult, however this method was chosen as it was statistically robust. 
 Missing data 
Other limitations with retrospective studies include missing data. Despite our efforts at 
sourcing missing data from paper and electronic medical records, some data were 
unable to be obtained. Missing data comprised of less than 5% of the entire dataset.  
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 Changes in clinical practice 
As this study included patients over a period of ten years, changes in management of 
liver transplant patients during this period may have had an effect on the results. A 
gradual introduction of pre-storage leukodepletion to packed red blood cells and 
platelets during this period was an important change to clinical practice. 
 Leukodepletion 
Pre-storage leukodepletion was introduced gradually across several years by the 
Australian Red Cross Blood Service. By 2008, all platelets and packed red blood cells 
underwent pre-storage leukodepletion. The data to identify which blood products had 
undergone leukodepletion in this study were not available. This is a significant 
limitation with the study in that the effect of leukodepletion may reduce the immune 
effects of platelet transfusion. Had leukodepletion not been introduced, it is possible 
that there may have been an association between the transfusion of platelets and 
packed red blood cells and decreased patient and graft survival. 
 Definitions within infection analysis 
One of the weaknesses of this study examining the effect of blood products on 
postoperative infection incidence is that the definition of postoperative infection 
included all patients who developed infective complications within the 90 days 
following orthotopic liver transplantation. Infection was defined as any infective 
complication reported within the 3-month period following liver transplantation. The 
parameters used to define an episode of infection included: antibiotic treatment, blood 
culture with bacterial growth, fungal culture treated with antifungal agents, and coding 
for infective complications or the term “sepsis” within the medical records. This was 
sourced through data coding within the medical records for the admission episode for 
the transplantation, intensive care unit discharge summary and the outcomes 
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database of the Australian and New Zealand Transplant Registry. Incidences of 
infective complications not reported in these data sources may have been missed, 
decreasing the sensitivity of the study. Another weakness of this study was that 
infective complications were not stratified into region of infection (wound, lung, 
abdominal, urinary etc.) or whether the infective complications were bacterial, fungal 
or viral in nature. Specificity may be limited as the postoperative infective 
complications may be caused by factors other than blood transfusion within the 90-
day postoperative period. The broad definition of postoperative infection may make 
the findings of this study difficult to compare with other centres. 
 Other limitations 
This study has some other limitations. This study was limited to patients in a single 
centre. Some specific factors to this centre may not be generalisable to other centres. 
Confounding factors may affect the results of the study, despite attempts to control for 
these within the multivariate analysis. Whilst we have attempted to adjust for 
confounding factors like degree of preoperative disease severity (controlling for MELD 
score) and other donor confounding factors such as the quality of graft (controlling for 
donor risk index), there may be other confounding factors which have not been 
identified. 
 What this study adds 
This study contributes to the body of transplantation knowledge in the following ways: 
 The effects of platelet transfusion 
We found that platelet transfusion was associated with decreased patient mortality 
and graft failure in the five-year survival analysis. This is in contrast to previous studies 
(de Boer et al., 2008, Pereboom et al., 2009). De Boer et al. highlighted an association 
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between platelet transfusion and increased one-year and five-year patient mortality on 
multivariate analysis, with hazard ratios of 1.359 and 1.429 per unit of platelets 
transfused respectively.  
Platelet derived serotonin has been identified as a contributor to hepatic regeneration 
following liver resection and has been postulated to also have a role in liver 
regeneration following liver transplantation (Pereboom et al., 2008). This beneficial 
effect would be expected to occur in the short term following liver transplantation. The 
improved survival in the longer term (five year patient survival and five year liver graft 
survival) would support an immunomodulatory hypothesis. 
 Transfusion Related Immunomodulatory Effects 
Transfusion related immunomodulation (TRIM) encompasses both beneficial and 
detrimental clinical effects following blood product transfusion. The beneficial effects 
of TRIM include improved allograft survival following transplantation through an 
immunosuppressive effect. This was first described in renal transplantation more than 
30 years ago. The detrimental clinical effects of TRIM include increased postoperative 
infection, increased mortality and multiple organ failure due to pro-inflammatory 
mechanisms (Vamvakas and Blajchman, 2007). 
Whilst transfusion related immunomodulation has not been previously described in 
liver transplant recipients, the transfusion of blood products has been associated with 
immunomodulation in renal transplant recipients. It is possible that a similar effect 
occurs in liver transplantation. Prospective randomised controlled studies by Opelz et 
al. and Marti.et al. demonstrated a beneficial effect of blood transfusion (specifically 
packed red blood cells) on renal graft survival at one and five years. This effect 
persisted on multivariate analysis and was observed with the use of modern 
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immunosuppressive medications (Marti et al., 2006, Opelz et al., 1997). A transfusion 
associated improvement in renal graft survival by 20% was identified with packed red 
cell transfusion initially in the 1970s (Opelz and Terasaki, 1974, Opelz  and Terasaki 
1978). The advent of improved immunosuppressive medications and marked 
improvements in graft and patient survival resulted in the abandonment of the process 
of deliberately transfusing renal transplant recipients for the purposes of 
immunosuppression in the 1990s (Carpenter, 1990).  
We speculate that the reduction in graft and patient mortality associated with platelet 
transfusion at 5 years post transplantation may be related to clinically beneficial 
transfusion related immunomodulation. However, there is a dearth of data about 
transfusion related immunomodulation resulting from platelet transfusion within the 
human transplantation cohort. Further research is required to investigate whether 
TRIM applies to the liver transplant population. 
The pre-storage leukodepletion (reduction of white blood cells) within blood products 
has been associated with reductions in short term mortality within cardiac surgery 
patients (Bilgin et al., 2004, Boshkov et al., 2006). A Cochrane systematic review 
showed that this effect has was not demonstrated in other surgical cohorts (Simancas-
Racines et al., 2015). Within our study, pre-storage leukodepletion of platelet products 
and packed red blood cells was introduced gradually over a number of years by the 
Australian Red Cross Blood Service. From 2008 pre-storage leukodepletion was 
performed on all platelets and packed red blood cells distributed by the Blood Service. 
We speculate that the short term increases in mortality associated with platelet 
transfusion reported by other studies (Chin et al., 2014, de Boer et al., 2008) were not 
observed in our cohort due to varied practices with regards to pre-storage 
leukodepletion. 
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 Infective complications 
The transfusion of platelets in patients undergoing liver transplantation has been 
associated with increased infective complications in the postoperative period within 
our study. The incidence of infective complications following platelet transfusion in liver 
transplantation has not been studied previously.  
Increased incidence of infection following platelet transfusion has been described in 
general literature (Corash, 2011). The reasons for an increased incidence of infective 
complications in the postoperative period is likely multifactorial. The administration of 
immunosuppressive medications for transplantation and transfusion related 
immunomodulatory effects of platelets may contribute to immunosuppression resulting 
in increased infective complications in the postoperative period.  
 The effect of packed red blood cell transfusion 
Our study found that the perioperative transfusion of packed red blood cells did not 
increase patient mortality or graft failure at one or five years following liver 
transplantation. The previous data examining the effect of packed red blood cell 
transfusion on patient survival and graft failure have been inconclusive. Whilst some 
studies have identified an association between packed red cell transfusion and poorer 
survival rates following liver transplantation (Cacciarelli et al., 1999, Cywinski et al., 
2014, de Boer et al., 2008, Wiederkehr et al., 2010), other studies have found no 
increase in mortality once underlying liver disease was adjusted for in multivariate 
analysis (Dai et al., 2016, Morais et al., 2011). A study by Rana et al. demonstrated a 
negative effect on survival only with a transfusion of 28 or more units of packed red 
blood cells (Rana et al., 2013). The transfusion of this magnitude of packed red cells 
is a rare occurrence within our cohort (mean PRBC transfusion 8.07 units) The findings 
of Rana et al. suggests that either the effect of packed red blood cells is small, or the 
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increased mortality and poor outcomes may be secondary to massive blood loss. It is 
likely that the difference in findings of our study in comparison to other studies is 
related to patient heterogeneity and variations in practice between liver transplant 
centres.  
 The effect of fresh frozen plasma transfusion 
This study identified an association between fresh frozen plasma transfusion and 
increased five-year mortality following liver transplantation (hazard ratio: 2.424, P = 
0.022, CI 1.134 – 5.183). This is consistent with other studies examining the effect of 
fresh frozen plasma on survival following liver transplantation (Massicotte et al., 2008, 
Massicotte et al., 2005b). We also identified an association between fresh frozen 
plasma transfusion and increased duration of endotracheal intubation. This suggested 
acute lung injury as a potential cause for this observation; however further research is 
required. Benson et al. identified an association between the transfusion of fresh 
frozen plasma and increased incidence of acute lung injury (Benson et al., 2011a), 
however our study was not designed to assess for acute lung injury. 
 The effect of cryoprecipitate transfusion 
Our study found that the perioperative transfusion of cryoprecipitate did not increase 
patient mortality or graft failure at one or five years following liver transplantation. Only 
one previous study has examined effects of cryoprecipitate in liver transplantation (Liu 
et al., 2013). Liu et al. found an increase in biliary complications associated with 
cryoprecipitate transfusion in liver transplant recipients. Our study was not designed 
to assess for biliary complications, but we did not identify an increase in graft failure 
associated with perioperative cryoprecipitate transfusion. 
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 Overall transfusion effects 
In contrast to previous studies examining the effect of blood product transfusion which 
included data on only intraoperative transfusion, this study examines the effect of 
perioperative transfusion (both intraoperative transfusion and transfusion within the 
intensive care unit) on outcomes following liver transplantation procedures. Blood 
product transfusion in the postoperative period had not been accounted for in many 
previous studies. This study allows evaluation of overall transfusion effects. 
 Australian data 
This study is the first examining the effects of blood product transfusion on outcomes 
following liver transplantation in the Australian setting. The patients in our cohort had 
a higher preoperative MELD score (mean MELD = 19.5) in comparison to the 
transplant cohort studied by De Boer et al. (mean MELD = 16) (de Boer et al., 2008). 
However, the patients in our cohort had a lower preoperative MELD score than other 
studies (Cywinski et al., 2014, Massicotte et al., 2015, Rana et al., 2013) 
 Clinical implications 
While perioperative platelet transfusion is associated with long term reductions in 
patient mortality and graft failure at five years in this study, it is also strongly associated 
with increased infective complications in the postoperative period. The potentially 
beneficial effects seen on graft survival with platelet transfusion must be interpreted 
with caution given the adverse effects of postoperative infection. Additionally, it is 
difficult to conclude from a retrospective study whether platelet transfusion is 
responsible for the decrease in patient mortality and graft failure at five years, or 
whether there is simply an association. 
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The perioperative transfusion of platelets and fresh frozen plasma was associated with 
an increased duration of endotracheal intubation which may suggest a degree of lung 
injury. However we were unable link these findings to transfusion related acute lung 
injury (TRALI) as the retrospective data to categorise this were unavailable. 
These findings challenge the concept that blood product transfusion is harmful to 
patients, as increased mortality and increased graft failure was not observed with 
blood product transfusion when confounding factors were adjusted for in the 
multivariate analysis.  
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 Directions for further research 
As this retrospective study identified potentially beneficial effects associated with 
platelet transfusion following liver transplantation, future prospective research is 
required on the effects of platelet transfusion on patient and graft survival following 
liver transplantation. As retrospective research is subject to unknown confounding 
factors, a prospective study would overcome this issue. A prospective study could 
examine goal directed platelet transfusion compared with the current transfusion 
strategies based on clinical indications. 
The association between perioperative blood product transfusion and acute lung injury 
in patients following liver transplantation could also be evaluated in future studies. 
However, the incidence of transfusion associated acute lung injury is low (1 in 4000 to 
1 in 12000 transfused units (Toy et al., 2012)) and a large multicentre study would be 
required to be adequately powered to assess the effect of blood product transfusion 
on pulmonary complications following liver transplantation. 
The analysis of perioperative blood product transfusion on incidence of dialysis in the 
postoperative period yielded some interesting findings. Although this study did not aim 
to investigate the effects of intraoperative crystalloid administration, the multivariate 
analysis found that increased crystalloid volume administration (greater than 5 litres) 
was associated with decreased postoperative dialysis. Further prospective studies 
utilising goal directed and liberal fluid strategies are required to clarify the association 
between fluid therapy and the need for postoperative dialysis.  
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